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The influence of the size and morphology of carrier particles on drug dispersion performance 
from passive dry powder inhalers has been extensively studied topic, and a consensus has been 
reached regarding the adverse effect that larger carrier particle diameters impart to aerosol 
performance.  However, previous studies have generally employed only a few carrier particle 
size fractions, generally possessing similar surface characteristics.   Accordingly, theories 
developed to explain the influence of the physical characteristics of carrier particles on 
performance relied heavily on both extrapolation and interpolation.   To fill in the gaps from the 
literature and simultaneously evaluate the influence of carrier particle size and morphology, a 
comprehensive study was undertaken using 4 lactose grades, each sieved into 13 contiguous 
sizes, to prepare 52 formulations incorporating a unique lactose grade-size population.  The 
aerosol performance results indicated that large carrier particles possessing extensive surface 
roughness can improve drug dispersion, in contrast to what has been previously reported. It is 
proposed that this may be attributed to mechanical detachment forces arising from collisions 
between the carrier particle and inhaler during actuation.  
Based on these observations, a novel dry powder inhaler platform was developed, employing 
carrier particles much larger (> 1 mm) than previously explored in both the scientific and patent 
literature.  Optimization of this technology required the judicious selection of a carrier material, 
and following an extensive screening process, low-density polystyrene was selected as a model 
candidate.  Given its low mass, diameters in excess of 5-mm could be employed as carriers while 
still generating high detachment forces. To minimize drug particle aggregation, a novel drug-
coating method employing piezo-assisted particle dispersion was developed to compensate for 
the reduced surface area of the novel carrier particles.  In addition, the selection of a suitable 
inhalation device prototype was instrumental to the overall performance of the technology.   In 
vitro testing of the novel large carrier particles yielded emitted fractions in excess of 85%, and 
overall drug delivery of up to 69% of the loaded dose.
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CHAPTER 1 
1. Introduction
1.1. PULMONARY DRUG DELIVERY 
The overall performance of a therapeutic inhalation regimen is a complex interplay 
between the physiology and anatomy of the patient’s pulmonary system and disease state, the 
physicochemical properties of the drug formulation, and the device employed to aerosolize and 
deliver the dose.  With regards to the patient, proper training and instruction on the use of their 
prescribed inhaler, though often neglected, can produce a marked improvement in 
performance. However, apart from the performance boon provided through education, the 
anatomy of a patient's airways will dictate both the inspiratory force they will produce and the 
duration over which it is sustained, and the formulation and device must compensate for any 
shortcomings in the patient's inspiratory output.      
Evolving from a common ancestor, the development of therapeutic inhalation devices 
has diverged into three distinct classes: nebulizers, pressurized metered-dose inhalers (pMDIs) 
and dry powder inhalers, with the latter being the most recent addition to the family [1].  Given 
their bulkiness, external power requirements, and time required for inhalation, nebulizers lack 
portability and are generally confined to the home or clinic, although hand-held nebulizers have 
been introduced [2].  In contrast, pMDIs employing a pressurized gas propellant to aerosolize 
the dose, are highly portable and inexpensive. Inaugurated in the 1950s, pMDIs dominated the 
portable inhalation drug delivery market for many years, essentially running unopposed until 
the unveiling of the first DPI late the following decade (SpinhalerTM, Aventis) [3].  Even then, 
nascent DPIs were characterized by low efficiency, and delivered a dose from a capsule that had 
to be manually loaded prior to each actuation; a sharp contrast to pMDIs and their 200 dose 
capacity.  However, pMDIs were not without their drawbacks, and chief among them was their 
use of the ozone-depleting chlorofluorocarbons (CFCs) as propellants [4]. In 1987, members of 
the international community, recognizing the irreparable damage CFCs have on the 
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environment, signed the Montreal Protocol pledging to phase out production of CFCs by 1996 
[2]. In need of an alternative propellant, CFCs have been replaced by hydrofluoroalkanes (HFAs), 
although the transition has not proven seamless, as density and solubility differences between 
the propellants have led to reformulation issues.  The high velocity of the emitted dose from a 
pMDI also requires coordination between patient inhalation and device actuation to avoid 
deposition in the throat, which many patients find difficult [5]. In addition, advanced 
therapeutics, including peptides, proteins and gene vectors, exhibit poor stability at room 
temperature when formulated into the aqueous solutions delivered by pMDIs [6].   
1.2. DRY POWDER INHALERS 
Developed as an alternative to the pMDIs, dry powder inhalers have their own unique 
advantages and limitations, and can be broadly categorized into either passive or active devices 
[3]. Passive DPIs are breath-actuated, deriving the energy for powder dispersion and aerosol 
formation solely from the patient's inspiratory maneuver, alleviating the coordination of 
actuation and inhalation that many patients find problematic with pMDIs [4].  However, patients 
can produce a wide range of flow rates, which is reflected in the high inter-patient variability in 
the dose delivered from these devices. Additionally, some patients can only generate flow rates 
too low to produce an aerosol cloud, and treatment with DPIs can be ineffectual.  In light of this, 
many DPI developers have concluded that the best strategy lies in decoupling powder dispersion 
from inhalation and, following the path of pMDIs, have designed active DPIs incorporating an 
assortment of auxilliary energy sources to aerosolize the dose. 
DPIs can be further classified as either single dose or multi-dose devices, the latter being 
delineated into multi-unit dose or reservoir inhalers.  The single-dose inhalers represent the first 
generation of DPIs (SpinhalerTM, RotahalerTM), although some devices in this category are still 
currently marketed (AerolizerTM, HandihalerTM).  These inhalers generally deliver the dose from a 
gelatin capsule inserted into the device prior to each actuation.  The multi-unit dose inhalers 
disperse individual doses pre-metered by the device manufacturer into blisters, while reservoir 
DPIs contain enough powder for multiple doses (typically 60 - 200) within the device, metering 
individual doses prior to actuation. Advantages of DPIs employing factory-metered doses 
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include environmental protection of the powder and consistency of the dose relative to their 
reservoir counterparts.  However, a drawback is the higher cost of these devices, stemming 
from the multi-component designs and dedicated factory production lines [4].  Regardless of 
how the dose is provided, all DPIs contain a de-agglomeration principle to address the 
challenges inherent to producing aerosols from a dry powder. 
1.3. TRADITIONAL DPI FORMULATIONS 
To be effectively delivered into the lung, drug particles are generally required to fall in 
the size range between 1 - 5 µm; particle size reduction is typically performed through “top 
down” processes such as jet milling, which yields highly cohesive particles with ill-defined size 
distributions and morphologies [5]. Particle engineering, a “bottom up” approach to producing 
respirable size particles at the initial particle formation step, holds promise in addressing the 
drawbacks of attrition processes such as jet milling. However, few technologies have been 
industrialized at least in part due to the increased cost of goods for these nascent techniques 
[7].  The cohesive interactions between the powder particles arise from a combination of 
electrostatic, capillary, and van der Waals forces, although by allowing the particles time to 
dissipate excess electric charges, and in the absence of high relative humidity, it is the latter that 
are most important [8].  Individually weak, but collectively robust, van der Waals interactions 
are the dominant attractive forces in particles with diameters under 10 µm, exerting a 'velcro 
effect' that impedes powder dispersion. To aid in the entrainment and deagglomeration of these 
cohesive  particles, dry powder formulations are generally binary, or interactive, blends, with 
the bulk, > 95% (w/w), comprised of large inert carrier particles (50 - 100 µm), to improve the 
flowability and metering properties of the formulation [9].  However, while the addition of the 
large carrier particles allows the powder to be readily entrained in a flow stream, the adhesive 
interactions between the drug and carrier hinders the formation of an aerosol comprised of 
primary drug particles. Consequently, drug particles that fail to detach from the carriers are 
deposited in the throat and upper airways [10].           
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1.4. PARTICLE ENGINEERING TECHNOLOGIES    
In lieu of developing inhalers that can enhance the de-agglomeration forces, an 
alternative approach is to reduce the cohesive and adhesive interactions within the powder 
through modifications to both drug and carrier particles [1].  For micronized drug, one strategy 
is to increase the diameter of the particle, thereby lowering the surface area-to-volume ratio, 
without compromising its aerodynamic diameter.  The aerodynamic diameter of particle (da) 
governs how it behaves in a flow stream, and is related to its true diameter (dp) and density (ρp) 
as: 
     √
  
  
 
where   is the unit density, and ρp/ρo is the specific gravity of the particle [8].  From 
the above, it can be seen that an increase in the diameter of a particle can be balanced by a 
concomitant reduction in its density, an approach embodied by the large porous particles [11].  
Additional developments in powder dispersion performance include smaller porous particles, 
Pulmospheres, and the use of supercritical fluid technology.  However, in comparison to 
unmodified drug, these particles can be costly to manufacture, requiring the use of spray drying 
or spray-freeze drying [1].  Moreover, given their increased volume, larger reservoir systems 
must be developed to accommodate the formulation, requiring the production of devices 
specific to the powder [1].  Thus, while particle engineering technologies have demonstrated the 
ability to markedly improve aerosol performance from traditional dry powder inhalers, at 
present, marketed DPI formulations are generally binary formulations that exhibit poor 
dispersion properties relative to the aforementioned particle technologies.  Accordingly, to 
improve performance of a DPI therapeutic regimen, strategies to optimize both the formulation 
and device are required.  What follows is a detailed discussion of the physicochemical properties 
of binary DPI formulations, particularly the parameters of the carrier particle population that 
have been examined in the literature and found to either enhance, or impair performance 
through various mechanisms.  Following this, the mechanisms by which dry powder inhalers are 
designed to improve drug delivery will be discussed in detail.   
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1.5. PARAMETERS GOVERNING PERFORMANCE OF BINARY BLENDS 
As mentioned above, therapeutic formulations administered via dry powder inhalers are 
typically interactive mixtures, comprised of the active pharmaceutical ingredient and a coarse 
carrier material blended together to produce a homogeneous powder.  Delivery to the deep 
lung requires drug particles possessing aerodynamic diameters between 1 and 5 µm.  However, 
given the high surface area-to-volume ratio of particles in this size range, van der Waals forces 
dominate the interactions, producing highly cohesive powders that flow poorly and are 
consequently resistant to re-dispersing back into primary particle sizes during inhalation.  Drug 
agglomerates that fail to de-aggregate sufficiently deposit in the mouth and throat, reducing the 
therapeutic efficacy of the treatment and increasing the potential of unwanted side effects. To 
improve powder flow and dispersion, as well as assist in dose metering, a population of coarse 
particles (50 – 100 µm) are incorporated into the formulation, typically in excess of 95% (w/w) 
to serve as carriers onto which the drug particles adhere during blending, and from which they 
are subsequently detached during inhalation [10]. Carrier particles must be inert, possess a 
physical and chemical stability compatible with the drug substance, and be readily available and 
inexpensive [12].  While a variety of materials, primarily sugars, have been evaluated in the 
literature for their suitability to serve as carrier particles, α-lactose monohydrate is the only 
material currently approved by the FDA for inhalation purposes [13-16].     
The previous two decades have borne witness to extensive research on dry powder 
inhalation systems, revealing the influence that the patient, formulation and device have on 
dispersion performance, coupled with the understanding that a judicious selection of both drug 
and carrier particle properties are crucial parameters in optimizing performance.  Production of 
a stable and homogeneous powder blend requires the interaction between drug and carrier 
particles be balanced, with forces strong enough such that drug preferentially adheres to the 
carrier during mixing, yet sufficiently tenuous to facilitate re-dispersion of drug particles during 
inhalation [17, 18]. Formulation factors affecting overall performance include the drug 
substance and concentration, mixing rate, mixing time, batch size, and the carrier particle 
population [19-21]. Studies focused specifically on the physical properties of carriers have 
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examined the particle size, size distribution, morphology, surface roughness, surface area, and 
surface energy of carrier particle populations [9, 22-28]. However, the absence of a uniform 
experimental methodology between research groups inhibits direct comparison of dispersion 
studies employing different drugs, carrier particle size fractions, and dry powder inhalers. 
Additionally, variations in blending method, time, batch size, and mixing container can 
significantly influence the forces experienced by the formulation during mixing, introducing 
further confounding factors [29, 30].   However, in spite of these caveats, reports from the 
literature have reached a general consensus on the detrimental effect larger carrier particles 
impart to overall aerosol performance. 
To account for this phenomenon, multiple theories have been proposed in the 
literature.  The following list will be examined in greater scrutiny below, but is presented now to 
illustrate the variety of adverse effects attributed to large carriers:  
1. Increasing the diameter of carrier particles enhances the van der Waals forces 
between drug and carrier.  
2. Larger carrier particle populations possess greater surface asperities and 
discontinuities.  
3. Blends with larger carrier particles increase drug-carrier adhesion forces during 
mixing. 
4. Higher carrier particle populations have a reduced surface area, below the threshold 
required for a drug particle monolayer (dependent on API concentration). 
5. Surface impurities and high energy sites increase with carrier particle diameter. 
6. Large carrier particle populations possess a lower fraction of fine particles (< 10 µm) 
relative to smaller carrier particles.  
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1.6. MECHANISM OF DRUG DETACHMENT FROM CARRIER PARTICLES 
It is important to note that these theories are not mutually exclusive, and the extent to 
which one predominates over another may vary as experimental parameters are altered. At this 
moment, let us briefly shift from our discussion of carrier particles and consider the mechanisms 
of drug dispersion in a dry powder inhaler.  Detachment of drug from the carrier particle surface 
occurs through three distinct pathways [8, 9, 31, 32]:   
1. Dispersion by acceleration flow or shear flow 
2. Dispersion by impaction of drug aggregates on a target 
3. Dispersion by mechanical forces 
The importance of carrier surface morphology is evident in the first two mechanisms. 
For detachment by acceleration flow, drug particles must be exposed to the flow stream on the 
carrier surface, with larger drug particles and agglomerates possessing a greater surface area for 
interaction with the flow stream.  Detachment by impaction of aggregates onto a target, where 
the drug is scraped off from the carrier during collisions with the inhaler and/or other carrier 
particles, similarly requires the drug be exposed on the surface.  The final mechanism, 
dispersion by mechanical forces, occurs when carrier particles impact with the inhaler walls as 
they exit the device, transferring the momentum of the collision to the adhered drug particles.    
1.7. MECHANICAL DETACHMENT FORCES 
If the force generated by the abrupt momentum change is both greater than the 
adhesion between the particles, and in a direction favorable for detachment (that is, if the 
particle is not oriented on the carrier so that the collision pushes the drug onto the carrier), the 
drug is dispersed [8, 9].  Of the three, the latter mechanism is largely independent of carrier 
particle shape, but directly proportional to carrier particle size, as larger carriers achieve higher 
momentums over smaller carriers traveling with comparable velocities [9].  As with the 
proposed theories accounting for the adverse effect of large carriers, the mechanisms of drug 
detachment are not mutually exclusive, and undoubtedly work in concert to promote 
dispersion.  Additionally, the relative contribution of any one mechanism to total drug 
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detachment can vary significantly between formulation, inhaler, and flow rate, which varies 
considerably across a patient population. It is not surprising then that studies aimed at 
elucidating the predominant mechanism of drug particle detachment have yielded conflicting 
results [31-38].   
While lacunae abound in our understanding of the precise forces governing drug particle 
detachment within a given inhaler, examining the list of proposed theories by which carrier 
particles influence formulation performance, and comparing it to the mechanisms of drug 
detachment, it is evident that dispersion by mechanical forces would seem incompatible with 
the requirements for good aerosol performance.  In other words, increasing the contribution of 
mechanical forces in detachment requires larger carrier particles, but evidence suggests larger 
carrier particles are detrimental to formulation performance.  Consequently, this mode of drug 
detachment from carrier particles has been traditionally overlooked, if not dismissed entirely 
[22].  However, given the dependence of impaction forces on the cube of the carrier diameter, 
we propose that forces generated from mechanical impactions between carrier particles in the 
inhaler can potentially overwhelm adhesion forces, significantly outweighing their proposed 
detrimental influences on dry powder formulation [8].  Accordingly, prior to presenting the case 
for large carrier particles, the case against them must be carefully cross-examined.           
1.8. DETRIMENTAL INFLUENCE OF LARGE CARRIER PARTICLES TO AEROSOL PERFORMANCE 
1.9. THEORETICAL PARTICLE-PARTICLE ADHESION FORCES 
Increasing carrier particle size is believed to enhance the van der Waals forces between 
drug and carrier.  Due to the high degree of asperities and surface roughness of pharmaceutical 
powders, an exact solution for the expected van der Waals forces between a drug particle and 
carrier particle has proven impossible to obtain.  However, to simplify the problem and arrive at 
an approximate value, the drug and carrier particles are often represented as perfectly smooth 
spheres, allowing the theoretical van der Waals forces to be then calculated by: 
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where A is the Hamaker constant (~ 10-19 J ), D is the inter-particle separation distance ( 
~ 0.4 nm), and dd and dc are the respective diameters of the drug and carrier particles [8].  The 
Hamaker value is constant between two materials, and the inter-particle distance is also 
considered to be unchanged as the size of the drug and carrier particles are altered. Thus, 
holding the size of the drug particle constant, increasing the diameter of the carrier particle will 
theoretically produce an accompanying increase in adhesion force.  However, a closer 
examination of the increase in the predicted van der Waals forces within the carrier particle 
populations of interest ( > 50 µm), reveals that the price exacted by larger carrier particles, in 
terms of higher van der Waals forces, is not as costly as presumed.  To illustrate this, consider 
the interactions between a drug particle and carrier particle as the diameter of the latter is 
increased.  As mentioned previously, the Hamaker constant and inter-particle distance are 
assumed constant, so variations in the equation depend entirely on the diameters of the drug 
and carrier 
 
      
    
     
 
 
Beginning with a drug particle and carrier particle both 5 µm in diameter, the size of the 
carrier is doubled to 10 µm, then increased five-fold to 50 µm, and once more up to 250 µm 
(Figure 1.1)   Inserting the diameter values into the above equation reveals that while the 
adhesion force is increased by 32% when the carrier particle is doubled from 5 to 10 µm, the 
next size increase is not accompanied by a commensurate raise, as the difference in adhesion 
force between 10 µm and 50 µm is roughly the same as the difference between 5 µm and 10 
µm.  Finally, raising the diameter of the carrier up to 250 µm brings with it an even smaller 
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difference with the preceding carrier particle; less than 10% between 50 µm and 100 µm.  The 
last comparison is the most relevant, as carrier particles are typically 50 – 100 µm. 
Thus, the cost of raising the size of the carrier particle is incurred primarily at smaller 
carrier particle diameters; much smaller than commonly employed in dry powder formulations.  
Another thing to note is that the value of the adhesive force begins to trend to a constant 
number, and it is not by coincidence that value is the same as the diameter of the drug particle.  
As the value of the carrier particle becomes much larger than that of the drug, the denominator 
is approximated simply as the value of the carrier particle, and the carrier diameter is eliminated 
entirely from the expression: 
 
              
       
    
     
     
    
  
       
 
Accordingly, as the size of the carrier become sufficiently large, the theoretical van der 
Waals forces between drug and carrier will become constant and depend solely on the diameter 
of the drug particle.  In conclusion, at the size ranges relevant to our discussion, increasing 
carrier particle size has a relatively low effect on the theoretical van der Waals forces.   
1.10. PRESS-ON FORCES 
Due to both their greater mass and improved flowability relative to their smaller 
counterparts, larger carrier particle populations can increase the press-on forces between the 
drug and carrier during blend preparation.  Blending of drug and carrier particles into a 
homogeneous powder is primarily performed with an orbital mixer.  During blending, the 
container holding the powder is rotated continuously, forcing the powder to slide back and forth 
between the ends of the container, repeatedly pressing against the particles below.  
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Accordingly, larger particles with greater mass and good flowability will collide against both the 
container walls and the particles underneath them, with greater force than smaller particles 
with poor flow [20].  Drug particles that are sandwiched between two carriers during a collision 
will be pressed against the carrier surface with high relative force, increasing the contact area 
between drug and carrier and thus the adhesion force between the two particles [9].  
Consequently, a greater force will be required to detach the drug during inhalation, potentially 
yielding a formulation with poor dispersion performance.  
However, examining the previous paragraph by the light of the proposed theories of 
large carrier particle performance reveals a dissonance between them.   Press-on forces requires 
the presence of a drug particle located between two lactose particles.  However, larger carriers 
have been associated with greater surface asperities and higher rugosity than smaller particles 
[9, 12, 29, 39].  Particles with rugged surfaces might then be expected to provide shelter to drug 
particles against press-on forces.           
The possibility that this occurs was noted by de Boer and coworkers [9]. However, they 
believed this effect was dependent on drug concentration in the formulation, and that 
increasing drug concentrations would expose more particles to press-on forces, eliminating the 
potential benefit high rugosity would impart to formulations [20].  To address this, an additional 
study was undertaken to examine drug detachment of three lactose carrier size fractions, 45 – 
63 µm, 150 – 200 µm and 250 – 350 µm, at two different flow rates, as the drug concentration 
was increased from 0.4% (w/w) up to 6 % (w/w)[20].  As the drug concentration was elevated, 
the fraction of the drug particles detached from the surface of the 45 – 63 µm carrier particles 
increased.  This could be explained by the increased drug-drug agglomeration as the amount of 
drug in the formulation was raised, and as carrier particles of this size range would have a 
relatively low mass and hence very low press-on forces, it was not surprising detachment 
increased with drug concentration.  In contrast, for the large carrier fractions, 250 – 350 µm, 
increasing drug concentration inhibited drug detachment, although the difference was almost 
negligible as the concentration was doubled from 3% (w/w) to 6% (w/w).    
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The authors concluded that at higher drug concentrations, drug particles are not 
afforded shelter from the press-on forces, and hence the overall adhesion between drug and 
carrier populations increases with concentration.  However, their assumption was based on a 
previous study by Podczeck, showing that micronized salmeterol sulphate particles exhibit an 
adhesive nature when mixed with lactose carriers, i.e. lactose-salmeterol interactions are 
favored over salmeterol-salmeterol interactions [40].  Dickhoff, et al., assumed that budesonide 
would exhibit a similar adhesive tendency, and cited this as evidence that larger carrier particle 
fractions increased press-on forces between the drug particles and the carriers during blending, 
because the drug would preferentially attach to the carrier.  However, a subsequent 
independent study examining the adhesive and cohesive tendencies of lactose with different 
drugs, concluded budesonide has strong cohesive properties, resulting in potential drug 
separation upon blending [17].  This finding was corroborated in a study examining the blending 
dynamics between budesonide and crystalline lactose, revealing the tendency of budesonide to 
both blend and segregate from the carrier as a function of time; a tendency attributed to a poor 
interaction between the drug and carrier [18]. Given the likelihood of budesonide to associate 
with itself in the presence of lactose, increasing the drug concentration would increase the 
extent of agglomeration at the expense of drug-carrier adhesion.   If the large carrier lactose had 
a smooth surface, and possessed insufficient rugosity to shelter the budesonide agglomerates as 
the drug concentration was raised, it would be expected that drug detachment would increase 
with concentration (as observed for smaller carriers), as larger drug aggregates would possess a 
greater surface area, making them more susceptible to detachment by flow.  However, this was 
not observed, and given the reported cohesive nature of budesonide, it is possible that the low 
detachment was a combination of the particles being sheltered from both the flow stream and 
detachment due to aggregate impactions, coupled with insufficient carrier particle-inhaler 
collisions at the low flow rate of 30 L min-1.       
As the flow rate was doubled, it was observed that the larger carrier particles detach a 
greater fraction of drug than the smaller carrier particles at all drug concentration levels (0.4%, 
1.6%, 3.0% and 6.0%).  Thus, smaller carrier particles, with low press-on forces, detached a 
smaller fraction of drug compared to large carrier particles, where high press-on forces coupled 
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with asperities would be expected to inhibit performance relative to the smaller carriers.  To 
reconcile this discrepancy, let us assume that both carrier particle populations have smooth 
surfaces and would be exposed to identical flow detachment forces and aggregate collision 
forces as they experience the same inhalation flow rate.  It would be expected that both 
formulation would behave similarly.  We now consider press-on forces, and the assumption that 
larger carrier would experience press-on forces to a greater extent the smaller carriers.  It would 
now be expected that the small carriers would outperform the larger carrier, i.e. the smaller 
carriers would detach a greater fraction of drug. Finally, include the high surface rugosity of 
carriers, and now detachment forces by flow and aggregate impaction would be diminished in 
the large carriers, and the small carrier would be expected to significantly detach more drug.  
However, the opposite occurs.  What then would account for the improved detachment 
properties of the larger carrier at higher flow rates?  This difference must then be attributed to 
the increased mechanical forces experienced by larger carrier particles as the velocity is raised.  
In this case, impaction forces begin to overwhelm adhesion forces as noted by the ability of the 
large carriers to detach up to 95% of the drug.  By contrast, for smaller carrier particles where 
impaction forces would not be as significant, the detachment forces that predominate, i.e. 
detachment by flow and aggregate impaction, are not as potent, lending support to our claim 
that detachment by mechanical forces is potentially the most dominant of the three.  That the 
fraction of detached drug increased with drug loading at each concentration provides evidence 
of budesonide agglomeration, refuting the authors’ assumption that budesonide would prefer 
to attach to the carrier, and that the extent of attachment would increase with higher drug 
concentrations.  The availability of drug dispersion data (FPF, FPD, etc.) in addition to the 
detachment data would have been a welcome inclusion, as high drug detachment but low FPD 
would correspond to a cohesive drug.     
In conclusion, the influence of press-on forces depends not only on the carrier particle 
size, but on the rugosity of the surface and the properties of the drug substance.  Accordingly, a 
general statement associating increased press-on forces simply with particle size would be 
disputable.  
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1.11. SURFACE ROUGHNESS 
Carrier particles with larger diameters possess greater surface roughness, affording drug 
particles shelter from detachment mechanisms relying on acceleration flow or impaction of drug 
aggregates on a surface [9]. Drug particles will accumulate in the discontinuities on the carrier 
particle surface, and a rougher surface potentially affords multiple contact points between the 
drug and carrier, increasing the adhesive force between the particles [41].  This view is 
supported by studies investigating the influence of carrier morphology, where smoother lactose 
carriers produced higher fractions of fine particle deposition [12]. An additional role of surface 
roughness was proposed by Podczeck, who believed that detachment of fine drug particles from 
the surface of coarse carriers occurs laterally to the surface, where the drug will slide until it 
reaches the edge of the carrier and fall-off [22]. The adverse influence of carrier particle size is 
then obvious, as it will extend the distance the drug particle must travel prior to detachment, 
requiring greater aerodynamic drag forces relative to a smaller carrier particle.   However, this 
theory is contested by reports indicating that elongated lactose carrier particles can improve 
dispersion performance [42].  The authors attributed this beneficial influence to the enhanced 
aerodynamic properties of the elongated particles, allowing them to travel longer distances than 
their equivalent volume-spherical counterparts and prolong the exposure of adhered drug 
particles to drag forces. 
Examining the detachment mechanisms, it is evident that smoother particles allow for 
greater detachment by flow and aggregate impaction, whereas detachment by mechanical 
forces is largely independent of carrier particle surface rugosity.  Accordingly, for rough surfaces 
detachment becomes less dependent on flow and aggregate impaction, relying more on 
mechanical forces.  Thus, it is not that high surface rugosity would inhibit detachment entirely, 
but rather it shifts the detachment mechanism to rely more on mechanical forces.  As such, it 
could then be theorized that the size ranges examined (63 – 90 µm) in the study investigating 
surface roughness might be too small to permit a significant contribution of detachment to arise 
from carrier particle collisions [41, 42].  As mentioned previously during the discussion of press-
on forces, impaction forces require both sufficiently high flow rates coupled with a relatively 
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large carrier particle diameter.   As an example, consider two spherical carrier particles, one 90 
µm and the other 350 µm (the respective upper limits of the Zeng, et al., and Dickhoff, et al., 
studies), moving with comparable velocity, impacting directly with a surface.  In this case, the 
momentum difference between the two particles is entirely dependent on their mass, which is 
related to the diameter: 
 
   
    
 
 
 
Increasing the carrier particle size from 90 to 350 µm, could potentially produce 
impaction forces 59-fold greater in the latter carrier particle; assuming similar particle velocities.  
In summary, carrier particle roughness may inhibit performance by causing a shift to a 
detachment mechanism highly dependent on mechanical forces.  Small carrier particles may 
possess insufficient mass for these forces to be effective at a given flow rate.  In contrast, 
surface roughness of very large carriers is less debilitating when compared against smaller 
carriers, as the mechanical forces generated may potentially dominate over the detachment 
mechanisms that require a smooth carrier surface for optimal performance.  
1.12. SURFACE AREA 
For a constant mass of carrier particles, increasing carrier diameter can significantly 
lower the available surface area to which drug can adhere during blending.  Consequently, drug 
particle agglomerates will form, and while they may be more readily detached by the flow 
stream relative to primary drug particles, dispersion performance will be reduced if the inhaler 
is unable to de-aggregate the flocculated particles.  For example, a study evaluating the 
relationship between specific surface of lactose particles with increasing carrier particle 
diameter noted that increasing the diameters of the carrier particle population from < 32 µm up 
to 63 – 90 µm and 125 – 180 µm markedly lowered the SSA of the carriers, from a high of 0.68 
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m2 /g for the smallest lactose size fraction to 0.36 m2 /g for the mid-range particles and down to 
0.19 m2/g for the largest diameter carriers  [19]. 
Thus, for a constant powder mass, the surface area available for drug attachment is 
halved as the carrier fraction is raised from 0 – 32 µm to 63 – 90 µm, and then halved again as 
the carrier particle diameter is increased to 125 – 180 µm.  In their studies examining the 
influence of drug concentration on drug detachment from carriers, Dickhoff, et al., calculated 
(using a simplified model where drug and carriers were presumed perfect spheres with mono-
disperse populations equal to their respective d50) that for a population of 32 – 45 µm carriers, 
0.4% (w/w) drug concentration would correspond to 4.6% surface coverage, and increasing the 
drug concentration 4-fold to 1.6% (w/w) would cover 18.4% percent of the available surface 
area.  By contrast, a 250 – 350 µm carrier particle population would have 36.2% percent surface 
coverage at 0.4% (w/w) concentration and 145% when the drug particle concentration is raised 
to 1.6% (w/w). This latter concentration exceeds the threshold of a theoretical drug monolayer, 
increasing drug-drug interaction and leading to agglomerates.  It should be noted that the 
tendency of drugs to form agglomerates varies with substance, but lowering the available 
surface area undoubtedly increases if not the extent, then at least the frequency, of interactions 
between drug particles [16].  
1.13. REDUCTION IN FRACTION OF FINE LACTOSE  
Studies have repeatedly observed that as the diameter of the carrier particle population 
is increased, the amount of fine lactose particles (< 10 µm) in the powder is reduced [22, 24, 26, 
43-47].  Intrinsic to the formulation, these fine lactose particles are produced during 
micronization, and adhere to the coarse carrier particles; during subsequent powder processing 
they can detach from the carrier surface [27].  The lactose fines are believed to modulate drug 
detachment by two distinct mechanisms: 
 
1. Lactose fines form agglomerates with drug particles, and the increased surface 
area of these aggregates increases their susceptibility to detachment by flow 
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2. Lactose fines occupy high energy sites on the surface of the coarse carriers, 
allowing drug to adhere to lower energy sites 
 
While both of these pathways can improve aerosol performance, the differences 
between them are not insubstantial. For the first mechanism, the formation of fine lactose-drug 
agglomerates with greater surface areas relative to primary drug particles would benefit 
dispersion by the flow stream, which dominates with smoother and smaller carriers.  For the 
latter mechanism, the ability of lactose fines to occlude high energy sites on the carrier surface 
would affect drug detachment by all three of the proposed mechanisms.  However, these high 
energy sites are thought to be located primarily in surface asperities and discontinuities, and 
thus attributed more to larger carriers [9, 27].   Furthermore, as high energy sites are primarily 
located in regions of high surface roughness, detachment by mechanical forces could play the 
major role in dislodging drug from high energy sites.  Correspondingly, that larger carriers 
possess a lower amount of fine particles could be balanced by their (theorized) improved 
detachment potential against drug adhered to high energy sites, as carrier particle size is 
increased.  However, this detachment potential depends on multiple factors, including inhaler, 
flow rate, drug substance and concentration and carrier particle morphology.   
Of the two mechanisms, is not known which one dominates for a given formulation.  
Support for the first hypothesis is provided by studies revealing mixing order between fine 
lactose and drug particles (to prepare ternary blends of coarse lactose/fine lactose/drug) is 
unimportant, contesting the supposition that fine particles must adhere first to high energy sites 
[24].  Additionally, Louey, et al., also noted an increase in the surface energy of coarse lactose 
carriers following mixing with fine lactose particles.  As the lactose fines are proposed to 
passivate the carrier surface, this result is inconsistent with the theory that lactose fines would 
expose lower energy sites to the drug.  However, the theory that lactose fines strongly adhere to 
the carrier surface is supported by an in vivo deposition study reporting higher concentrations of 
fine particles in carrier population do not produce a concomitant increase in deep-lung fine 
particle deposition [48]. The authors attributed this observation to the formation of a stable 
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mixture between coarse and fine lactose particles, as would be assumed if the lactose fines 
principally interact with the high energy sites on the carriers. 
1.14. SURFACE ENERGY 
Given the numerous publications supporting the positive influence of lactose fines on 
dispersion, their overall ability to improve aerosol performance is uncontested.  However, it is 
worth examining if larger carrier particle populations do indeed possess higher surface energies; 
or alternatively, that lactose with high energies exhibit reduced performance comparable to low 
energy carriers.  Evidence conflicting with both of these theories has been observed in the 
literature, and raises doubts on the perceived relationship between surface energy and drug 
detachment.   Studies employing atomic force microscopy (AFM) and inverse gas 
chromatography (IGC) to probe the surface energies of inhalation-grade lactose carriers 
(Respitose®, DMV-Fonterra) found that the milled (ML) and sieved carriers have very similar 
surface energies, in spite of the wide differences in particle size distribution between milled and 
sieved Respitose® carriers [27].  Additionally, milled lactose was found to have a greater degree 
of surface roughness, and would be expected to lower dispersion performance.    
However, the observation of Louey, et al., that addition of fine particles actually 
increased the surface energies of carrier particles, precludes a direct relationship between 
surface energy and particle size [24].  In the case of the fine lactose, it is believed that the 
comminution process required to generate particles < 10µm would leave the resulting fines with 
a very high surface energy.  Accordingly, if the surface energy of lactose is believed to increase 
at low particle sizes, and then again at high particle sizes, where would the trend reverse?  That 
is, at what size ranges could we expect reduced surface energies as the particle size is lowered?   
Alternatively, lactose powder with higher relative surface energy would be expected to 
perform worse than lower energy populations.  However, Cline and Dalby observed the opposite 
trend, with improved dispersion performance associated with higher surface energies [28].  The 
authors attributed this correlation to the requirement of a minimum interaction energy, 
sufficient to pull apart highly cohesive drug aggregates into primary particles; lactose with a 
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higher energy will then be better able to attract drug particles onto the carrier surface, such that 
the drug is now found in its primary particle size.  Accordingly, while it is intuitive to think lower 
carrier particle surface energies would improve dispersion by lowering adhesive interactions, 
the relationship appears ambiguous at best.     
1.15. SUMMARY 
In addressing the different mechanisms by which large carrier particles are perceived to 
be detrimental to dry powder formulations, it becomes clear that the role of large carrier 
particles is not as clearly defined as the literature might lead us to believe.  Specifically, carrier 
particles with large diameters and high surface rugosity could potentially deviate from the 
expected trend, highlighting the incomplete nature of the proposed theories, while 
simultaneously illustrating the role of mechanical forces in the delivery of dry powder 
formulations.   
1.16. MECHANISMS OF DPI PERFORMANCE 
 As was mentioned earlier, in addition to modifying the formulation, optimizing 
the performance of the DPI through which the formulation is dispersed is an additional pathway 
to enable improvements in DPI therapy.  
From a pragmatic viewpoint, the development of a novel dry powder inhaler (DPI) is 
centered on two objectives: creating a device that can efficiently entrain and disperse a 
powdered drug formulation for inhalation therapy, while utilizing a design and function 
sufficiently novel to avoid patent infringement.  Accordingly, this has produced no shortage of 
prospective designs, prototypes and devices incorporating a diverse array of powder dispersion 
strategies and de-agglomeration principles. Running the gamut from cyclones, baffles, and 
impellers, to the inclusion of external energy sources applying mechanical, electrical and 
pneumatic forces to the powdered dose, this abundance reflects the carte blanche at an 
inventor's disposal when conceptualizing a new inhaler. However, while the harvest from the 
patent literature may be bountiful, very few patented DPI designs reach the market, as an array 
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of factors including development cost, manufacturability, portability, and ease of use distinguish 
between a design that is plausible and one that is practical.  The objective of this review is to 
provide a survey of the plurality of dispersion strategies employed in DPIs, drawing on examples 
from both the scientific and patent literature, and is not intended to compare the relative merits 
of one specific device to another.  
1.17. TURBULENCE INDUCEMENT 
In its most basic form, a dry powder inhaler is comprised of three regions: an air inlet 
port through which outside air enters the device during inhalation, a powder-holding chamber, 
and an outlet port delivering the dose to the patient.  However, simply passing a flow stream 
across a static powder bed does not provide sufficient shear forces to effectively aerosolize the 
dose. When a particle is in a flow stream, it is subjected to two types of forces.  The first of these 
are the body forces, such as gravity and electromagnetism, which act throughout the bulk of the 
particle and are described in terms of force per unit mass. The second category are the surface 
forces, generally provided as force per unit area and consisting of normal and shear, or 
tangential, stresses; it is the tangential stresses that are most important in powder de-
agglomeration [49].   
Turbulent flows are marked by highly irregular and rapid fluctuations of velocity in both 
time and space, containing high energy eddies that continuously buffet the drug particles, 
subjecting them to shear stresses through accelerations in different directions [8].  When these 
accelerations generate forces of sufficient magnitude, the drug can detach from an aggregate 
particle or carrier.  A frequently encountered mode of inducing turbulence in an inhaler is to 
supply spiraling channels for the dose as it exits the device; a design popularized by the 
TurbuhalerTM [50].  However, while effective at generating turbulence, spiral paths also increase 
the surface area of the flow channel, enhancing the amount of particle deposition within the 
device.  An example of this can be seen in the TurbuhalerTM, where over 20% of the dose may be 
retained in the mouthpiece. By comparison to the DiskhalerTM, possessing a straight-channel 
mouthpiece with a much smaller surface area, approximately 5% of the nominal dose is lost 
[51].   
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In lieu of spiraling flow channels, many DPIs of more recent vintage contain tangential 
inlets opening into a cylindrical chamber to generate a high energy cyclone within the device. As 
an example, the NEXTTM DPI, a reservoir inhaler, contains a cyclone chamber composed of two 
non-concentric arcs (US Patent No. 7,107,988).  CFD analysis was used to optimize the design 
and dimensions of the chamber, and the resulting geometry was shown to eliminate 'dead 
spots' where drug deposition may have occurred [52]. An alternate example is found in the 
ConixTM inhaler, using a patented reverse cyclone technology.  When the patient inhales, air is 
drawn into a cyclone chamber, establishing a vortex.  As the flow stream travels down the 
cyclone, it encounters a blocked path at the bottom of the chamber, inducing the air flow to 
reverse direction and travel back up through a circular outlet [53].   
1.18. MECHANICAL FORCES 
In contrast to providing swirl channels or cyclone chambers, other inhalers incorporate 
designs applying mechanical forces to the powder. An example is the SpirosTM inhaler, where a 
powder-laden flow stream is carried through a battery-driven impeller to form an aerosol . An 
alternative embodiment (US Patent No. 6,237,591) uses a turbine to drive the impeller, labeling 
it a passive DPI, as the turbine is propelled when the patient inhales.   
Apart from impellers, mechanical forces are provided by low density beads contained 
within the dispersion chamber (US Patent No. 6,971,384).  When the patient inhales, the 
lightweight beads are driven by the entrained flow, repeatedly colliding with each other and the 
walls of the inhaler.  As the dose is carried through the chamber, the powder is de-agglomerated 
as it is caught between the bead-bead and bead-wall impactions.  Additionally, powder can be 
dispersed by employing a spring-driven hammer to strike a blister containing the dose (US 
Patent No. 5,655,523)[54].   
When compared to inhalers that rely on turbulence, mechanically driven devices are 
more complex, requiring additional moving parts that may be prone to failure.  However, an 
alternate strategy to generate mechanical impaction forces, without overly increasing the 
complexity of a device, is through the use of baffles (US Patent No. 5,724,959).  Located 
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downstream of the powder-holding chamber, a narrow channel opens into a larger volume 
region containing an impactor plate, producing an abrupt change in the flow path.  Due to their 
increased stopping distance, larger particles will be unable to follow the flow stream and 
navigate around the plate, colliding with the impactor and detaching drug from both aggregates 
and carriers.  The width of the plate and the distance between it and the narrow-channel 
opening alters the cut-off size of the particles that will be intercepted.               
1.19. PNEUMATIC FORCES 
1.19.1. Compressed Gas 
The most straightforward way to impart pneumatic forces to a powder bed is via a 
compressed gas source.  However, while dry powder inhalers have been designed that utilize an 
external compressed gas source (US Patents, No. 5,875,776, and 5,775,320 as examples), more 
recent designs incorporate a method to compress air within the device through a manual pump.  
The most notable example is the Nektar Pulmonary Inhaler used to deliver Exubera (previously 
known as the Inhale DPI, Inhale Therapeutic Systems, US Patent No. 6,257,233). The DPI, which 
decouples device actuation from inhalation, is comprised of a lower pressurization chamber 
where the compressed air is generated, and an upper receiving chamber that holds the 
aerosolized powder following actuation. The air is compressed when the patient manually 
primes a handle coupled to a piston within the lower chamber.  When actuated, the compressed 
air is discharged past the dose, drawing the powder into the upper chamber from where the 
patient subsequently inhales.  Another example is the Vectura AspirairTM, employing a bolus of 
air that is manually compressed by the patient via a corkscrew-type manual pump, and 
discharged into the powder bed upon inhalation.    
1.19.2. Vacuum 
An alternative approach to pneumatically driven dispersion is provided in US Patent No. 
6,138,673, illustrating a reservoir DPI that creates a vacuum within the body of the device.  The 
inhaler body can be extended by twisting the top portion relative to the lower portion two 
 23 
revolutions, expanding the volume of the container from 550 mL to 750 mL, and creating a 
vacuum inside when the body is closed to the atmosphere. The device is manually actuated by 
the patient, inhaling while pressing a trigger that opens a valve within the body, exposing it to 
ambient air which enters the device through the dose holding chamber and aerosolizes the 
powder. 
1.19.3. Synthetic Jetting Technology 
The application of synthetic jets to powder dispersion is another means of applying 
pneumatic forces and is described in US Patent No. 7,334,577.   Synthetic jetting may be 
produced in a chamber bounded on one end by a wave generating device and on the opposite 
end by a rigid wall with a small orifice [55]. When acoustic waves are emitted at high frequency 
and amplitude from the generator, a jet of air, directed outward from the chamber, is produced. 
This 'synthetic' jet is comprised of vortical air puffs corresponding to the generator's frequency, 
which may be a piezoelectric element (discussed in detail below) or an electrodynamic 
transducer. When actuated, a dry powder dose located in the jet-producing chamber and 
resting above the generator, is levitated and dispersed by the high frequency vibrations.  As the 
aerosolized powder nears the orifice, it is expelled from the chamber by the synthetic jet and 
into a flow channel where it is carried to the patient.       
1.20. SUSTAINED EXPOSURE TO FLOW STREAM 
One of the drawbacks commonly cited with passive DPIs is that their reliance on the 
patient's inspiratory flow rate can render them incapable of providing sufficient energy to 
effectively aerosolize and deagglomerate the dose [31].  However, when considering that the 
duration of an inspiratory maneuver can last well beyond three seconds, and that the majority 
of the powder departs the inhaler within the first second of inhalation (well before the peak 
inspiratory flow rate is reached), it becomes clear that much of the energy available in the flow 
stream is never allowed the opportunity to interact with the dose [56]. Accordingly, the poor 
performance that plagues these devices cannot be solely attributed to an inadequate supply of 
energy, but also to an inefficient application of the available energy.  To address this problem, 
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inhalers have been developed incorporating designs that can lengthen the time through which 
the dose interacts with the flow stream, sustaining the energy transfer between the air and 
powder. Alternatively, the device can delay the exposure of the dose to the flow stream until a 
pre-determined flow rate through the device has been attained, exposing the powder to the 
maximum energy levels of the flow.   
1.20.1. Delayed Exposure 
An example of this design incorporates a diverting flow channel in parallel with a 
secondary channel passing through the dosing chamber (US Patent No. 6,561,186). The flow 
channels share a common occluding mechanism connected by a rotatable vane, such that when 
one channel is open, the other is closed.  When the flow rate reaches a pre-determined level, 
the vane closes, occluding the first channel, while simultaneously opening the second channel 
and allowing the flow access to the dose. In the SkyehalerTM (US Patent No. 6,182,655) a valve 
shield is moved within the inhaler in response to the suction generated from inhalation.  When 
this force is sufficiently strong ( > 1.5 kPa) the valve shield opens a shutter, exposing the dose 
cavity to the flow stream.  While these examples are from passive devices, the use of more 
complex air flow sensors is becoming a common feature in many active DPIs under development 
to automatically coordinate aerosol production with inhalation.       
1.20.2. Air Classifier Technology 
A vector quantity, the detachment forces acting on a drug particle adhered to a carrier 
are characterized by both a magnitude and a direction. When holding the magnitude constant, 
detachment forces exert their maximum effect when they act in a direction directly opposite to 
the adhering force [8]. However, due to the short duration of time to which a dose is subjected 
to separation forces in a typical DPI, coupled to the random nature of the detachment forces, 
only a small fraction of the drug particles will be correctly aligned to experience a force having a 
favorable combination of magnitude and direction sufficient to detach them from the carrier 
particle surface.   
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Air classifier technology was developed as a particle de-aggregation principle to sustain 
the interaction between the dose and the flow stream.  A basic classifier is comprised of a  
cylindrical chamber, containing at least one tangential air inlet and a discharge outlet beginning 
at the center of one of the circular ends of the chamber [9]. Named for its ability to segregate, 
or classify, particles according to their size, it operates as a balance between centrifugal and 
drag forces.  The drag force is proportional to the first power of the particle diameter and 
dominates for fine particles, while proportional to the cube of the particle diameter, larger 
carrier particles will experience a greater centrifugal force. When the powder is carried into the 
classifier through the tangential inlet, the large carrier particles, subjected to strong centrifugal 
forces, will be confined to the edge of the chamber, repeatedly impacting against the inner wall. 
As smaller drug particles are detached from the carriers through either drag forces or inertial 
forces arising from the carrier collisions, they will be pulled into the center of the chamber, 
under the discharge outlet, and removed from the classifier. Aggregated drug particles are 
broken up through collisions with both carrier particles and the classifier wall; the geometry of 
the classifier can be modified to alter the cut-off diameter of particle exiting the chamber [9, 
57].      
While the major fraction of drug that will detach does so within the first half-second of 
inhalation, these are the particles that are subjected to the strongest removal forces, generally 
drug aggregates and large primary particles [21]. As the dose continues circumnavigating the 
classifier, a secondary population, primarily smaller drug particles located in higher sites on the 
carrier and less susceptible to removal forces, is further released; studies indicate that the 
amount of drug exiting the classifier over the time interval from 0.5 to 2 seconds following 
inhalation can exceed 50% of the amount released within the first half-second [58].  Moreover, 
low flow rates can be compensated by sustaining the detachment forces acting on the dose, and 
produce fine particle fractions comparable to higher flow rates. Examples of DPIs incorporating 
air classifiers as their de-agglomeration principle are provided by the TwincerTM and NovolizerTM  
[57, 59].  
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The TwincerTM is a single-dose device containing two air classifiers in parallel; a design 
that permits a large dose, up to 25 mg, for delivering antibiotics as treatment for cystic fibrosis 
[59]. Delivering the dose from a blister, the powder is entrained and divided between two 
separate channels, each feeding into a discreet classifier; two additional tangential air inlets per 
classifier provide the necessary turbulence to detach the drug from the carrier. That the carrier 
particles are retained within the classifier following actuation is of no consequence, as the 
inhaler is a low-cost device, formed from three layered, molded plastic plates, and is intended to 
be disposable following each use. In contrast, the NovolizerTM is a reservoir inhaler, and 
eliminating the deposition of drug and carrier within the classifier following inhalation becomes 
important [57].  To achieve this, the NovolizerTM employs an eight-sided classifier, where each 
opening is a tangential air inlet.  In addition, the classifier  walls are not isometric, consisting of 
four long sides to accelerate the carriers and four short sides to generate impactions, and 
distributed in an alternating pattern.  Using this arrangement the NovolizerTM can expel upwards 
of 95% of the dose from the device following each actuation.                     
1.21. VIBRATION INDUCED DISPERSION 
1.21.1. Capsule Vibrations 
Though not always explicit, inhalers that employ capsules to deliver a pre-metered dose 
rely heavily on mechanical vibrations to facilitate powder de-agglomeration.  An example of a 
DPI that induces rapid capsule oscillations is the HandihalerTM. When a patient inhales through 
this device, the airflow enters the DPI opposite the mouthpiece, passing through a short, narrow 
inlet tube and abruptly opening into a larger volume capsule chamber [60].  As the flow stream 
emerges from the narrower passage into the larger, the flow decelerates, causing the boundary 
layer to separate from the inner walls of the inhaler and re-attaching further upstream.  This 
produces an annular region in the interim where fluid does not flow downstream, instead 
recirculating as a turbulent eddy resulting in a low pressure area [49].  The Handihaler exploits 
this phenomenon to rapidly vibrate the capsule during inhalation; the flow stream entering the 
larger chamber pushing the capsule forward while the low pressure region pulls its back. The 
capsule chamber was designed to be ample enough to allow the capsule room to oscillate, but 
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sufficiently confined to prevent the capsule from tilting on its side and inadvertently occluding 
the inlet.  As shown in studies with the AerolizerTM, the rapid capsule vibrations, coupled with 
the shear forces produced from passing the powder through the narrow perforations in the 
capsule wall, provides an effective means of powder deaggregation [35]. 
1.21.2. Aeroelastic Vibrations  
An alternative form of vibration-induced dispersion is a passive DPI (US Patent No. 
11,713,180) that operates on the aerodynamic principle of 'flutter.'  When an aeroelastic object 
is placed within the path of a flow stream, it begins to oscillate, the energy of which in turn 
feeds further oscillations, rapidly intensifying the amplitude and frequency of its vibration.  
When a powdered dose is placed on an aeroelastic film, it is effectively aerosolized, requiring 
very low threshold flow rates to induce flutter in the film [61].              
1.21.3. Piezoelectric Driven Dispersion 
The piezoelectric effect was initially observed in 1880 by the Curie brothers, who 
noticed that anisotropic crystals, i.e. crystals absent a center of symmetry, emit an electrical 
signal when stressed.  Conversely, the application of an electrical signal produces mechanical 
deformation in the crystal; when this electrical stimulus is supplied in the form of an oscillating 
potential, rapid crystal vibrations are generated [62]. Piezoelectric polymers have long found 
wide application in numerous fields, including as components of nebulizers for pulmonary drug 
delivery, and have recently been introduced as a dispersion mechanism in dry powder inhalers.  
An example of the piezoelectric de-agglomeration principle is found in the Microdose 
inhaler (US Patent No. 5,687,710), where a drug-containing blister is brought into contact with a 
piezoelectric vibrator housed within the device. The DPI includes an air flow sensor that 
activates the piezoelectric element as the patient inhales, transferring mechanical energy to the 
blister and imparted into the dry powder formulation within to disperse the dose through the 
blister openings [63]. Additionally, the frequency at which the piezoelectric element operates is 
not arbitrary, but set to match the blister's resonance frequency.  Briefly explained, the acoustic 
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resonance of a system is its tendency to absorb more energy when oscillated at one of its own 
natural frequencies of vibration. By matching the frequency of the piezoelectric element to the 
resonance frequency of the blister, stronger oscillations can be generated without augmenting 
the effort required from the energy source.        
 An alternative application of the piezoelectric effect has been developed by Oriel 
Therapeutics, Inc. (US Patent No. 6,889,690), disclosing a multi-dose inhaler wherein the blisters 
containing the powder are comprised of a piezoelectric polymer material, incorporating the 
piezoelectric element into the blister itself.  During inhalation, an electrical stimulus is provided 
to the blister, prompting the piezoelectric substrate to oscillate rapidly, vibrating the blister and 
ejecting the dose into the flow stream.  Adjusting the shape of the blister can yield specific 
oscillation frequencies tailored to the flow characteristics of the formulation contained within; 
vibrating the blister to match the resonance frequency of the powder can optimize the 
dispersion potential [64].  Both of the above inhalers are active devices, requiring a self-
contained power source to stimulate piezoelectric element.   
1.22. ELECTRIC AND MAGNETIC FIELDS 
While less common, de-agglomeration principles capitalizing on the high charge-to-mass 
ratio of micronized powders are found in the patent literature. In one example (US Patent No. 
6,089,227), a DPI is comprised of two separate chambers, the barrier between them containing 
a rotating cylinder with a portion of its perimeter located in each chamber. One chamber is a 
powder reservoir, and the other is in fluid communication with an air inlet and outlet.  When an 
electric field is generated in the reservoir, the charged powder is attracted to the surface of the 
electrically neutral cylinder, which slowly rotates, exposing the adhered drug particles to a 
second electric field, opposite in polarity from the first, in the adjacent chamber.  This prompts 
the drug to detach from the dosing drum and flock to the electrode producing the field, 
although as this detachment is coordinated with inhalation, the particles are carried to the 
patient.  
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US Patent No. 6,328,033 also discloses an inhaler that utilizes an electric field, albeit an 
oscillating one.  In this device, the electric field is oscillated between the top and bottom of the 
powder-holding chamber, entraining the drug particles as they are rapidly drawn from one side 
to the other.  The electric field is maintained while the patient inhales through the device, and 
the flow passing through the chamber conveys the dose downstream. An additional 
embodiment of this design relies on a magnetic field for de-agglomeration, wherein the dry 
powder formulation is coated onto particles having a magnetic core. Upon actuation, a rapidly 
oscillating magnetic field is applied between the upper and lower sections of the dose package, 
causing the larger magnetic particles to rapidly vibrate, expelling the powder from their surfaces 
where the flow stream carries the dose to the patient.  The magnetic field is sustained 
throughout the duration of the inhalation maneuver, confining the magnetic particles within the 
device. 
1.23. DEVICE RESISTANCE AND FLOW RATE 
The role of resistance in DPIs, and the extent to which it influences device performance, 
is ambiguous.  The equation relating flow rate (Q), device resistance (R), and the pressure drop 
(∆P) across an inhaler was provided by Clark and Hollingsworth [65]:  
√      
For a given pressure drop, a higher flow rate will be generated through a lower 
resistance device. But how does device resistance translate into performance?  When increasing 
the resistance in a DPI, either the air inlet is narrowed, or there is a constriction along the flow 
path, usually at the point where the fluid stream encounters the dose.  As known from the flow 
continuity equation, reducing the cross sectional area increases the flow velocity, which in turn 
increases the kinetic energy carried by the flow stream; accordingly it seems intuitive that 
increased resistance would improve performance [49]. However, high resistance is not the only 
determinant of device performance.  A comparison between the high resistance PulvinalTM and 
the lower resistance TurbuhalerTM, both passive inhalers, demonstrated better dispersion 
performance in the latter DPI [66]. Equally important is the method in which the kinetic energy 
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from the flow rate is employed; in other words, the efficiency of the powder de-agglomeration 
principle.  However, the importance of device resistance is being diminished through the 
introduction of inhalers that no long rely solely on a brief, almost instantaneous interaction 
between the flow stream and powder (ACT, cyclones), and active DPIs providing external energy 
sources. 
Studies comparing low and high resistance passive inhalers generally conclude that 
while low resistance devices allow a much wider range of flow rates, the performance of high 
resistance inhalers exceeds that of its low resistance counterparts [67, 68].  However, high 
resistance devices show significant flow rate dependence, and the amount of delivered drug 
varies widely across the  spectrum of generated flow rates.  In contrast, low resistance devices 
provide a more consistent dose across a wider range of inspiratory efforts.  Additionally, a 
significant patient population, especially children and the elderly, have difficulty generating a 
sufficient flow rate through the higher resistance devices [69].           
Closely related to resistance, is the flow rate through the device.  While higher flow 
rates improve the kinetic energy levels imparted to the dose, increasing the flow rate through 
an inhaler does not improve performance ad infinitum.  As shown in studies with the Aerolizer 
there is a flow rate where the fine particle fraction is maximized and throat deposition is 
minimal; increasing the flow rate beyond this point hinders performance as a larger fraction of 
the dose will deposit in the throat and mouth [36].  Accordingly, while high flow streams are 
desirable when encountering the dose, they are counterproductive if the velocity is not 
dampened as it exits the inhaler.  One strategy to accomplish this is to widen the flow path in 
the mouthpiece, which significantly lowers the axial velocity of the flow stream as it exits the 
device, reducing throat and mouth deposition without comprising the turbulence levels [38].   
Alternatively, other DPIs employ a co-axial sheath of air produced by flow bypass channels to 
form a buffer that surrounds the aerosol as it exits the device (NovolizerTM), or incorporate 
baffles and curved paths to reduce flow velocity (SkyehalerTM), although particle deposition may 
become problematic in these designs.   
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1.24. MESHES AND SCREENS 
Ubiquitous to many commercial DPIs is a mesh, or screen, situated between the powder 
holding chamber and the inhaler exit, commonly tasked with performing the often overlooked, 
yet vital role of preventing the escape of the capsule, and capsule fragments, from the device 
during inhalation.  However, it is also noted that meshes are integral components of inhalers 
that do not employ capsules, but rather disperse powder from blisters packs or reservoirs.  The 
presence of the mesh can influence the flow field generated within an inhaler, both upstream 
and downstream of its location, and accordingly impact the overall performance of the device.   
A mesh can be thought of as a distributed resistance that can effect a change in the flow 
direction of a fluid stream, coupled with a reduction in pressure [70], and can act as both a 
suppressor and generator of turbulence.  In its role as a suppressor, the turbulence downstream 
of the mesh has been dampened in both scale and intensity subsequent to its passage through 
the mesh.  In this case, the aim is obtaining a spatially uniform flow to both avoid generating 
further turbulence, and to remove existing turbulence from the flow stream. Meshes can also 
serve to increase the turbulence downstream of their location up to 10% relative of the 
upstream value. In this case, the meshes are commonly coarse, with porosities exceeding 45% of 
the total area.   
Reports in the literature examining the influence of meshes on inhaler performance are 
at odds with each other, casting meshes in the role of both spectator and active participant in 
affecting device performance. A study investigating the influence of a mesh on carrier particle 
dispersion concluded that no benefit to overall performance (as measured by the FPFtotal) was 
obtained when powder was passed through a mesh, compared to the absence of the mesh [31].  
Any small improvement in particle deaggregation the mesh may have provided was offset by the 
drug retained on the mesh ( ≈ 5% of the nominal dose), resulting in no significant difference in 
performance. In contrast, Coates, et al., examining the effect of the grid inside the AerolizerTM 
DPI, concluded that the grid does significantly affect overall inhaler performance.  For these 
studies, dispersion performance of the AerolizerTM outfitted with three different grids (the 
original grid geometry and two grids of increasing porosity) was compared, showing that the 
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original Aerolizer grid yielded no significant differences in the fine particle fraction of the 
emitted dose.  This implies that the mesh had no effect on drug deaggregation, as noted in Voss 
and Finlay, but rather exerted its influence through reducing the number of impactions between 
the mouthpiece and the inhaler, as a significantly higher fraction of drug deposits inside the 
inhaler mouthpiece with increasing grid voidage.  In the AerolizerTM, the grid serves as a 
turbulence suppressor, straightening the flow by reducing the level of tangential flow generated 
in the device [34].  As the turbulence is suppressed downstream of the powder dispersion 
chamber, overall performance is unaffected. In reconciling these opposing views, the length of 
the inhaler downstream of the mesh becomes important, and the dispersion apparatus used by 
Voss and Finlay was not a commercial inhaler, but an experimental set up with an extended flow 
path downstream of the grid.  In this case, the laminar flow created by the mesh may have 
degenerated into turbulence flow prior to exiting the device.        
1.25. SUMMARY 
A diverse array of technologies have been designed to address the challenges of 
effectively aerosolizing a dry powder formulation.  Recent years have seen an increase in the 
number of active DPIs in development, although passive devices, with their low costs and simple 
designs, will undoubtedly remain an active area of inhaler research, as they are especially 
attractive as disposable platforms for dry powder vaccine delivery. However, while much effort 
has been devoted to improving the powder dispersion performance of inhalers, the ability of the 
device to optimize inhalation therapy must be placed into perspective, as no matter how 
cleverly designed and masterfully crafted an inhaler may be, it cannot overcome patient misuse 
or a poorly prepared formulation.  Future developments in DPIs will benefit greatly from parallel 
advancements in patient education and powder formulation technology.  It is noted that the 
devices presented here were generally those that have been commercialized, which represent a 
small fraction of inhalers encountered in the patent literature.   
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1.26. CONCLUSION 
Despite the myriad designs that have been developed to improve device performance 
overall delivery remains low, as typically less than 30% of the total dose is delivered to the deep 
lung (for reported performance values, see Appendix).  This is attributed to both the formulation 
and the inhaler, and thus accordingly, improving the performance of both will be the objective 
of this research. 
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Figure 1.1.  Influence of Carrier Particle Size on Theoretical van der Waals Forces   
Variation in theoretical van der Waals forces as carrier particle size is increased 
and the drug particle diameter is held constant.         
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CHAPTER 2 
2. Research Objectives 
The main objective of this Ph.D. thesis was to understand the mechanisms of drug 
detachment from carrier particles in binary DPI formulations, which generally deliver less than 
30% of the dose to the deep lung (Appendix).  As highlighted in the previous chapter, while the 
influence that carrier particle physical properties impart to the aerosol performance of a 
formulation has been an extensively examined topic, much of the previous research has focused 
primarily on similar particle diameters (typically < 100 µm) and morphologies (α-lactose 
monohydrate).  Accordingly, the theories that were developed to explain and predict 
performance of DPI formulations were based upon observations obtained from limited data 
sets, and much of the carrier particle landscape, in terms of size and surface roughness, has 
remained unexplored.    
We proposed that given the underlying physical equations governing momentum and 
collision forces, large carrier particles may prove more beneficial to performance than 
previously believed.  Accordingly, the specific aims of this thesis were to: 
1. Provide a comprehensive study evaluating the influence of carrier particle diameter 
and morphology on the aerosol performance of binary DPI formulations. 
 
2. Examine the mechanism by which the surface roughness of the carrier particle 
population affects performance as a function of the diameter of the carrier particle. 
 
 
3. Investigate the influence that the diameter and surface roughness of the carrier 
particle population impart to the performance of a dry powder inhaler.  Specifically, 
this will evaluate the performance from different inhalers as a function of the size 
and surface roughness of the carrier particle population.  
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4. The final study will assess the influence of the volumetric flow rate through a DPI as 
a function of the diameter and surface roughness of the carrier particle population.   
These topics will be addressed in Chapters 3 through 6, and the experimental outlines of 
these studies are shown in Tables 1 – 4.  The observations gleaned from these experiments will 
then guide the development of a novel mechanism of dry powder dispersion, which will be the 
focus of Chapters 7 through 10.   
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Table 2.1. Chapter 3: Comprehensive Study of Lactose Carrier Particles in Binary Blends 
Carrier Particle  
Material 
 
Carrier Particle  
Size Fractions  
(µm) 
 
API Concentration 
Volumetric 
Flow Rate  
( L min-1 ) 
DPI 
      
α-Lactose Monohydrate < 20 Salbutamol 1 %  (w/w) 60 Aerolizer® 
Anhydrous Lactose 20 – 32     
Spray Dried Lactose 32 – 45     
Granulated Lactose 45 – 63     
 63 – 75     
 75 - 90     
 90 – 106     
 106 – 125     
 125 - 150     
 150 – 180     
 180 – 212     
 212 – 250     
 250 - 300     
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Table 2.2. Chapter 4: Influence of Carrier Particle Diameter and Surface Roughness on Aerosol 
Performance 
Carrier Particle 
 Material 
 
Carrier Particle  
Size Fractions  
(µm) 
 
API Concentration 
Volumetric 
Flow Rate  
( L min-1 ) 
DPI 
      
Anhydrous Lactose < 32 Budesonide 2 %  (w/w) 60 Aerolizer® 
Granulated Lactose 32 – 45     
 45 – 63     
 63 – 75     
 75 - 90     
 90 – 125     
 125 - 150     
 150 – 180     
 180 – 212     
 212 – 250     
 250 - 300     
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Table 2.3. Chapter 5: Influence of DPI Device on Aerosol Performance as a Function of Carrier 
Particle Diameter and Surface Roughness 
Carrier Particle  
Material 
 
Carrier Particle  
Size Fractions  
(µm) 
 
API Concentration 
Volumetric 
Flow Rate  
( L min-1 ) 
DPI 
      
Anhydrous Lactose < 32 Budesonide 2 %  (w/w) 60 Aerolizer® 
Granulated Lactose 32 – 45    Handihaler® 
 45 – 63     
 63 – 75     
 75 - 90     
 90 – 125     
 125 - 150     
 150 – 180     
 180 – 212     
 212 – 250     
 250 - 300     
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Table 2.4. Chapter 6:  Influence of Flow Rate on Aerosol Performance as a Function of Carrier 
Particle Diameter and Surface Roughness 
 
 
 
 
 
  
Carrier Particle 
Material 
 
Carrier Particle 
Size Fractions 
(µm) 
 
API Concentration 
Volumetric 
Flow Rate 
( L min-1 ) 
DPI 
      
α-Lactose Monohydrate 45 – 63 
Salbutamol 
Sulphate 
1 %  (w/w) 30 Aerolizer® 
Granulated Lactose 125 - 150 Budesonide  60  
 250 - 300   90  
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CHAPTER 3 
3. Comprehensive Study on the Influence of Size and Morphology of 
Lactose Carrier Particles on the Aerosol Performance of Binary DPI 
Formulations 
3.1. INTRODUCTION 
Dry powder formulations for pulmonary delivery are generally binary blends, comprised 
of micronized drug particles with aerodynamic diameters between 1 – 5 µm and coarse, inert 
carrier particles that comprise the bulk ( > 98% (w/w)) of the formulation.  The carrier particles 
assist in powder entrainment and fluidization during inhalation, as the cohesive forces between 
micronized drug particles are too strong to allow adequate dispersion. Additionally, the carrier 
particles facilitate dose metering, as typically 10 – 200 mcg of drug are required per dose, and 
such small quantities are difficult to measure accurately and reproducibly.  However, while 
carrier particles are beneficial to the performance of dry powder systems, detachment of drug 
particles from the surface of the carriers remains problematic, and drug that remains adhered to 
the coarse carriers will deposit in the throat and upper airways, exerting no therapeutic effect 
and inducing unwanted side effects.  Consequently, commercially available dry powder inhalers 
are inefficient, delivering only approximately 20 – 30% of the total dose to its intended target of 
the deep lung.     
The understanding that a judicious selection of both drug and carrier particle properties 
are crucial parameters in optimizing performance is universally acknowledged.  Production of a 
stable and homogeneous powder blend requires the interaction between drug and carrier 
particles be balanced, with forces strong enough such that drug preferentially adheres to the 
carrier during mixing, yet sufficiently tenuous to facilitate re-dispersion of drug particles during 
inhalation. Studies focused on the physical properties of carriers have examined the particle 
size, size distribution, morphology, surface roughness, surface area, and surface energy of 
carrier particle populations [1-11]. The influence that the physical properties of the carrier 
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particles can impart to the aerosol performance of the formulation has been well documented 
in the literature, and a general consensus has been reached in the field that increasing the 
diameter of the carrier particle population hinders drug dispersion performance.   
As discussed in chapter 1, to account for this observation multiple explanations have 
been proposed in the literature, and the previous two decades have witness extensive research 
on the various physicochemical properties of lactose carrier particles that most influence 
aerosol performance. However, when one examines these studies, it quickly becomes apparent 
that while the conclusions are intended to be predictive for a wide range of carrier particle 
physical properties, the sample size upon which they are based is generally limited, consisting of 
only a few experimental formulations.   
Specifically, studies that focus on examining the influence of carrier particle diameter on 
aerosol performance have tended to employ only a single lactose grade, specifically α-lactose 
monohydrate, characterized by relatively flat surfaces and a morphology commonly described 
as a ‘tomahawk’ shape.  Conversely, studies that focus on evaluating the influence of surface 
roughness have employed only a single carrier particle size fraction; typically well below 100 µm.  
From these relatively small sample sizes, theories predicting the performance of a wide range of 
carrier particle sizes and surface roughness levels have been developed, thus relying extensively 
on interpolation and extrapolation to account for the broad swathes of terra incognita that 
remain unexplored on the carrier particle landscape.     
Specific Aim 
Accordingly, the aim of this chapter is to fill in the gaps from the literature by 
performing a comprehensive study using 4 lactose grades fractionated into narrow and 
contiguous particle diameter populations up to 300 µm.  In addition to evaluating the aerosol 
performance of the resulting DPI formulations, the physicochemical parameters of the carrier 
particle populations that have been previously cited as being important to performance were 
measured to examine their influence on dispersion from the lactose carriers. These parameters 
include the particle size distribution, concentration of lactose fines, specific surface areas, and 
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surface energies of the carrier particles, and also the blend uniformities of the resulting 
formulations.     
3.2. EXPERIMENTAL 
3.2.1. Materials 
Salbutamol was purchased in bulk (Jinhuo Chemical Company, China) and micronized 
with a high energy jet-mill with pusher and grinding pressures of 80 and 110 PSI, respectively 
(Aljet; Fluid Energy Processing and Equipment Co., PA, USA).  500 g samples of lactose 
monohydrate (Pharmatose® 80 Mesh), anhydrous lactose (SuperTab® 21AN), spray-dried lactose 
(SuperTab® 14SD), and granulated lactose (SuperTab® 30GR) were provided by DMV-Fonterra 
(New Zealand).  Size-3 HPMC capsules (VCaps®) were gifted by Capsugel (NJ, USA). Analytical 
grade ethanol was purchased from Sigma (Sigma-Aldrich, Corp., MO, USA).  
3.2.2. Fractionation of Carrier Particle Populations 
Samples of each lactose batch were fractionated on an Autosiever® vibrating sieve 
shaker (Gilson Company Inc., OH, USA) with a sieve intensity, or amplitude, setting of 40 for 5 
minutes through the following sieves: 300 µm, 250 µm, 212 µm, 180 µm, 150 µm, 125 µm, 106 
µm, 90 µm, 75 µm, 63 µm, 45 µm, 32 µm, and 20 µm. Following the initial fractionation, the 
lactose carriers were sieved two additional times, at 3-minute sieving intervals, to obtain narrow 
particle size distributions.  In total, lactose was obtained to produce binary blends of 13 size 
fractions each for α-lactose monohydrate, anhydrous lactose, spray-dried lactose and 
granulated lactose for a total of 52 formulations. 
3.2.3. Preparation of Binary Blends 
Approximately 5 mg of salbutamol were mixed with 495 mg of the fractionated lactose 
populations via geometric dilution to obtain 500 mg of a 1% binary blend.   The formulations 
were prepared in 30 mL glass vials and blended with a Turbula® orbital mixer (Glen Mills, NJ, 
USA) for 40 minutes at 46 RPM.  Following blending, the formulations were stored in a 
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desiccator at least 5 days prior to use.  The drug content uniformity of the resulting blends was 
assessed by randomly selecting eight 20-mg samples from each mixture, and analyzing the drug 
content in the powder.  The blend uniformity for each formulation is provided as the coefficient 
of variation; the percent ratio of the standard deviation to the mean for N = 8 samples. 
3.2.4. Physical Characterization of the Powders 
The size distribution and surface roughness of the lactose carrier particle populations 
were visually examined by scanning electron microscopy (SEM; Supra 40VP, Zeiss, Germany). 
Prior to SEM, approximately 20 nm of a platinum::palladium (80::20) mixture was deposited 
onto the particles via sputter coating.  
The drug and carrier particles were sized via laser diffraction using a Sympatec HELOS 
(Sympatec GmbH, Germany) apparatus equipped with a 6-mL cuvette dispersing system.  
Mineral oil was used as the dispersing fluid, which included 1% Span 85 to aid in particle de-
aggregation.  The powders were suspended in the mineral oil and, if physically stable, sonicated 
for 60 seconds to disrupt aggregates.  Measurements were collected following elimination of all 
visible air bubbles.  The ‘forced stability’ option was used to ignore the signal from errant dust 
or residual air bubbles.  The span of the carrier particle size was obtained according to the 
following formula: 
      
   
       
 
To evaluate the concentration of fine lactose particles present in each carrier particle 
population, the percent volume of lactose particles below 10 µm in each of the fractionated 
lactose samples was also measured by laser diffraction.   
The specific surface area of the lactose carrier particle populations was evaluated via 
nitrogen adsorption with a single-point BET method with a Monosorb® surface area analyzer 
(Quantrachrome Instruments; FL, USA).  Samples were outgassed under nitrogen at 40 °C for 24 
hours prior to each measurement.   
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3.2.5. Inverse Gas Chromatography (IGC) 
Inverse Gas Chromatography (IGC) was employed to measure the surface energy of 
three different size fractions of each lactose type.  A Hewlett Packard (now Agilent) 5890 Series 
II gas chromatograph with a flame ionization detector (FID) was converted to IGC by removing 
the internals of the oven and replacing them with glass tubing (ID 5 mm).  A piece of glass tubing 
(L = 8 in) was packed with between 1-2 g of powder, and plugged with silanized glass wool on 
either end.  All glass tubing pieces were silanized by soaking in a 0.5% (v/v) dichloromethyl 
silane solution in toluene, rinsing in toluene and ethanol.  Glass tubing was stored in a desiccator 
prior to use.  
To determine the dispersive component of the powder surface energy, a series of 
injections of the normal alkanes from n-hexane to n-decane were used.  THF, chloroform, 
acetone, ethanol, ethyl ether, and ethyl acetate were employed as polar probes to determine 
the specific component of the surface energy.  All injections were performed at infinite dilution.  
The original enthalpy method was used instead of assuming constant entropy (which, 
experimentally, was shown to not occur); thus, each powder was subjected to three 
temperatures: 60 deg C, 48 deg C, and 36 deg C.  Lower temperatures were not possible to 
control with the built-in oven of the IGC. 
3.2.6. In vitro Aerosol Performance 
20 (± 1) mg of powder were loaded into size-3 HPMC capsules and dispersed through an 
Aerolizer® (Plastiape S.p.A., Italy) DPI  into a next generation cascade impactor (MSP 
Corporation, MN, USA) at a volumetric flow rate of 60 L min-1.  HPMC capsules were selected 
instead of traditional gelatin capsules as the latter have a tendency to fracture when their walls 
are perforated by the piercing mechanism of the inhaler.  Accordingly, when the capsule 
fractures the size of the perforations are altered, and it has been demonstrated that the size of 
the perforations can alter performance through the Aerolizer.  HPMC capsules perforated 
reproducibly, such that deviations in aerosol performance were not attributed to variations in 
the capsule.  Actuation time was set to 4 seconds to allow 4 L of air to pass through the device.  
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To inhibit particle re-entrainment upon deposition, the NGI stages were coated with a 2% (v/v) 
solution of silicon oil in hexane and allowed to air dry prior to each impaction.  Before each 
actuation 15 mL of EtOH were added to the pre-separator and collected following powder 
dispersion from each capsule.   Drug depositing in the capsule, inhaler, mouthpiece adaptor, and 
induction port were collected by rinsing each component with 10 mL of EtOH, while the NGI 
stages were each rinsed with 5 mL.   
Drug content was assessed using UV-VIS absorption spectroscopy at 230 nm.  The 
emitted fraction was calculated as the ratio of the drug mass depositing in the mouthpiece, 
induction port, pre-separator, and impactor stages over the cumulative mass of drug collected 
following actuation (total drug deposited in the capsule, inhaler, mouthpiece, induction port, 
pre-separator and stages).  The fine particle fraction (FPF) of each dose was the ratio of the drug 
mass depositing on stages 3 through 8 (corresponding to an aerodynamic diameter less than 
4.46 µm) of the impactor over the emitted dose [12].  The respirable fraction (RF) was the ratio 
of the drug mass depositing on stages 3 – 8 over the entire dose recovered following each 
actuation.      
3.2.7. Statistics 
Statistical significance between performance values was determined with one-way 
ANOVA with Post Hoc tests between groups according to the Bonferroni method    (P < 0.05). 
3.3. RESULTS AND DISCUSSION 
3.3.1. Physical Characterization of Lactose Particles 
From the SEM images depicted in Figure 3.1 - Figure 3.4, it is noted that the four lactose 
grades possess markedly diverse morphologies and surface characteristics.  Lactose 
monohydrate and anhydrous lactose are characterized by relatively low surface roughness.  
Spray dried lactose and granulated lactose exhibit extensive surface roughness with increasing 
carrier particle size; it is noted that the surface asperities are more pronounced for the 
granulated carrier particles, specifically as diameter is increased.    
 57 
Table 3.1 lists the measured specific surface areas (SSA).  For both the lactose 
monohydrate and anhydrous populations, SSA values generally exhibited a progressive decline 
with increasing carrier particle size, diminishing from 0.98 m2/g to 0.18 m2/g for the former, and 
0.79 to 0.31 m2/g for the latter between the < 20 µm and 250 – 300 µm particle size fractions. It 
is noted that for anhydrous carriers the drop in surface area was not as steep, nor continuous, 
by comparison with lactose monohydrate.  Indeed, a small increase in SSA was observed for 
larger carrier particle size ranges relative to the preceding size fraction.  Additionally, there was 
a marked disparity in SSA values at the largest size fractions for anhydrous lactose when 
compared to lactose monohydrate, suggesting that larger carrier particles of anhydrous lactose 
possess some degree of surface roughness.   
SSA values from the spray dried lactose were erratic, as overall performance between 
the 20 – 32 µm and 250 – 300 µm size fractions declined from 0.42 m2/g down to 0.34 m2/g.  
However, in between these size ranges the specific surface area fluctuated between 0.31 m2/g 
and 0.43 m2/g, indicating that small spray dried particles possessed relatively low surface areas 
(as would be expected based on their spherical morphology), and large carrier particles were 
characterized by extensive surface roughness.  The SSA values from granulated particles initially 
diminished between the 20 – 32 µm and 75 – 90 µm carrier particle populations.  However, 
following this size range the SSA of the particles increased up to 0.43 m2/g for the 250 – 300 µm 
size fraction, indicating that large granulated particles possess extensive surface roughness, with 
values generally comparable to those of the spray dried carriers.   
3.3.2. Fine Lactose Concentration 
Of the four lactose grades, the respective size fractions of α-lactose monohydrate 
generally contained the highest concentration of fine lactose particles (diameters < 10 µm) 
(Tables 3.2 – 3.5). Moreover, in contrast to the other lactose grades, only α-lactose 
monohydrate populations possessed a noticeable concentration of fines for the larger diameter 
size fractions.  As the carrier particle populations were triple-sieved, fines that remained were 
likely very strongly adhered to the surface of the large carriers.  This may be indicative of the 
high surface energy of the lactose monohydrate carriers relative to the other lactose grades, as 
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the strong attachment between the fines and carriers could be due to the ‘active’ sites on the 
carrier surface.          
Extensive research has repeatedly demonstrated that formulations with higher 
concentrations of fine particles typically outperform formulations possessing a lower amount of 
lactose fines [13-15]. To explain this observation two principle theories have been presented in 
the literature.  The ‘active site’ theory proposes that fine excipient particles will predominately 
adhere to regions on the surface of the lactose carrier particles possessing the highest energies, 
or active sites, thereby promoting strong interparticle interactions [14].  Accordingly, if the high 
energy sites on the coarse carriers are already occupied by excipient fines, when the micronized 
drug particles are blended with the carrier population the API will then occupy lower energy 
sites, facilitating detachment from the carriers during inhalation.  An alternate theory proposes 
that during blending the fine excipient particles and micronized drug can form loose aggregates, 
termed ‘multiplets,’ that promote detachment from the carrier surface due to their larger 
diameter, and thus surface area, relative to individual drug particles [7, 13, 16].  The greater 
surface area increases the force exerted on the multiplets by the flow stream, allowing them to 
be more readily liberated from the carrier surface compared to primary API particles.  The 
multiplets formed between the adhesive forces of the drug and excipient are predicted to be 
less stable than aggregates comprised solely of drug particles and held together via cohesive 
interactions. 
Accordingly, from the previous theories it would be expected that lactose monohydrate 
carriers, specifically the smaller size fractions possessing extensive lactose fines concentrations, 
would produce relatively high aerosol performance due to passivation of active sites on the 
carrier particles or the formation of readily detached multiplets.  It is noted that anhydrous, 
spray dried and granulated lactose populations exhibited some degree of lactose fines, though 
for these three lactose grades only smaller size fractions possessed a measurable amount.  
Studies examining the potential of anhydrous lactose to serve as carrier particles in binary DPI 
formulations have noted a relatively high concentration of fine particles following jet sieving, 
which was attributed to the relatively brittle nature of this lactose grade [17].  For spray-dried 
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and granulated carriers, fine lactose particles were not observed in the SEM images, in contrast 
to the lactose monohydrate and the anhydrous lactose grades.  However, it is likely that these 
fines were primarily located within the surface asperities, where multiple contact points 
between the fine particle and the coarse carrier would induce strong adhesive interactions.               
3.3.3. Blend Uniformity 
Production of a stable and homogeneous binary DPI formulation requires the adhesive 
interaction between the drug and carrier be sufficiently robust such that the drug particles 
preferentially bind to the carrier during blending, and then remain adhered to the carrier from 
its production, through transit, and until used by the patient.  However, good aerosol 
performance dictates that the drug-carrier interaction be sufficiently tenuous to permit drug 
detachment and re-dispersion during inhalation [18].  The inability to satisfactorily balance 
these competing conditions yields the low drug delivery efficiency traditionally associated with 
binary DPI blends [2].  Indeed, studies evaluating blend stability and uniformity have noted an 
inverse relationship with aerosol performance, where binary blends demonstrating excellent 
drug content homogeneity displayed significantly reduced aerosol performance relative to 
counterparts with comparatively lower blend uniformity [19].   
Governing the relative strength of these adhesive interactions are the physicochemical 
properties of the carrier particle population, including carrier particle size, size distribution, 
mass, surface roughness, available surface area, and surface energy.  In addition to the 
physicochemical properties of the carrier particle population, content uniformity may also be 
influenced by the API in the blend [18, 20, 21].  Furthermore, the drug-carrier interactions may 
be modified by the drug concentration (% w/w) and blending parameters, including mixing 
times, blending speeds, and batch size [9, 22].      
As the surface area available for drug binding is diminished, the potential for drug-drug 
interactions increases, promoting the formation of stable drug agglomerates that may be 
resistant to dispersion during inhalation. Accordingly, it was not unexpected that the largest 
carrier size fraction of lactose monohydrate would exhibit low blend uniformity (%CV = 9.3%), as 
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it possessed the lowest SSA values of all the carrier particle populations.  However, it was 
surprising that the smallest size fractions of lactose monohydrate would also exhibit poor blend 
uniformity.  Indeed, the < 20 µm lactose monohydrate fraction produced the least uniform 
blend despite possessing the greatest overall surface area available for drug binding.  
To explain this apparent contradiction, it is necessary to examine the theories describing 
the blending of binary formulations.  As noted by de Boer, there are two types of drug 
agglomerates encountered during blending; the ‘natural’ agglomerates and the ‘blending’ 
agglomerates [5]. The natural agglomerates are initially present in the drug powder when it is 
added to the formulation, and these must be broken down via abrasion by the coarse carriers 
during blending.  This abrasion process requires that the carrier particles be sufficiently heavier 
than the drug particles, otherwise the contact between drug and carrier will be insufficient to 
disrupt these natural agglomerates.   
Conversely, blending agglomerates are formed during mixing due to repeated and 
extensive contact between drug particles. Blending agglomerates would be expected to arise 
when insufficient carrier particle surface area is available, thus inducing extensive drug-drug 
interactions.  It is expected that the formation of agglomerates would be especially problematic 
when using a cohesive drug such as budesonide.  Accordingly, it is speculated that despite its 
high surface area, the < 20 µm fraction possesses insufficient mass and surface roughness to 
disrupt drug agglomerates, resulting in the observed poor blend uniformity (Table 3.6). Of the 
four lactose grades, anhydrous carriers produced the most consistently uniform blends, with 
coefficients of variation < 5% for nearly all size fractions and indeed, typically below 2%.   
3.3.4. Surface Energies of the Carrier Particles 
The values of the dispersive component of the surface area of each lactose sample was 
plotted versus the temperature, and the slope of each of these plots was analyzed [23].  There 
was a general trend with the slope; a more negative slope was indicative of a formulation which 
performed better (higher RF) for the size fractions 32 - 45 μm and 106 - 125 μm.  This trend, 
however, broke down for the 250 - 300 μm size fraction.  The relative acid and base constants, 
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Ka and Kb, yielded no discernable trend. Ultimately, given the relatively large amount of sample 
required per run, following sieving there was insufficient lactose from many of the carrier 
particle populations to permit analysis of replicates during IGC testing.  Accordingly, while it has 
been previously noted in the literature that surface energy measurements of the carrier particle 
populations may be predictive of aerosol performance, in the present study no direct 
relationship between this parameter and drug dispersion was observed.   
3.3.5. In Vitro Aerosol Performance 
Performance values from the DPI formulations dispersed at 60 L min-1 are presented in 
Figure 3.5.  All four lactose grades displayed unique performance profiles as would be expected 
considering their diverse physicochemical properties.  Of the four carrier grades, α-lactose 
monohydrate exhibited a performance trend most consist with that predicted from the 
literature, as increasing carrier particle diameters progressively diminished overall performance, 
with RF values declining from 48% for < 20 µm to 21% for the largest carrier population. 
Similarly, anhydrous lactose exhibited its highest RF value from the smallest size fraction, with 
performance then declining sharply from 40% to approximately half this level (22%) for the 45 – 
63 µm carriers.  However, following the 45 – 63 µm formulation, performance values exhibited a 
slight increase and plateaued between 25 – 30% for the remaining carrier size fractions.  Thus, in 
contrast to the α-lactose monohydrate formulations, performance did not progressively decline 
with increasing carrier size.   
As with the previous two lactose grades, the smallest size fraction produced the highest 
dispersion performance for spray dried carriers.  This was followed by a sharp decline as the 
respirable fraction diminished from 44% at the < 20 µm size fraction to 42%, 34%, 26%, and 17% 
for successive carrier diameters. Performance continued to diminish for the 75 – 90 µm carriers, 
as RF declined to a low of 11%.  However, following this size fraction a significant improvement 
was observed, and in contrast to anhydrous lactose, deposition performance doubled as carrier 
particle diameter increased, reaching 24% at 125 – 150 µm, and remaining above 20% up 
through the 250 – 300 µm size range.         
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Granulated lactose also exhibited a performance profile that deviated markedly from 
that of α-lactose monohydrate. In contrast to the other lactose grades, the highest RF values 
were not produced by the < 20 µm formulation, as performance statistically similar to the 
smallest carrier population was observed for all size ranges following the 75 – 90 µm carrier 
population.  However, this is not because the granulated carriers failed to exhibit a performance 
decline.  To the contrary, RF significantly declined immediately following the < 20 µm blend, as 
performance dropped to 26% for the 20 – 32 µm carriers.  However, RF values proceeded to 
increase slightly, fluctuating between 28 – 33%, and then exhibited a significant improvement to 
37% for the 90 – 106 µm size range, remaining above 33% through the largest size fraction.   
It was not unexpected that α-lactose monohydrate and anhydrous lactose would 
produce similar performance trends given their morphological similarities.  While α-lactose 
monohydrate carriers have been extensively examined in the literature, there are only a few 
published studies for anhydrous carriers, despite their use in the commercial Asmanex® 
formulation delivered via the Twisthaler®[24].  One such study examined the performance of 
anhydrous and α-lactose monohydrate carrier particle populations fractionated with an air-jet 
sieve to obtain size fractions between 63 - 90 µm, and it was speculated that the improved 
performance observed from the anhydrous carriers may be due to the higher concentration of 
fine lactose particles for this grade relative to lactose monohydrate [17].  The authors attributed 
this to the increased friability of anhydrous lactose, which induced extensive fragmentation 
during air-jet sieving.  By comparison, in the present study the carrier particles were 
fractionated in triplicate, and via a milder process than air-jet sieving, to obtain narrow size 
distributions and remove as much of the lactose fines from the coarse carrier populations as 
possible.  Accordingly, anhydrous lactose did not possess a markedly higher concentration of 
fines, as noted from the particle sizing data. Anhydrous lactose carriers displayed performance 
comparable to α-lactose monohydrate beginning from the 106 – 125 µm size fraction, with the 
latter grade significantly outperforming the former for all preceding sizes.  However, at the 250 
– 300 µm fraction a significantly higher RF value was observed from the anhydrous carrier 
formulations, as it did not exhibit the progressive decline in performance seen with α-lactose 
monohydrate.  Previous studies in our lab employing anhydrous carriers to disperse budesonide 
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from the Aerolizer at 60 L min-1 also noted a similar plateau as performance (again measured by 
RF) declined significantly from 15% (45 – 63 µm) to 10% for the following size fraction (63 – 75 
µm), and generally remained between 8% - 10% for the larger diameter carrier populations [25].    
As with anhydrous carrier particles, reported studies with spray dried and granulated 
lactose are sparse.  One notable study that examined both of these lactose grades using sieved 
size fraction of 63 – 90 µm concluded that granulated lactose exhibited the worst overall 
performance due to its extensive surface roughness, which would enhance the adhesive 
interaction with micronized drug particles by providing multiple contact points relative to 
smoother surfaces [3].  In the present study, it is noted that the smallest granulated particles did 
indeed produce performance significantly lower than the other lactose carriers, however 
performance soon improved from the granulated carriers such that by the 75 – 90 µm size 
fraction, RF values were no longer significantly lower compared to the other grades.   
Overall, the highest RF value was produced by α-lactose monohydrate, specifically the < 
20 µm diameter size fraction, with 48% of the recovered dose depositing on the lower stages of 
the NGI.  As was noted earlier, this size fraction corresponded to both the formulation with the 
highest surface area, and the greatest concentration of fine lactose particles.  Additionally, this 
lactose grade exhibited the poorest blend uniformity, which has been speculated to be a 
predictor of good dispersion performance.  Accordingly, it is noted that this particular size 
fraction conformed to essentially every theory developed to predict carrier particle 
performance.  Overall, α-lactose monohydrate carrier particles matched well with the predicted 
theories, as performance progressively declined with increasing carrier particle diameter.   
However, when the experimental parameters were broadened to include lactose grades 
and size ranges that have not been as extensively studied as α-lactose monohydrate, these 
theories are no longer applicable.  This is especially true for large carrier particle size fractions 
possessing extensive surface roughness.  Accordingly, while trends matching well with the 
literature were observed for certain carrier particle subpopulations, there did not appear to be a 
direct link between the examined physicochemical properties and aerosol performance across 
all tested particle populations.      
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3.4. CONCLUSION 
In this chapter a comprehensive study was undertaken to evaluate the in vitro aerosol 
performance of binary DPI formulations with carrier particle populations derived from four 
lactose grades fractionated into 13 narrow particle size ranges.  The results from this study 
indicate that for a given particle size fraction, the physicochemical properties and aerosol 
performance of lactose carriers may vary considerably, deviating from the predicted trend that 
smaller carrier particle diameters generally outperform their larger diameter counterparts.  
Indeed, this trend was only observed in two of the four lactose grades examined, as the other 
two grades did not exhibit a progressive decline in performance.  Specifically, for lactose grades 
with relatively low surface roughness (α-lactose monohydrate and anhydrous lactose) the 
results generally followed the predicted trend that performance diminishes as the diameter of 
the carrier particle population is increased.  However, for lactose grades possessing extensive 
surface roughness, in vitro deposition deviated considerably from the predicted trend, especially 
for granulated carriers, as the performance of the largest fractions was comparable to the 
smallest carrier particle size fraction.   
The results of this study imply that large carrier particles possessing extensive surface 
roughness may potentially aid dispersion performance, though at present the mechanism by 
which this occurs remains unknown. Accordingly, it will be the focus of the following chapter to 
explore this mechanism in greater detail.       
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Figure 3.1.  SEM Images of α-lactose monohydrate. 
Scale bars denote 200 µm 
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Figure 3.2.  SEM Images of anhydrous lactose. 
Scale bars denote 200 µm 
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Figure 3.3.  SEM Images of spray dried lactose. 
Scale bars denote 200 µm 
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Figure 3.4.  SEM Images of granulated lactose. 
Scale bars denote 200 µm 
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Figure 3.5.  In vitro Aerosol Performance from the Fractionated Lactose Carrier 
Particle Populations 
Aerosol performance was evaluated at 60 L min-1.  Values are given as mean (± stdev) 
for N = 3 replicates.       
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Table 3.1. Measured Specific Surface Areas of Fractionated Lactose Carrier Particles 
Sieve Fraction 
(µm) 
Specific Surface Area (m2/g)  
LMH AN SD GR  
< 20 0.98 0.79 --- ----  
20 – 32 0.63 0.54 0.42 0.88  
32 – 45 0.57 0.43 0.31 0.63  
45 – 63 0.39 0.42 0.37 0.52  
63 – 75 0.39 0.34 0.32 0.36  
75 – 90 0.35 0.34 0.31 0.34  
90 – 106 0.29 0.32 0.37 0.35  
106 – 125 0.27 0.29 0.31 0.37  
125 – 150 0.25 0.32 0.40 0.37  
150 – 180 0.24 0.30 0.40 0.39  
180 – 212 0.20 0.28 0.43 0.41  
212 – 250 0.19 0.26 0.39 0.41  
250 – 300 0.18 0.31 0.34 0.43  
 
Specific surface areas of α-lactose monohydrate (LMH), anhydrous lactose (AN), spray dried 
lactose (SD) and granulated lactose (GR) carrier particle populations.  It noted that for SD and GR 
carrier populations < 20 µm, there was insufficient sample recovered following sieving to both 
prepare the formulations and measure the specific surface area in triplicate.   
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Table 3.2. Particle Sizing Data of Fractionated α-Lactose Monohydrate Carrier Particle 
Populations 
 
  
Carrier Sieve 
Fraction                
(µm) 
α-Lactose Monohydrate  
d(10) d(50) d(90) Span % Fines  
< 20 4.3   (0.4) 18.2   (0.8) 33.5  (1.8) 1.6 25.8  (2.0)  
20 – 32 16.1  (0.2) 31.2  (0.2) 44.3  (0.8) 1.1 14.1 (0.6)  
32 – 45 30.6   (0.7) 43.6   (0.4) 63.6  (1.6) 1.2 9.8  (0.5)  
45 – 63 40.8   (1.5) 65.3   (1.5) 90.9  (4.6) 0.8 5.0   (0.3)  
63 – 75 54.9   (2.2) 85.5   (1.7) 122.3  (3.8) 0.8 5.0   (1.4)  
75 – 90 61.1  (2.7) 94.8  (1.9) 128.7  (5.5) 1.2 3.5   (0.1)  
90 – 106 84.0    (1.9) 128.3   (2.4) 182.2    (9.4) 0.8 3.1   (0.3)  
106 –125 104.5   (2.5) 158.3   (6.7) 224.4   (14.6) 0.8 2.6   (0.3)  
125 – 150 115.9   (6.9) 183.3   (3.5) 250.3   (5.3) 0.7 2.9   (0.6)  
150 – 180 147.5   (8.7) 231.2   (6.2) 333.9  (12.3) 0.8 2.3   (0.7)  
180 - 212 178.6   (12.1) 270.0   (9.8) 409.7  (21.9) 0.9 1.1   (0.4)  
212 – 250 203.3   (13.9) 311.0  (6.7) 443.3   (15.0) 0.8 1.9   (0.5)  
250 – 300 230.0   (6.5) 352.8  (6.2) 479.9   (13.8) 0.7 2.4   (0.4)  
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Table 3.3. Particle Sizing Data of Fractionated Anhydrous Lactose Carrier Particle Populations 
 
  
Carrier Sieve 
Fraction                
(µm) 
Anhydrous Lactose  
d(10) d(50) d(90) Span % Fines  
< 20 3.7 (0.1) 20.2 (0.2) 32.8 (0.3) 1.4 20.5 (0.4)  
20 – 32 16.0 (0.4) 33.6 (0.3) 48.7 (0.4) 1.0 8.0 (0.1)  
32 – 45 32.2 (0.3) 48.5 (0.4) 65.8 (1.2) 0.7 3.9 (0.1)  
45 – 63 43.5 (0.4) 64.7 (1.2) 85.0 (2.2) 0.6 3.4 (0.1)  
63 – 75 49.0 (2.5) 79.5 (0.8) 106.4 (3.2) 0.7 4.6 (0.9)  
75 – 90 65.3 (5.8) 97.9 (2.1) 130.0 (6.4) 0.7 3.1 (0.2)  
90 – 106 90.8 (2.3) 121.9 (2.2) 165.5 (7.6) 0.6 ---  
106 –125 101.9 ( 7.6) 142.7 (1.5) 184.9 (6.5) 0.6 ---  
125 – 150 121.6 (4.5) 168.2 (2.6) 218.5 (7.2) 0.6 ---  
150 – 180 146.9 (6.5) 205.5 (6.7) 287.7 ( 14.0) 0.7 ---  
180 - 212 169.7 (14.9) 243.3 (3.0) 335.0 ( 11.1) 0.7 ---  
212 – 250 199.7 (9.3) 277.1 (6.0) 349.6 (9.4) 0.5 ---  
250 – 300 239.7 (13.2) 318.0 (4.4) 404.9 (15.6) 0.5 ---  
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Table 3.4. Particle Sizing Data of Fractionated Spray Dried Lactose Carrier Particle Populations 
  
Carrier Sieve 
Fraction                
(µm) 
Spray Dried Lactose  
d(10) d(50) d(90) Span % Fines  
< 20 4.5   (0.1) 20.6    (0.1) 30.8    (0.3) 0.8 14.1 (0.1)  
20 – 32 16.1   (0.6) 31.2    (0.2) 44.3    (0.8) 1.1 8.3   (0.1)  
32 – 45 30.6   (0.1) 44.8    (0.2) 59.1    (0.4) 1.6 5.0   (0.1)  
45 – 63 42.5   (0.3) 57.7    (0.6) 71.4    (0.3) 2.0 3.5   (0.1)  
63 – 75 51.4   (1.9) 69.2    (0.5) 87.8    (0.9) 1.9 6.5   (0.5)  
75 – 90 65.3   (1.2) 84.7    (0.6) 104.1   (1.2) 2.2 5.2   (0.2)  
90 – 106 81.9   (2.0) 94.8    (1.9) 127.4   (4.0) 2.1 3.1   (0.4)  
106 –125 98.9   (1.3) 128.8   (1.6) 172.4   (4.6) 1.8 5.0   (0.2)  
125 – 150 118.9   (0.5) 166.0    (2.5) 234.2   (14.4) 1.4 ---  
150 – 180 144.4   (4.0) 204.6    (4.1) 298.0   (11.7) 1.3 ---  
180 - 212 166.1   (3.5) 254.7   (11.8) 362.3   (14.9) 1.3 ---  
212 – 250 188.9   (8.7) 278.8   (12.5) 367.5   (19.9) 1.6 ---  
250 – 300 219.4   (2.6) 313.1    (4.3) 396.5    (8.8) 1.8 ---  
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Table 3.5. Particle Sizing Data of Fractionated Granulated Lactose Carrier Particle Populations 
Carrier Sieve 
Fraction                
(µm) 
Granulated Lactose  
d(10) d(50) d(90) Span % Fines  
< 20 5.3    (0.4) 22.4    (0.6) 35.3   (1.7) 1.3 14.7 (0.4)  
20 – 32 20.4    (0.3) 35.8    (0.4) 51.0   (1.2) 0.9 7.5 (0.2)  
32 – 45 32.8    (0.3) 52.5    (0.5) 73.5   (2.1) 0.8 4.7 (0.1)  
45 – 63 35.4    (1.2) 62.9    (0.9) 87.6   (2.8) 0.8 4.9 (0.1)  
63 – 75 45.3    (0.9) 77.1    (0.9) 108.7  (2.5) 0.8 3.5 (0.2)  
75 – 90 44.0    (2.7) 87.7    (1.1) 136.4  (4.5) 1.1 4.1 (0.5)  
90 – 106 82.7    (2.0) 123.9  (1.6) 175.1  (4.8) 0.7 ---  
106 –125 105.6   (1.1) 147.5  (1.5) 202.2  (6.8) 0.7 ---  
125 – 150 125.7   (1.9) 176.4  (2.2) 265.0  (14.4) 0.8 ---  
150 – 180 151.2   (2.7) 207.0  (4.0) 277.5   (13.7) 0.6 ---  
180 - 212 160.7   (4.2) 231.4  (4.9) 297.8   (10.3) 0.6 ---  
212 – 250 198.3   (7.3) 279.8  (3.8) 353.0   (6.1) 0.6 ---  
250 – 300 230.3   (8.1) 303.8  (10.9) 364.9   (20.0) 0.4 ---  
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Table 3.6. Drug Content Uniformity Measurements of the Experimental 1% (w/w) Salbutamol 
Binary Formulations 
 LACTOSE GRADE 
 
 
Carrier Particle  
Sieve Fraction (µm) 
 
α-Lactose  
Monohydrate 
Anhydrous Spray Dried Granulated 
 
< 20 13.7 % 5.3 % 6.6 % 2.6 % 
 
20 – 32 10.6 % 3.8 % 2.8 % 5.3 % 
 
32 – 45 6.0 % 2.3 % 2.1 % 2.7 % 
 
45 – 63 1.2 % 1.4 % 2.9 % 1.9 % 
 
63 – 75 3.7 % 0.3 % 1.6 % 2.7 % 
 
75 – 90 2.1 % 0.7 % 2.7 % 6.4 % 
 
90 - 106 2.2 % 2.2 % 3.9 % 8.4 % 
 
106 – 125 1.9 % 0.8 % 2.7 % 5.1 % 
 
125 – 150 2.7 % 1.4 % 1.4 %  6.2 % 
 
150 – 180 2.5 % 2.3 % 3.2 % 4.7 % 
 
180 – 212 4.2 % 1.9 % 1.5 % 6.1 % 
 
212 – 250 6.3 % 1.2 % 3.0 % 2.7 % 
 
250 - 300 9.3 % 1.7 % 1.6 % 4.3 % 
 
 
The drug content uniformity of each blend is expressed as the percent coefficient of variation 
for N = 8 replicates. 
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CHAPTER 4 
4. Influence of Carrier Particle Diameter and Surface Roughness on the 
Performance of Binary DPI Formulations 
4.1. INTRODUCTION 
Therapeutic formulations administered via dry powder inhalers are typically interactive 
mixtures, comprised of the active pharmaceutical ingredient and a coarse carrier material 
blended together to produce a homogeneous powder.  Delivery to the deep lung requires drug 
particles possessing aerodynamic diameters between 1 and 5 µm [1].  However, given the high 
surface area-to-volume ratio of particles in this size range, the ubiquitous van der Waals forces 
dominate the interactions, producing highly cohesive powders that flow poorly and are 
consequently resistant to dispersing into primary particle sizes during inhalation [2, 3].  
Previous studies investigating the physical properties of lactose carriers on aerosol 
performance have generally been limited to broad particle size distributions, and/or carrier 
particle fractions below 200 µm [4-6]. In addition, examination of larger carrier particles have 
focused primarily on a single particle morphology, that of α-lactose monohydrate, while studies 
investigating the role of surface roughness are restricted to a single particle size range [7-9].  
In the previous chapter, a comprehensive analysis of the influence of carrier particle 
diameter and morphology was performed.  The in vitro deposition profiles from 52 formulations 
prepared with 13 narrow size fractions of four lactose grades were evaluated.  The results 
indicated that performance can deviate markedly from the predicted trend, especially for larger 
carrier particle populations of both spray dried and granulated lactose.  It was speculated that 
the increased surface roughness of the spray dried and granulated particles relative to α-lactose 
monohydrate and anhydrous carriers was in part responsible for the observed differences in 
performance.  However, the mechanism by which the combination of large carrier particle 
diameters and extensive surface roughness modulates drug detachment is presently not known.     
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Specific Aim 
It was therefore the specific aim of this chapter to concurrently evaluate the influence 
of carrier particle size and surface roughness on the aerosol performance of binary dry powder 
formulations.  To this end, 2% (w/w) budesonide blends were prepared incorporating 11 carrier 
particle size fractions ranging up to 300 µm and derived from two morphologically distinct 
lactose grades (anhydrous and granulated).  In vitro drug deposition was used to assess the 
aerosol performance of the dry powder formulations.  It is noted that both the drug and 
concentration differed from that of the previous study, when the formulations were prepared to 
possess an API concentration of 1% (w/w) with salbutamol.  This difference was designed to 
determine if the aerosol performance trends of the previous study were due in larger part to the 
carrier particle population, or to the influence of the API. 
4.2. EXPERIMENTAL 
4.2.1. Materials 
Micronized budesonide (EP) was purchased from Spectrum Chemicals (CA, USA) and 
used as received.  Analytical grade ethanol was supplied by Sigma Chemical Company (MO, 
USA).  As inhalation grade lactose is processed to yield particles predominately below 200 µm, 
lactose grades typically employed in tablet preparation were used as carrier particles.  Samples 
of anhydrous (SuperTab® 22AN), and granulated (SuperTab® 30GR) lactose were provided by 
DMV-Fonterra (New Zealand).  Size 3 gelatin capsules were obtained courtesy of Capsugel® (NJ, 
USA).     
4.2.2. Fractionation of Lactose Carrier Particles 
Samples of each lactose batch were fractionated on a vibrating sieve shaker (Gilson 
Company Inc., OH, USA) for 5 minutes through the following sieves: 300 µm, 250 µm, 212 µm, 
180 µm, 150 µm, 125 µm, 90 µm, 75 µm, 63 µm, 45 µm, and 32 µm.  Following the initial 
fractionation, the lactose carriers were again sieved for an additional 5 minutes to obtain 
narrow particle size distributions.   
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4.2.3. Preparation of Budesonide/Lactose Binary Blends 
Budesonide and lactose were mixed in a ratio of 1:50 (w/w) via geometric dilution to 
obtain 500 mg of a 2% binary blend.   The formulations were blended with a Turbula® orbital 
mixer (Glen Mills, NJ, USA) for 40 minutes at 46 RPM.  Samples were stored in a dessicator at 
least 5 days prior to use.  Blend uniformity was determined by randomly selecting eight 20-mg 
samples from each mixture, and assessing the drug content in the powder.  Formulations were 
considered well blended if the coefficient of variation (% CV) between the samples for a given 
blend was below 5%.   
4.2.4. Scanning Electron Microscopy 
Carrier particle size and surface roughness were visually assessed by scanning electron 
microscopy (SEM; Supra 40VP, Zeiss, Germany).  Prior to SEM, approximately 20 nm of platinum 
were deposited onto the particle surfaces via sputter coating.    
4.2.5. Surface Area Analysis 
Specific surface areas of the lactose carrier particle populations were determined via 
nitrogen adsorption with a single-point BET method using a Monosorb® surface area analyzer 
(Quantachrome, FL, USA). 
4.2.6. Atomic Force Microscopy 
Atomic Force Microscopy was performed on a Multimode SPM NanoScope IIID (Veeco 
Instruments, CA, USA) in tapping mode using RTESP cantilevers with a nominal spring constant 
of 40 N/m. AFM settings were tuned to provide the best topographical image. Image processing 
and analysis was done in NanoScope Analysis software (v1.10, Veeco Instruments). 
4.2.7. Density of Lactose Carriers 
The true densities of the lactose carrier particles were determined with a helium 
multipycnometer (Quantachrome, FL, USA). 
 83 
4.2.8. In Vitro Drug Deposition 
Size 3 gelatin capsules filled with 20 (± 1) mg of powder were dispersed through an 
Aerolizer® DPI (Plastiape S.p.A., Italy) into a next generation cascade impactor (Copley Scientific, 
UK) at a volumetric flow rate of 60 L min-1 actuated for 4-second intervals.  Prior to each 
actuation the pre-separator was loaded with 15 mL of ethanol, which was collected following 
powder dispersion from each capsule.  Additionally, the drug deposited in the capsule, inhaler, 
adaptor mouthpiece, throat, and NGI stages was collected by rinsing with ethanol.  Drug content 
was assessed via UV-VIS absorption spectroscopy at 244 nm.  The emitted fraction was 
calculated as the ratio of the drug mass depositing in the throat, pre-separator, and impactor 
stages over the cumulative mass of drug collected following actuation (total drug deposited in 
the capsule, inhaler, mouthpiece, throat, pre-separator and stages).  The fine particle fraction 
(FPF) of each dose was the ratio of the drug mass depositing on stages 3 - 8 (corresponding to an 
aerodynamic diameter less than 4.46 µm) of the impactor over the emitted dose.  The respirable 
fraction was the ratio of the drug mass deposited on stages 3 – 8 over the entire dose recovered 
following each actuation.        
4.2.9. Statistics 
Statistical significance between performance values was determined with one-way 
ANOVA with Post Hoc tests between groups according to the Bonferroni method (P < 0.05). 
4.3. RESULTS 
4.3.1. Physical characterization of Lactose Carrier Particles 
Narrow lactose carrier particle fractions were generated by the double-sieving 
technique (Figure 4.1).  Although the vast majority of studies examining binary dry powder 
formulations are restricted to only α-lactose monohydrate carriers, different grades of lactose 
have been employed as carrier particles in the literature.  These include both granulated lactose 
and anhydrous lactose [41, 75, 84]. Granulated lactose is α-lactose monohydrate generated via 
fluidized bed granulation, producing particles with extensive surface rugosity (Figure 4.1 and 
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Figure 4.2). Anhydrous lactose is a form of β-lactose, absent the water of crystallization of the 
monohydrate form, and is characterized by relatively flat particle surfaces.  The increased 
surface roughness of the granulated lactose carriers becomes increasingly evident at the larger 
particle size ranges, though at the smaller fractions the distinction between anhydrous and 
granulated carriers is less apparent. Notably, the anhydrous carriers exhibited a greater degree 
of fine particles on their surface (Figure 4.2).   
The specific surface areas (SSA) of all 11 carrier fractions, for both anhydrous and 
granulated lactose, are listed in Table 4.1.  The extensive surface roughness of the granulated 
particles yielded SSA values up to four-fold higher than the anhydrous particles.  Additionally, 
the SSA of the granulated particles does not diminish with increasing carrier particle size to the 
same extent as the anhydrous carriers.     
4.3.2. Surface Roughness of Carrier Particles 
Theoretically, given the higher surface area-to-volume ratio of smaller particles, the 
specific surface area (SSA) of a carrier powder diminishes as the diameter of the particles is 
increased.  For a constant mass of carrier particles (e.g. 20 mg), the surface area available for 
drug binding is reduced for larger carriers, potentially leading to drug-drug particle 
agglomeration which can hinder aerosol performance.  Practically, surface area may be 
significantly influenced by the extent of surface roughness, particularly as the carrier particle 
size is varied [9, 11]. Therefore, surface area can be effectively used as a relative measure of 
surface roughness for a series of size fractions of the lactose carriers. The experimentally 
observed SSA for each size fraction of each lactose grade was determined and was compared to 
the theoretical SSA for equivalent sized spheres possessing a diameter corresponding to the 
mean particle diameter of the sieve fraction. For example, the mono-disperse spherical particle 
population for the carrier sieve fraction 63 – 75 µm possesses a theoretical diameter of 69 µm.   
To facilitate comparison, the SSA was normalized to that of the smallest size fraction of each 
population (spherical, anhydrous, and granulated); the SSA of each subsequent carrier particle 
fraction (CPF) was divided by that of its smallest size fraction (< 32 µm): 
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Figure 4.3 depicts the decline in SSA as particle diameter is increased, normalized to the 
SSA of the < 32 µm particles for each population. This plot allows the direct comparison of how 
closely each lactose grade follows the theoretical relationship between particle size and surface 
area, and provides excellent insight into the degree of surface roughness. The theoretical SSA of 
the perfectly spherical particles declines as an exponential function.  However, in reality lactose 
has significant surface roughness coupled with the presence of fine particles. Thus, the observed 
decline in SAA of the lactose particles is not as severe as that of the spherical particles (Figure 
4.3).  For anhydrous lactose, the SSA begins to noticeably deviate from theoretical at the 45 – 63 
µm carrier fraction, and converges to approximately 40% of the < 32 µm SSA value over the 
remaining size ranges.  By contrast, the SSA of the granulated lactose is within 80%, and in a few 
instances over 90%, of the smallest particle size fraction despite large increases in particle size.  
Accordingly, given the higher rugosity of granulated particles relative to their anhydrous 
counterparts, increasing carrier particle size does not severely diminish the surface area 
available for drug attachment during blending.  This difference may be important for limiting the 
extent of drug-drug particle agglomerate formation that occurs during blending for formulations 
with granulated carriers relative to anhydrous.   
To supplement SSA data on surface roughness, Atomic Force Microscopy (AFM) studies 
were performed on selected lactose size fractions. Figure 4.4 shows representative examples of 
the surface topography of both small anhydrous carrier particles (75 - 90 µm) and larger 
anhydrous carrier particles (250 – 300 µm). Statistical differences in surface roughness were 
identified in the root mean square (RMS) value of the roughness between large and small 
carriers.  RMS surface roughness values of the 250 – 300 µm anhydrous samples was 568 (± 31) 
nm compared to 385 (± 60) nm for the 75 – 90 µm samples for three replicates.  The surface 
roughness of granulated lactose was difficult to measure using AFM due to the large and abrupt 
changes in the surface structures, particularly in the z-direction. Therefore, AFM results for 
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granulated lactose should be interpreted with caution, as the successful imaging attempts will 
bias the results in favor of smoother surfaces.  
4.3.3. In vitro Aerosol Performance  
Aerosol performance is governed by the combined influence of both carrier particle size 
and surface roughness, and the results of the present study reveal that poor dispersion 
performance is not a property inherent to larger carrier particles.  For anhydrous carrier 
formulations, performance did not progressively decline with carrier size (Figure 4.5). Three 
distinct plateaus in RF values were noted as the size of the carriers was increased, with 
performance abruptly dropping off as carrier size increased to 32 - 45 µm (RF decreased from 
18.4% to 13.7%), and once more at the transition to the 63 – 75 µm size range (14.6% compared 
to 10.4%) (Table 4.2).  Additionally, following a drop in performance at the 150 – 180 µm size 
range (RF = 7.5%), a slight but statistically significant improvement was seen as RF values 
climbed for the three largest carrier size fractions, ranging from 8.7% to 9.9%.  The observation 
that performance did not continually decline with carrier size, but rather exhibited a minor 
resurgence at the largest size ranges, was unexpected in the context of the current literature.   
In contrast to anhydrous formulations, the drug deposition performance of granulated 
carriers exhibited a distinct overall trend (Figure 4.6).  Although the smallest three fractions 
demonstrated a decline in performance, with RF values progressively dropping from 11.2% to 
6.6%, dispersion improved markedly for larger carriers.   A progressive increase in RF was 
observed beginning with the 90 – 125 µm size range, eventually surpassing the performance of 
even the < 32 µm carrier population, such that the three largest carriers significantly 
outperformed all but the 125 – 150 µm size fraction.   
4.4. DISCUSSION 
The influence of carrier particle surface roughness on drug dispersion performance has 
been previously examined in the literature [7 - 9, 11, 12].  It has been observed that there are 
two distinct types of roughness, differing by the scale of the carrier surface asperities relative to 
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the drug particles [7]. Micro-scale rugosity refers to carrier surfaces with asperities smaller than 
the drug particles, reducing the contact surface area between drug and carrier. By providing a 
corrugated surface for drug particle attachment, micro-scale rugosity has been demonstrated to 
benefit dispersion performance by diminishing the adhesive interaction with the carrier particle 
[7, 13, 14]. However, carriers with micro-scale surface asperities have also been observed to 
inhibit aerosol performance relative to smooth lactose by enhancing friction forces between 
rougher carriers, to the detriment of powder flow properties [8].   
In contrast to the corrugated surface, macro-scale rugosity describes surface features 
larger than the drug particles, which are believed to increase the extent of contact with the 
carrier [11, 12].  Furthermore, drug particles located within these large surface asperities are 
sheltered from the flow stream during inhalation, limiting the detachment forces acting on 
them. Consequently, carrier particles with macro-scale rugosity have been shown to hinder 
aerosol performance [7, 11].  However, previous work specifically examining the influence of 
surface roughness has been limited to a single carrier size range.   Accordingly, the effect of 
surface roughness on aerosol performance over a wide range of carrier particle sizes had to be 
extrapolated in previous studies, with speculation that the greater degree of surface roughness 
on larger carriers was a major contributor to their reduced dispersion performance relative to 
smaller carriers [7, 11, 12].  Our results indicate that surface roughness influences performance 
by altering the relative contributions of the mechanisms governing drug detachment from 
carrier particles.  Moreover, as the detachment potential of these mechanisms can vary greatly 
with carrier particle size, the view that large carrier particles are detrimental to aerosol 
performance is re-evaluated in light of the present study.                   
4.4.1. Mechanisms of Drug Detachment from Carrier Particles 
Drug detachment and dispersion from carrier particles during inhalation is thought to 
proceed through two major mechanisms: detachment by the flow stream (fluid forces) and 
detachment by impaction (mechanical forces) [15, 16].  While these mechanisms are not 
mutually exclusive, they are distinct and depend on different physical characteristics of the drug 
and carrier particles to maximize their potential to cause detachment. Detachment by flow 
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requires a relatively flat carrier particle surface, with minimal asperities, allowing the flow 
stream an unobstructed path to access and remove the drug particles.  Additionally, detachment 
by flow is facilitated for larger drug particles (either drug agglomerates or primary particles) due 
to the increased surface area available for interaction with the flow stream [11].   
Mechanical forces arise from the abrupt momentum transfer that occurs when a carrier 
particle contacts the inhaler wall [3, 16].  As momentum is dependent on the mass of the 
particle, detachment by mechanical forces are proportional to the cube of the carrier particle 
diameter, such that large particles will generate greater detachment forces (assuming constant 
velocity between carrier particle size fractions) [17].  Moreover, detachment by mechanical 
forces is not inhibited by carrier particle surface roughness to the same degree as detachment 
by flow, and all drug particles adhered to a carrier will equally experience the carrier-inhaler 
collision force [16]. However, only those drug particles for which the detachment force both 
exceeds the adhesive interaction with the carrier, and is in a direction favorable to detachment, 
will be dislodged from the carrier. 
Although drug particles are simultaneously subjected to both flow and mechanical 
forces, they do not begin to act upon the drug at the same instant.  In order for a drug particle 
to experience mechanical forces the carrier to which it is attached must be in motion, and this 
motion is generated by the flow stream acting on the carrier particle.  However, the instant that 
the flow stream begins to influence the carrier, it has begun to exert fluid detachment forces on 
drug particles on the carrier surface.  Thus, drug particles are exposed to fluid forces prior to 
mechanical forces.  This distinction is important, as drug particles readily exposed on the surface 
will likely be detached by the flow stream at the onset of inhalation, prior to the existence of 
mechanical forces.  Accordingly, mechanical forces do not influence all of the drug particles on 
the carrier, but rather those that still remain adhered to the carrier following fluid detachment, 
when the carrier-inhaler impactions occur.             
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4.4.2. Surface Roughness and Particle Size Influence the Predominant Mechanism of 
Detachment 
Figure 4.7 schematically illustrates the distinction between detachment by flow and 
mechanical forces in carriers with different surface roughness.  For carriers with low surface 
roughness, the drug is readily exposed to the flow stream.  Thus, for smoother carriers 
detachment by flow may be effective at drug detachment, and is likely the dominant 
mechanism.  With increasing carrier surface roughness, drug is sheltered within asperities, and 
drug detachment becomes less dependent on the flow stream and more reliant on mechanical 
forces.  Accordingly, when examining the carriers from the two lactose grades used in this study, 
it is speculated that detachment by flow will predominate for the relatively smoother anhydrous 
particles while mechanical forces will dominate for the granulated carriers where surface 
roughness will shelter drug particles from the flow stream to a greater degree (e.g. Figure 4.2).    
The wide disparity in aerosol performance between the lactose types is therefore 
attributed to their diverse surface roughness characteristics.  The influence of surface roughness 
on aerosol performance is evidenced by the divergent trends in RF values between the two 
lactose types as carrier size is increased (Figure 4.8).   Anhydrous lactose exhibits a decline in 
overall performance with increasing particle size, whereas the granulated carriers yielded the 
opposite trend.  The overall reduction in performance observed in the formulations with 
anhydrous carrier particles is consistent with detachment by flow.  From the literature, it has 
been noted that smaller carrier particles possess smoother surfaces relative to larger size 
fractions [11, 12].  It is then proposed that more drug particles are sheltered within asperities on 
larger carriers, and thus less susceptible to detachment by the flow stream.  Additionally, the 
reduction in available surface area for larger anhydrous size fractions would lead to more 
extensive drug agglomeration, hindering aerosol performance (Table 4.1). Thus, with larger 
anhydrous carriers not only are fewer drug particles dislodged from the surface, much of the 
detached drug is aggregated (as measured by MMAD and discussed below).  Consequently, 
most of the drug that can be removed by the forces generated within a given inhaler at a 
specific flow rate is likely detached rapidly by the initial fluid forces, and a limited number of 
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drug particles remain available for detachment by the mechanical forces that occur subsequent 
to the flow forces.      
Conversely, it is proposed that drug detachment from granulated particles was primarily 
dependent on mechanical forces.  As the magnitude of mechanical detachment forces increases 
with carrier particle size, the larger granulated carrier particles significantly outperformed the 
smaller size fractions (Figure 4.8). The relatively high performance of < 32 µm granulated 
particles can be attributed to the small surface roughness of this size fraction, which enabled 
detachment by flow to predominate.  
4.4.3. Evidence for Mechanical Detachment Mechanisms for Larger Carrier Particles: 
Flow Rate Dependent Detachment 
Mechanical detachment forces rely on the abrupt momentum transfer generated by 
carrier-inhaler collisions [3]. Thus, as both the mass and velocity of the carrier particle are 
important, the performance would depend on carrier particle size and inhalation flow rate, all 
other factors being equal.  Accordingly, the influence of flow on the performance of large carrier 
particles is an area that remains to be fully explored.  However, while only a single volumetric 
flow rate was examined in this study, evidence for improved drug detachment from large 
carriers with increasing flow can be found in the literature.  In their studies with α-lactose 
monohydrate carrier particles, Dickhoff and coworkers observed the drug detachment from 
particle size fractions including both a small (32 – 45 µm) and large (250 – 355 µm) population 
[18].  For 1.6% (w/w) budesonide formulations at 30 Lpm, smaller carriers detached 
approximately half of the drug adhered to their surface, while the 250 – 355 µm size range 
dislodged only 42%.  Doubling the flow to 60 Lpm, the large carrier particles outperformed their 
smaller counterparts, detaching 93% compared to 81%.    
For smaller carrier particles with low surface rugosity, the drug is readily exposed to the 
flow stream, and increasing the flow rate would augment the magnitude of the pneumatic 
detachment forces.  However, it is known that large carriers possess greater surface roughness, 
allowing drug particles to be sheltered from the flow stream [11].  Supposing drug dispersion is 
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governed solely by detachment due to flow, two particles with equally smooth surfaces would 
be expected to perform comparably, regardless of carrier particle size. The observations made in 
these studies that larger, higher rugosity particles outperformed the smaller, smoother carriers 
at 60 Lpm provides evidence for additional detachment mechanisms other than flow forces [18]. 
Moreover, while this mode of detachment benefits larger carrier particles, its influence is not 
observed at lower flow rates.  Accordingly, a mechanism that enhances detachment forces with 
increasing carrier particle size (i.e. mass) and velocity strongly supports the role of mechanical 
forces arising from carrier particle-inhaler collisions.  In fact, these forces may be stronger in 
magnitude than fluid forces and provide more efficient methods of detaching particles from 
carrier surfaces. 
4.4.4. Relationship Between Carrier Particle Size Fraction and Detached Drug Particle 
Size 
Given their increased detachment potential due to mechanical forces, larger carriers 
may dislodge drug particles resistant to the flow stream.  These “detachment-resistant” drug 
particles may be smaller drug particles (less susceptible to flow-related detachment due to their 
small surface area) or drug particles attached to high energy sites on the carriers. When 
attached to larger carriers, these may be available for detachment via mechanical impactions.  
In addition, drug particles located within small surface asperities in a depth sufficient to obstruct 
their interaction with the flow stream would have more potential for detachment.  Indeed, a 
study examining the relationship between impact forces and particle detachment revealed that 
greater impaction magnitudes were required to separate particles from a surface as the 
diameter of the particles decreased [19].  It follows then that the diameter of drug particles 
depositing in the cascade impactor would be smaller from formulations with larger carriers, as 
they will be able to generate greater impaction forces.  Our observations are consistent with this 
theory (Figure 4.9), for both anhydrous and granulated carriers, where the mass median 
aerodynamic diameter (MMAD) of the deposited budesonide particles exhibited a decreasing 
trend with increasing carrier particle size.   
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Examining only the MMAD values for the carrier particle fractions, it might be concluded 
that large carriers would demonstrate the best performance across both lactose types. This was 
true for granulated lactose, but for anhydrous lactose decreases in SSA likely lead to drug-drug 
aggregates as carrier size increased. Indeed, with the exception of the 45 - 63 µm size range, the 
SSA plateau is also reflected in the respirable fractions (Table 2), where values initially drop-off 
significantly from the smallest particle size range, and again following the 45 – 63 µm fraction.    
4.4.5. Transition from Flow Detachment to Mechanical Detachment 
To reconcile the opposing trends of MMAD and overall drug deposition performance for 
anhydrous carriers with particle size, it is proposed that the drug aggregates formed during 
blending are readily detached by the flow stream due to their augmented surface area but they 
are not dispersed into primary particles (accounting for the diminished RF values).  However, 
larger carriers increased the mechanical forces arising from particle-inhaler collisions, and drug 
particles impervious to detachment by flow were eventually dislodged. As these are believed to 
be smaller primary drug particles, detachment correlates with deep lung deposition, 
contributing to the RF values.  At precisely what size range this shift in detachment mechanism 
occurs is unclear, but as noted previously from Figure 4.5, aerosol performance of anhydrous 
particles deviates from the declining trend at the 180 – 212 µm carrier fraction, where a slight 
but significant improvement in RF value is observed. From Table 3, this coincides with the carrier 
particle fraction when MMAD begins to trend to smaller values, supporting the theory that 
mechanical detachment forces generated by larger carriers dislodge drug particles resistant to 
the flow stream. 
An alternative explanation for the MMAD decline is the ability of larger carriers to 
comminute aggregated drug particles during blending.  It has been observed that two types of 
drug agglomerates exist in dry powder formulations: natural agglomerates present in the pure 
drug powder, and mixing agglomerates that arise as drug and carrier particles are blended [9].  
While the lower SSA of larger carriers can induce mixing agglomerates, their greater mass and 
flowability improves their potential to breakup natural agglomerates during blending, allowing 
them to potentially aid and hinder performance simultaneously.  Whether disruption of natural 
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agglomerates surpasses the formation of mixing agglomerates depends not only on formulation 
conditions such as drug (w/w) concentration, blending time and batch size, but also on the drug 
itself.  For the beneficial aggregate disruption to dominate, the interaction between drug and 
carrier must be stronger than that amongst drug particles, such that drug dislodged from 
agglomerates will adhere to the lactose, and remain attached throughout blending.  Conversely, 
aggregate formation prevails when the drug possesses a high cohesive tendency, preferentially 
associating with other drug particles over the carriers [20].   
Begat and colleagues have previously demonstrated the cohesive nature of budesonide, 
the model drug employed in the present study [20]. We also observed similar phenomena when 
we previously performed dynamic blending studies with budesonide and different lactose types 
[21].  Accordingly, it is speculated that agglomerate formation may predominate during 
blending, accounting for the decline in aerosol performance for larger anhydrous carriers.  The 
reduction in MMAD is also observed with granulated lactose, where the high surface rugosity 
would shelter drug particles and inhibit the breakup of natural drug agglomerates. This supports 
the view that larger carriers can potentially dislodge smaller primary drug particles that would 
generally resist fluid detachment, as the increased amount of natural agglomerates with larger 
granulated carriers (due to increased surface roughness) would be expected to shift MMAD 
values higher, but they are instead compensated by a number of smaller detached drug 
particles, such that MMAD actually trends lower with carrier size.  The difference between the 
two lactose types, where granulated carriers generally produced smaller MMAD values at each 
carrier size fraction, may be explained by the greater SSA of granulated particles, which can limit 
the extent of drug-drug particle interaction relative to the anhydrous carriers, reducing 
formation of blending agglomerates.               
4.4.6. Effects of Increasing Carrier Particle Diameter and Mass  
Aerosolization performance can be improved by increasing the size of the carrier 
particles, thereby increasing the mechanical impaction forces that can be very efficient at 
detaching drug particles from the carrier surface. However, the improvement to aerosol 
performance imparted by large carrier particles will not continue indefinitely, as the mass of 
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carriers (and gravitational forces acting upon them) eventually become prohibitively large.  The 
benefit to momentum that is conferred by the increased mass of the carrier particle will be 
countered by a reduction in particle velocity, as the carriers’ inertia will resist the flow stream, 
resulting in a diminishing force of the carrier-inhaler impactions.  In our studies, the RF values of 
the 250 – 300 µm formulations for both lactose types were not significantly different from those 
of the size fraction immediately preceding them (212 – 250 µm) (Table 4.2).  Therefore it is 
unclear precisely when the mass of carrier begins to inhibit drug dispersion. The maximum 
particle size employed in this study was limited to 300 µm, as at the next largest size range a 
fraction of the carrier particles were retained within the capsules following actuation from the 
Aerolizer®, due to some particles being too broad to pass through the capsule perforations. It is 
speculated that the performance of size ranges greater than 300 µm would not increase 
significantly from those of the 250 – 300 µm fractions given the density of the carrier particles 
(between 1.54 – 1.56 g/cm3, data not shown).  
4.4.7. Previous Studies Examining Anhydrous and Granulated Lactose 
As stated earlier, both granulated and anhydrous lactose have been employed as carrier 
particles previously in the literature.  Granulated lactose particles were used by Kawashima and 
colleagues, who studied the influence of carrier particle surface morphology on the dispersion 
of pranlukast hydrate [7]. Particles with high surface roughness were produced via fluidized bed 
granulation, and sieved between 63 – 90 µm.  Their results demonstrated that the granulated 
particles yielded the lowest aerosol performance of the experimental carrier populations.  This 
was attributed to the high adhesive force between the drug and granulated carrier particles, as 
a consequence of the increased number of contact points resulting from the high surface 
roughness of the carriers.  That the authors concluded that granulated particles were poor 
carriers is understandable, as the fraction they employed fell into a size range that was not 
sufficiently large to generate high mechanical forces, as demonstrated by our observations. 
Consequently, detachment relied on the flow stream, which was unable to interact extensively 
with the drug particles due to the high surface roughness of the carriers.  In comparison with the 
present study, the 63 – 75 µm and 75 – 90 µm granulated carriers exhibited relatively low 
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performance relative to the larger carriers.  By contrast, Dickhoff and coworkers employed 250 – 
355 µm granulated lactose carriers in their studies on surface roughness, and observed that 
granulated carriers could detach a higher fraction of drug from their surface relative to 
crystalline lactose carrier particles [9].  The authors proposed that the increased surface 
roughness of the granulated carrier particles allowed drug particles to be shielded within surface 
asperities from press-on forces during mixing, which hindered drug dispersion from the 
crystalline carriers.   Our results were in agreement with those of Dickhoff, where the largest 
granulated carriers outperformed their smoother anhydrous counterparts.  
Studies including a 63 – 90 µm anhydrous lactose fraction observed a significantly 
greater dispersion performance by comparison to α-lactose monohydrate carriers of 
comparable size [10].  The authors attributed this enhanced performance to the higher content 
of fine lactose on the surface of anhydrous particles relative to the other carriers.  However, the 
performance of anhydrous carriers as their size fraction was altered was not examined.  Thus, 
although both anhydrous and granulated lactose have been previously studied, including both 
small (63 – 90 µm) and large (250 – 355 µm) granulated fractions, the influence of carrier size on 
the two lactose types was not investigated until the present study.  
4.5. CONCLUSIONS 
The work described here continued in part from Chapter 3, as the influence of carrier 
particle size and surface roughness was evaluated by employing a drug and concentration that 
differed from that of the previous study.  This was done to ensure that the performance was 
reproducible irrespective of API, indicating that the observed profiles through the Aerolizer at 60 
L min-1 depended primarily on the carrier population rather than the drug.  Although differences 
were noted, specifically between the overall performance levels of salbutamol and budesonide, 
with the former producing markedly high RF values, overall deposition followed a similar pattern 
to that observed in Chapter 3, as performance from large carriers with extensive surface 
roughness again exhibited levels at least comparable to the smallest size fraction.   
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As was noted in Chapter 1, the prevailing theories in the literature have been proposed 
to account for a relatively narrow carrier particle size distribution, and have focused primarily on 
a single particle morphology; the 'tomahawk' shape of α-lactose monohydrate.  Indeed, for 
anhydrous lactose carrier particles with relatively flat surfaces, the results in our studies 
generally followed the expected trend with dispersion performance diminishing with increasing 
carrier particle diameter.  However, improvements in aerosol performance were observed with 
larger size fractions in the formulations with granulated carrier particles, which were 
characterized by a high degree of surface roughness.  Additionally, even the largest anhydrous 
carrier sizes were also seen to improve drug dispersion, possibly by dislodging smaller primary 
drug particles that were less susceptible to detachment by the flow stream, as indicated by the 
decline in MMAD of deposited budesonide.  The present study strongly suggests that surface 
roughness may influence aerosol performance by shifting the detachment mechanism to rely 
heavily on the mechanical forces generated from collisions between the carrier particle and the 
inhaler walls.  Given that mechanical forces can potentially increase with larger carrier particles, 
the role of carrier particle size on dispersion performance was shown to vary markedly with 
surface roughness.   
The aerosol performance of a given formulation may be strongly dependent on the 
inhaler through which it is dispersed. Thus, it is recognized that the performance trends 
observed in Chapters 3 and 4 may deviate appreciably if the powder is dispersed through a 
device that does not promote either carrier particle-inhaler interactions or interparticle 
collisions to the same extent as the Aerolizer.  Accordingly, the following chapter will focus on 
the influence that the selected DPI can have on dispersion performance as the size and surface 
roughness of the carrier particles are altered.  Furthermore, the use of two inhalers will allow us 
to simultaneously evaluate how the physical properties of the lactose carrier population can 
affect performance from a dry powder inhaler, which to our knowledge, has not been previously 
investigated in detail.    
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Figure 4.1.  SEM Images of Anhydrous and Granulated Lactose Carrier Populations 
 
SEM micrographs of uncoated (A) 45 – 63 µm anhydrous lactose (B) 45 – 63 µm 
granulated lactose (C) 90 – 125 µm anhydrous lactose (D) 90 – 125 µm granulated lactose (E) 
212 – 250 µm anhydrous lactose (F) 212 – 250 µm granulated lactose sieve fractions.  Scale bars 
denote 200 µm. 
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Figure 4.2.  SEM Images of Uncoated and Coated Carrier Particles 
SEM micrographs of 250 – 300 µm (A) anhydrous lactose carrier particles without drug 
(B) anhydrous lactose carrier particles with 2% (w/w) budesonide (C) granulated lactose carrier 
particles without drug, and (D) granulated lactose with 2% (w/w) budesonide.  Scale bars denote 
100 µm.     
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Figure 4.3.  Decline in Specific Surface Area as Carrier Particle Size is Increased   
Reduction in specific surface area (SSA) with increasing carrier particle size for 
anhydrous (AN) and granulated (GR) lactose carrier particles, as compared to populations of 
mono-disperse spherical particles.   
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Figure 4.4.  AFM Images of Anhydrous Lactose Carrier Particles 
Surfaces of uncoated 75 – 90 µm (left) and 250 – 300 µm (right) anhydrous lactose 
particles determined by tapping mode atomic force microscopy. 
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Figure 4.5.  RF values from Anhydrous Lactose Carrier Particles 
In vitro drug deposition results for 2% (w/w) budesonide formulations employing 
anhydrous lactose carrier particles. Values are given as mean (± standard deviation) for N = 3 
replicates.   
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Figure 4.6.  RF values from Granulated Lactose Carrier Particles 
In vitro drug deposition results for 2% (w/w) budesonide formulations employing 
granulated lactose carrier particles.  Values are given as mean (± standard deviation) for N = 3 
replicates.   
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Figure 4.7.  Mechanisms of Drug Particle Detachment from ‘Smooth’ and ‘Rough’ 
Carriers     
Drug detachment occurs by the flow stream, or from mechanical forces arising from 
impactions between the carriers and inhaler as the particles exit the device during inhalation.  
The relative influence of the two mechanisms varies with surface roughness.  Adapted from de 
Boer et al., 2003b.     
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Figure 4.8.  Aerosol Performance of AN and GR Formulations 
Respirable fractions (RF) of 2% (w/w) budesonide formulations with anhydrous (AN) and 
granulated (GR) carrier particles following aerosolization at 60 L min-1. Values are given as mean 
(± standard deviation) for N = 3 replicates. 
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Figure 4.9.  MMAD Values of Budesonide Dispersed from Anhydrous and 
Granulated Carriers  
Mass median aerodynamic diameters (MMAD) of budesonide particles deposited from 
anhydrous (AN) and granulated (GR) carriers.  Values are given as mean (± standard deviation) 
for N = 3 replicates.     
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Table 4.1. Specific surface areas (SSA) of anhydrous and granulated lactose carrier particles 
 
Carrier Size Fraction          
(µm) 
 
Anhydrous 
(m
2
/g) 
 
Granulated 
(m
2
/g) 
 
SSA(GR) / SSA(AN) 
< 32 0.94 1.87 2.0 
32 – 45 0.48 1.71 3.6 
45 – 63 0.38 1.62 4.3 
63 – 75 0.43 1.64 3.8 
75 – 90 0.37 1.52 4.1 
90 – 125 0.41 1.56 3.8 
125 - 150 0.38 1.81 4.8 
150 – 180 0.38 1.73 4.6 
180 – 212 0.40 1.44 3.6 
212 – 250 0.42 1.67 4.0 
250 - 300 0.36 1.46 4.1 
 
Measured specific surface areas (SSA) of anhydrous and granulated lactose by sieve 
fraction.  The column on the right lists the SSA ratio of the granulated particles over anhydrous 
particles for a specific size range.      
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Table 4.2. Aerosol Performance Values of Anhydrous and Granulated Lactose Formulations 
 
In vitro drug deposition results for 2% (w/w) budesonide formulations employing anhydrous and 
granulated lactose carrier particles.  Values are given as mean (± standard deviation) for N = 3 
replicates.   
  
Carrier Sieve 
Fraction (µm) 
Anhydrous (AN) Lactose Granulated (GR) Lactose 
% Emitted FPF RF % Emitted FPF RF 
       
> 32 63.5   (1.6)  29.1   (1.4) 18.4   (0.7) 57.0   (1.4) 18.5  (1.2) 11.2  (1.6) 
32 – 45 64.5   (1.8) 21.3   (0.9) 13.7   (0.3) 69.1   (3.7) 11.1  (0.6) 7.7  (0.1) 
45 – 63 63.2   (2.2) 23.1   (1.8) 14.6   (1.4) 74.4   (4.1) 8.9  (1.2) 6.6  (0.6) 
63 – 75 68.9   (1.8) 15.1   (0.4) 10.4   (0.3) 73.9   (3.7) 12.7  (1.4) 9.3  (0.6) 
75 – 90 71.9   (2.4) 15.2   (0.3) 10.9   (0.5) 73.9   (6.6) 9.7  ( 2.1) 7.1  (1.1) 
90 – 125 62.3   (1.9) 13.7   (0.6) 8.5   (0.4) 77.8   (1.8) 11.6   (0.9) 9.0  (0.5) 
125 - 150 62.7   (2.1) 15.6   (1.4) 9.8   (1.2) 71.3   (4.2) 18.9   (1.5) 13.4  (0.3) 
150 – 180 62.3   (2.0) 12.1   (0.8) 7.5   (0.3) 73.8   (2.5) 14.2   (1.3) 10.5  (0.7) 
180 – 212 61.8   (1.9) 14.1   (1.1) 8.7   (0.5) 72.6   (3.2) 20.8   (1.1) 15.1  (0.8) 
212 - 250 63.5   (2.3) 15.5   (0.8) 9.9   (0.6) 68.7   (5.4) 20.2   (1.5) 13.8  (0.7) 
250 - 300 61.6   (1.7) 15.0   (1.1) 9.3   (0.9) 68.5   (4.5) 20.2   (1.5) 14.5  (0.6) 
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Table 4.3. MMAD Values of Budesonide Particles Dispersed from Anhydrous and Granulated 
Lactose Carrier Particles. 
 Anhydrous (AN) Lactose Granulated (GR) Lactose 
Carrier Sieve Fraction (µm) MMAD (µm) MMAD (µm) 
< 32 3.24  (0.12) 2.85  (0.09) 
32 – 45 3.11  (0.09) 3.00  (0.15) 
45 – 63 2.96  (0.07) 3.15  (0.14) 
63 – 75 3.15  (0.05) 3.03  (0.21) 
75 – 90 3.11  (0.04) 3.06  (0.19) 
90 – 125 3.16  (0.01) 2.93  (0.03) 
125 – 150 3.07  (0.02) 2.70  (0.15) 
150 – 180 3.07  (0.06) 2.66  (0.13) 
180 – 212 2.94  (0.07) 2.55  (0.06) 
212 – 250 2.74  (0.03) 2.43  (0.10) 
250 - 300 2.72  (0.09) 2.41  (0.09) 
 
Mass median aerodynamic diameters (MMAD) of micronized budesonide drug particles 
detached from anhydrous and granulated lactose carrier particles as determined by in vitro drug 
deposition. Values are given as mean (± stdev) for N = 3 replicates.       
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CHAPTER 5 
5. Performance of Dry Powder Inhalers as a Function of the Diameter and 
Surface Roughness of the Carrier Particle Population  
 
5.1. INTRODUCTION 
Dry powder inhaler formulations are typically binary mixtures comprising micronized 
active agent blended with a coarse carrier particle population that constitutes the bulk of the 
formulation (> 95% w/w) [10].  When a patient inhales through a dry powder inhaler (DPI), the 
energy derived from their inspiratory effort fluidizes the powdered dose, detaching a fraction of 
the drug from the larger carrier particles and depositing it in the deep lung where it exerts its 
intended therapeutic effect [8].  It is well recognized that dry powder inhalers possess distinct 
mechanisms of powder dispersion [87].  Passive DPIs rely solely on the patient’s inspiratory 
effort to fluidize and disperse the powdered formulation, and have evolved considerably from 
their inception, incorporating a diverse array of geometries, including vortices and cyclones, to 
induce turbulence and particle-inhaler collisions to maximize the detachment potential of the 
available flow stream[3, 6].   
The use of computational fluid dynamics (CFD) to model the inhalation flow stream, 
pressure profiles, and particle trajectories within therapeutic inhalers has become increasingly 
prevalent, finding employment in the optimization of device parameters during development or, 
ex post facto, to elucidate the de-agglomeration principle of a commercially available inhaler 
[34-38, 60]. By coupling CFD simulations with in vitro aerosol performance, information on the 
relative contributions of device and formulation can be obtained.  A notable example of this 
approach is a series of studies by Coates and colleagues on the Aerolizer® dry powder inhaler, 
where the device geometry (e.g. air inlet area, mouthpiece length) and operating parameters 
(volumetric flow rate, capsule size) were varied to assess their influence on in vitro aerosol 
performance [34-38]. 
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Drug detachment from carrier particles is believed to proceed through two primary 
mechanisms: (1) aerodynamic, or fluid-based, detachment arising from the direct interaction of 
the flow stream with drug particles located on the carrier surface, and (2) mechanical, or 
impaction-based, detachment due to collisions between carrier particles and the inhaler walls 
during particle transit through the device [31, 87].  Although the diverse internal geometries of 
inhalers will vary the relative contributions between aerodynamic and mechanical detachment 
forces, it has been reported that the magnitude of impact-based events may exceed those of 
flow-based events, and could potentially be the dominating factor in drug detachment from 
carrier particles[9, 32, 87, 93].      
Previous research in our laboratory has demonstrated that large lactose carrier particles 
( > 180 µm) can improve drug deposition in vitro for both anhydrous and granular lactose 
populations, although the improvement with carrier particle size was more pronounced in 
formulations with granulated carrier particles [80].  It is speculated that the surface roughness 
of the granulated particles shifted the drug detachment mechanism from flow-based 
detachment for carrier particles with minimal surface roughness, to impaction-based 
detachment forces as carrier particle size and roughness increased.  The aerosol performance 
improvement was thought to result from an increased incidence of carrier particle-inhaler 
collisions, given the higher inertia of larger carrier particles, which inhibit their ability to travel 
with the flow stream through the inhaler.  However, it is recognized that the aerodynamic 
behavior of carrier particles can vary significantly based on the inhaler through which a 
formulation is dispersed, and improved performance may be observed if the carrier particle 
design matches the predominant mechanism(s) of detachment induced by specific inhaler types.  
Accordingly, the specific aim of this study was to assess the role of the DPI design on aerosol 
performance as the size and shape of the carrier particle population is varied. CFD simulations of 
carrier particle trajectories were coupled with in vitro drug deposition studies to investigate the 
combined influence of device and carrier on formulation performance.     
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5.2. EXPERIMENTAL 
5.2.1. Materials 
Micronized budesonide (EP) was purchased from Spectrum Chemicals (CA, USA) and 
used as received.  Analytical grade ethanol was supplied by Sigma Chemical Company (MO, 
USA).  Samples of anhydrous (SuperTab® 22AN), and granulated (SuperTab® 30GR) lactose were 
obtained from DMV-Fonterra (New Zealand).  Size 3 gelatin capsules were provided by 
Capsugel® (NJ, USA).     
5.2.2. Fractionation of Lactose Carrier Particles 
Samples of each lactose batch were fractionated on an Autosiever vibrating sieve shaker 
(Gilson Company Inc., OH, USA) with a sieve intensity, or amplitude, setting of 40 for 5 minutes 
through the following sieves: 300 µm, 250 µm, 212 µm, 180 µm, 150 µm, 125 µm, 90 µm, 75 
µm, 63 µm, 45 µm, and 32 µm. Following the initial fractionation, the lactose carriers were again 
sieved to obtain narrow particle size distributions.   
5.2.3. Preparation of Budesonide/Lactose Binary Blends 
Budesonide and lactose were mixed in a ratio of 1:50 (w/w) via geometric dilution to 
obtain 500 mg of a 2% binary blend.   The formulations were blended with a Turbula® orbital 
mixer (Glen Mills, NJ, USA) for 40 minutes at 46 RPM.  Samples were stored in a desiccator at 
least 5 days prior to use.  Blend uniformity was determined by randomly selecting eight 20-mg 
samples from each mixture, and assessing the drug content in the powder.  Formulations were 
considered well blended and ready for use if the coefficient of variation (% CV) between the 
samples for a given blend was below 5%.   
5.2.4. Scanning Electron Microscopy 
The size and morphology of carrier particles were visually assessed by scanning electron 
microscopy (SEM; Supra 40VP, Zeiss, Germany).  Prior to SEM, approximately 20 nm of platinum 
were deposited onto the particle surfaces via sputter coating.    
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5.2.5. Surface Area Analysis 
Specific surface areas of the lactose carrier particle populations were determined via 
nitrogen adsorption with a single-point BET method using a Monosorb® surface area analyzer 
(Quantachrome, FL, USA). 
5.2.6. Density of Lactose Carriers 
The true densities of the lactose carrier particles were determined with a helium 
multipycnometer (Quantachrome, FL, USA). 
5.2.7. In Vitro Drug Deposition 
  20 (± 1) mg of powder were loaded into size 3 gelatin capsules and dispersed 
through an Aerolizer® (Plastiape S.p.A., Italy) and Handihaler® (Boehringer Ingelheim Inc., CT, 
USA) DPI  into a next generation cascade impactor (MSP Corporation, MN, USA) at a volumetric 
flow rate of 60 L min-1 actuated for 4-second intervals.  Prior to each actuation, 15 mL of EtOH 
were added to the pre-separator and collected following powder dispersion from each capsule.   
Drug depositing in the capsule, inhaler, mouthpiece adaptor, and induction port were collected 
by rinsing each component with 10 mL of EtOH, while the NGI stages were each rinsed with 5 
mL.  Drug content was assessed via UV-VIS absorption spectroscopy at 244 nm.  The emitted 
fraction was calculated as the ratio of the drug mass depositing in the mouthpiece, induction 
port, pre-separator, and impactor stages over the cumulative mass of drug collected following 
actuation (total drug deposited in the capsule, inhaler, mouthpiece, induction port, pre-
separator and stages).  The fine particle fraction (FPF) of each dose was the ratio of the drug 
mass depositing on stages 3 through 8 (corresponding to an aerodynamic diameter less than 
4.46 µm) of the impactor over the emitted dose.  The respirable fraction (RF) was the ratio of 
the drug mass deposited on stages 3 – 8 over the entire dose recovered following each 
actuation.      
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5.2.8. Computational Fluid Dynamics    
CFD analysis was employed to study the flow field and assess carrier particle trajectories 
within the DPIs during actuation. The geometry of the Aerolizer was generously provided as a 
CAD file by the manufacturer (S.p.A. Italy); the computational mesh consisted of approximately 
3.7 million unstructured computational volumes.  By comparison, the Handihaler is composed of 
relatively simpler internal geometric features, which were modeled from measurements 
obtained with a caliper.  The Handihaler geometry was modeled using 3 million unstructured 
computational volumes. The computational mesh, in each case, was clustered near the walls to 
provide better resolution of the near-wall turbulence. For instance, the y+ value, which is a 
normalized distance used to characterize the near-wall resolution with respect to the boundary 
layer, was roughly 15. For both the configurations, the incoming mass flow rate was set at 60 L 
min-1. A size 3 capsule was placed in the capsule chamber. The flow inside the inhaler is 
turbulent, comprising of a range of length and time scales. To ensure computational tractability, 
this turbulent flow field is modeled using the Reynolds-averaged Navier Stokes (RANS) 
approach[94]. In this work, the commercial solver FLUENT® (ANSYS, Inc., Canonsburg, PA) is 
used to solve the RANS equations. The turbulence properties of the flow field are described 
using the shear-stress transport (SST) based k- model. The flow equations were discretized 
using a first-order numerical scheme. Although a higher order scheme would provide better 
accuracy with lower number of computational volumes, it was found to significantly reduce the 
convergence characteristics. By using a large number of computational volumes, the dissipative 
errors associated with a first order scheme were minimized. Extensive grid convergence studies 
demonstrated that the mesh used here provides mesh-converged results. The RANS equations 
were solved until a steady state solution was reached. After this step, discrete particles 
corresponding to the drug carrier particles were introduced in the flow. The particles evolved 
using a drag law, with non-spherical corrections imposed to account for particle shape effects 
(Fluent Inc. (2006) Centerra Resource Park, Lebanon, NH). The flow rate is high enough for 
gravitational forces to be important. The initial locations of the particles were different for the 
two configurations (as shown in the particle trajectory images in the Results and Discussion 
section below).  These locations were based on the assumption that the capsule was perforated 
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from one side, and the particles leave the capsule with identical velocities. Since the mass 
loading of the particles in relation to the local fluid mass is very small, the effect of the particles 
on the flow field is neglected. Three different particle diameters were simulated for each 
inhaler. The particles were assumed to be a monodisperse population of uniform spheres with 
diameters of 32, 108, and 275 m. In each simulation, roughly 1000 particles were initiated with 
zero velocity. Since the mass loading is small, collisions amongst the particles are neglected. The 
particles are evolved using discrete particle equations.  The number of collisions that each 
particle experienced with different sections of the DPIs were tracked as the particles travelled 
through the inhaler. In order to ensure statistical convergence of the results, different particle 
numbers were considered. It was found that using 500 particles was sufficient to obtain 
converged statistics for the average number of collisions that the particles undergo with the 
inhaler walls. 
5.2.9. Statistics 
Statistical significance between performance values was determined with one-way 
ANOVA with Post Hoc tests between groups according to the Bonferroni method (P < 0.05). 
5.3. RESULTS AND DISCUSSION 
5.3.1. Physical Characterization of Carrier Particle Populations 
The double-sieving technique yielded narrow particle size distributions (Figure 5.1).  
While α-lactose monohydrate is typically used as the carrier particle population in binary dry 
powder formulations, other grades including anhydrous and granulated lactose have been 
studied, affording the opportunity to assess the influence of carrier morphology on aerosol 
performance [41, 75, 79, 80].  The disparity in surface roughness between the anhydrous and 
granulated lactose particles increases with particle size, as evidenced by the diminishing specific 
surface areas of the anhydrous particles relative to their granulated counterparts with 
increasing carrier sieve fraction (Table 5.1). Surface areas of larger granulated lactose did not 
diminish appreciably as particle sizes were increased (as would be expected for perfectly 
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smooth spherical particles). Instead, the increasing roughness (due to granulation) causes a 
relatively minimal decline in surface area as the size of the particles within the powder is 
increased. The true densities of all carrier particle size fractions in both grades of lactose ranged 
between 1.54 and 1.58 g/cm3.   
5.3.2. CFD Analysis 
Internal geometries of the Handihaler and Aerolizer are illustrated in Figure 5.2.  The 
flow stream enters the Aerolizer via two tangential inlets found on opposite sides of the capsule 
chamber [37].  The resulting turbulent flow field induces the capsule to rotate and rattle with 
high frequency during inhalation, assisting in ejecting and dispersing the powdered dose 
through the perforations in the capsule wall [35].  It is noted that although the motion of the 
capsule itself is not simulated in this work, it may affect particle release and transport in the 
fluid flow, and it has been speculated that the emitted powder particles may collide with the 
capsule, though a previous investigation concluded that impactions between the powder 
particles and the spinning capsule do not significantly contribute to dispersion performance in 
the Aerolizer[35]. However, those studies were performed on pure micronized mannitol, and 
the inclusion of carrier particles may potentially alter this result and is a topic that merits future 
study.   
A key feature of the internal geometry of the Aerolizer is a grid dividing the capsule 
chamber and the mouthpiece to prevent capsule egress from the device during inhalation.  
Additionally, it is noted that the grid has been demonstrated to straighten the flow and suppress 
turbulence downstream of its location [34].  On the other hand, the mechanism of the 
Handihaler is based on the sudden expansion of the inhalation flow stream as it passes from the 
inlet into the larger capsule chamber. The abrupt opening from the smaller inlet chamber to the 
capsule chamber causes the boundary layer of the flow stream to separate at the corner of the 
expansion, creating an annular region where a portion of the flow re-circulates, resulting in a 
pressure loss in this region [49].  The incoming flow stream pushes the capsule toward the grid 
while the low pressure region simultaneously attracts the capsule toward the inlet, causing the 
capsule to spin and vibrate in the chamber [60].  Similar to the Aerolizer, the Handihaler also 
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contains a mesh between the capsule chamber and the mouthpiece. However, this grid is made 
of thinner wires and its effect on the flow field is comparably less significant than the grid 
located in the Aerolizer, as the blockage represented by the wires is a very small fraction of the 
total surface area.  
Figure 5.3 depicts the velocity magnitude of the flow stream in the inhalers at 60 L min-1. 
In the Handihaler, the maximum flow speed is found upstream of the capsule with very high 
shear flow around the capsule itself. In contrast, the Aerolizer exhibits a much more complex 
flow pattern, as the incoming flow generates a swirling motion inside the capsule chamber. The 
grid between the capsule chamber and the mouthpiece constricts the flow, and consequently 
the velocity magnitude is very high when the fluid exits the capsule chamber through the grid 
spacing. The grid also regulates the swirling flow generated by the capsule chamber [34].  
Carrier particle trajectories were simulated through the DPIs to quantify the frequency 
of their collisions with the internal geometry of the inhaler (Table 5.2).  It was expected that the 
distinct internal geometries of the inhalers would yield distinct particle trajectories.  As seen in 
Figure 5.4, the fluid flow inside the Aerolizer actively promotes particle collisions with the 
inhaler wall. The tangential air inlets introduce a swirl component to the flow stream that is 
imparted to the powder as they exit the capsule, causing particles to swirl through the 
mouthpiece.  
In contrast to the Aerolizer, carrier particles within the Handihaler experience markedly 
fewer collisions with the inhaler (Figure 5.5). The wake region downstream of the cavity causes 
the particles to accelerate and travel at an angle to the vertical direction, directing the particle 
trajectory towards the inhaler wall. As the particles have significant inertia (increasing with 
carrier particle size), once they are launched on this trajectory the fluid flow is unable to 
significantly alter the particle trajectory. The initial acceleration around the capsule introduces 
the collisional movement, pushing the particles downstream towards the inhaler exit.  
Table 5.2 shows the influence of particle diameter on the number of collisions with the 
mouthpiece wall experienced by the particles. It should be noted that the fluid flow corresponds 
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to particles with zero diameter, or zero Stokes number. Increasing the particle diameter 
increases the Stokes number and causes a departure of the particle trajectory from the fluid 
trajectory. As the particles become larger, their response to changes in the fluid flow is slower. 
Consequently, larger particles can possess ballistic trajectories and undergo more collisions, and 
increasing the particle diameter increases the number of collisions. It is seen that the Aerolizer 
exhibits greater sensitivity to particle size relative to the Handihaler. This is primarily attributed 
to the fact that the Handihaler does not introduce a swirling motion inside the mouthpiece, 
which causes the particles to have a longer residence time (or trajectory length) inside the 
mouthpiece. 
5.3.3. In vitro Aerosol Performance 
In vitro drug dispersion profiles for all experimental formulations are presented in 
Tables 5.3 to 5.4. The percentage of the nominal dose emitted from the Handihaler exceeded 
that emitted from the Aerolizer, yielding over 75% emitted fraction (EF) for all carrier particle 
sizes between both lactose grades.  For anhydrous lactose formulations dispersed from the 
Handihaler, the enhanced EF did not correspond to improved drug deposition compared with 
the Aerolizer, as respirable fraction (RF) values were generally comparable between devices 
across most carrier particle size fractions.  The disparity between EF and RF is reconciled by the 
higher fine particle fraction (FPF) values obtained from the Aerolizer, indicating that although 
for anhydrous formulations the Handihaler is more effective at emitting drug from the device, 
the Aerolizer demonstrates a greater tendency for detaching drug from the carrier particles. In 
contrast, granulated carrier particle formulations dispersed from the Handihaler outperformed 
those from the Aerolizer for all but the largest carrier particle size fractions.   
From the drug dispersion profiles, it is observed that the increased number of collisions 
between the carrier particles and inhaler does not directly translate into improved aerosol 
performance, as measured by RF.  For a given dry powder formulation, RF values reflect the 
combined EF and FPF, revealing an inhaler’s potential to both emit the drug from the device and 
detach it from the carrier, such that it can travel to the deep lung[41]. By itself, EF is a metric 
describing the inhaler’s ability to emit the drug from the device and deliver it to the patient, but 
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reveals nothing as to whether the drug is detached from the carrier, and drug that remains 
adhered to the coarse carrier particles will deposit in the mouth, throat and upper airways.  
Accordingly, FPF is a better measure of an inhaler’s drug detachment potential, providing the 
fraction of detached drug exiting the device relative to the total amount that leaves the inhaler. 
A high EF coupled with a high FPF will generate excellent RF values, but opposing EF and FPF 
performance (e.g. high EF and low FPF) will only yield moderate respirable fractions. 
Although significant differences in emitted dose were observed between the devices, 
this did not yield a consistent disparity in overall performance, as the relatively high EF from 
Handihaler was offset by the Aerolizer’s enhanced tendency to emit drug particles detached 
from the carriers. To provide an approximate measure of the relative drug detachment potential 
of the DPIs, the ratio of FPF values from the Aerolizer over the Handihaler (FPFAerolizer / 
FPFHandihaler) against the carrier particle size fraction were plotted (Figure 5.6). Values > 1 indicate 
the Aerolizer may be more effective at drug detachment while a ratio less than unity gives the 
advantage to the Handihaler.  It must be noted that detached drug particles may be 
agglomerates of primary drug particles, which due to their large size will deposit in the throat 
and conducting airways.  This is especially relevant for the corticosteroid budesonide, which has 
been demonstrated to be a relatively cohesive drug [17, 18].  However, as the same formulation 
was used for each size fraction within a lactose grade, the extent of drug agglomeration was 
presumed constant between samples, with the inhaler as the variable.  For the anhydrous 
carrier formulations, all but a single size fraction (90 – 125 µm) exceeded 1, indicating the ability 
of the Aerolizer to emit drug particles detached from the carrier outperforms the Handihaler. 
Conversely, most granulated carriers yielded better drug detachment from the Handihaler 
(ratios were less than 1).  However, at carrier particle sizes greater than the 75 – 90 µm and the 
90 – 125 µm fractions for the granulated and anhydrous carriers respectively, the FPF ratio 
began to increase, indicating an improvement in drug detachment potential of the Aerolizer 
relative to the Handihaler for large carrier particle formulations. It is speculated that the higher 
frequency of carrier-inhaler collisions within the Aerolizer as carrier size is increased may 
account for the observed improvement in drug detachment. In these larger carrier formulations, 
impaction-based forces may be a significant mechanism of drug detachment as discussed below.   
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5.3.4. Influence of Device on Performance 
Due the marked variation in the internal geometries of the two inhalers, differences in 
aerosol performance were expected between the Aerolizer and Handihaler.  Regarding device 
resistance, the Aerolizer and Handihaler reside on opposing ends of the spectrum, as the 
Aerolizer has less than half the resistance (0.072 (cmH2O)
0.5 / (L min-1)) of the Handihaler (0.158 
(cmH2O)
0.5 / (L min-1))  [37, 95].  This increased resistance of the Handihaler arises from the 
narrow inlet tube at the base of the capsule chamber (Figure 5.2) [60]. It is noted that the flow 
rate selected for this study (60 L min-1) is much higher than that typically generated through the 
Handihaler, but is readily attainable by > 90% of adult patients through an Aerolizer[95-97].  The 
relationship between inhaler resistance (R), volumetric flow rate (Q), and pressure drop (∆P) 
across a device is (∆P)0.5 = QR  [65].  For a fixed flow rate, a higher resistance device will produce 
a greater pressure drop, which has been found to correlate with improved aerosol performance 
[67, 68, 98]. Additionally, the overall energy passing through an inhaler can be approximated 
from the product of the pressure drop across the device, volumetric flow rate , and actuation 
time [33].  Thus, although the volumetric flow rate is the same through both inhalers (60 Lpm), a 
greater pressure drop, and hence a higher energy value is calculated for the Handihaler, which is 
predicted to improve performance from this DPI.  However, despite the device differences, RF 
values exhibited minimal dependence on the inhaler for the anhydrous carrier particles, varying 
instead as a function of carrier particle size, with larger carrier particle diameters diminishing 
overall performance (Figure 5.7).  By comparison, granulated lactose formulations showed some 
device dependency, notably in the smaller carrier particle size fractions, with both inhalers 
demonstrating comparable performance as carrier size increased.      
For anhydrous lactose formulations, the relatively flat surfaces of the carriers permit 
direct interaction between the drug particles and inhalation flow stream.   The overall dispersion 
performance between the devices is similar across all anhydrous carrier size fractions, indicating 
the comparable ability of the DPIs to detach drug readily accessible to the air flow.  However, in 
granulated lactose formulations, where direct interaction between the drug and flow stream is 
inhibited by the surface roughness of the carriers, the Handihaler exhibited higher RF values up 
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to the largest size fractions, when it is speculated that increasingly larger mechanical forces 
allowed the Aerolizer to improve its detachment potential (as indicated by the increasing FPF 
ratio), and attain comparable RF values.  The improved performance at smaller carrier sizes of 
granulated lactose in the Handihaler may be attributed to the greater overall aerodynamic 
energy passing through this device (as mentioned above).  A previous study on the Handihaler 
revealed that a pressure gradient develops across the capsule chamber, pulling drug particles 
primarily from the lower capsule perforation located nearest the corner of the flow stream 
expansion[60].   This mechanism may enable drug within the surface asperities of the granulated 
particles to be pulled-off of the carriers, allowing performance to be relatively independent of 
carrier particle diameter and thus surface roughness, as the surface roughness of granulated 
carriers tended to increase with carrier size.  
5.3.5. Interparticle Collisions 
In addition to carrier particles colliding with the inhaler walls, interparticle collisions 
between carriers during actuation may provide an additional source of mechanical detachment 
forces.  For a fixed mass of powder, increasing the diameter of the carrier population diminishes 
the overall number of carrier particles in the dose, such that formulations with the largest 
lactose sizes contain a fraction of the number of carrier particles relative to the smallest carrier 
size ranges.  Previous studies have reported that lactose fluidizes from capsules via two distinct 
mechanisms dependent upon the flowability, and hence the cohesiveness, of the powder [99-
101].  Powders with good flowability are entrained by an ‘erosion’ mechanism, where the 
powder is fluidized by layers and exits the inhaler gradually as a continuous stream [100, 101]. 
By contrast, for poorly flowing powders fluidization occurs by the ‘fracture’ mechanism whereby 
the powder fluidizes as multiple agglomerates, and in extreme cases may fluidize as a single 
aggregated powder plug.   
It has been proposed that smaller carrier particle size fractions, particularly those with a 
significant concentration of lactose fines, improve aerosol performance by coupling the fracture 
entrainment mechanism with an extensive number of carrier particles, thereby generating a 
high density aerosol cloud that promotes collisions between lactose carriers[100, 101].   In the 
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present study, only anhydrous formulations exhibited performance consistent with this 
mechanism, but performance from granulated carriers was incompatible with this theory, as the 
< 32 µm carrier populations did not yield RF values significantly higher than the larger carriers.  
However, variables apart from carrier particle size can affect the extent to which interparticle 
collisions may occur.  For instance, the DPI employed may influence interparticle collisions, as 
devices with more complex internal geometries may enhance the frequency and/or magnitude 
of interparticle collisions relative to inhalers with simpler internal geometries. Additionally, the 
cross-sectional area of the capsule perforation may likewise affect interparticle collisions, as 
smaller openings can prevent the powder from exiting the capsule as agglomerated plugs, thus 
limiting the density of the aerosol cloud. Thus, it is noted that the inhalers employed in these 
studies may not be ideal for promoting interparticle interactions, as the swirling particle 
trajectories in the capsule chamber of the Aerolizer may be offset by the small cross-sectional 
area of the capsule perforations, while the larger diameter capsule openings from the 
Handihaler are coupled with an internal geometry that may not induce extensive interparticle 
collisions relative to the Aerolizer.  Accordingly, although interparticle collisions may influence 
aerosol performance under certain conditions, this detachment mechanism was not supported 
by the data for both lactose grades, and thus CFD simulations capturing carrier-carrier 
interactions were deemed beyond the scope of the present study. 
5.3.6. Mass Median Aerodynamic Diameter 
In contrast to the respirable fraction, the mass median aerodynamic diameter (MMAD) 
of drug depositing on the stages of the cascade impactor varies significantly between inhalers 
for both anhydrous and granulated lactose formulations (Figure 5.8).  Furthermore, while the 
MMAD from the Aerolizer displayed an overall decreasing trend with increasing carrier particle 
size for both lactose populations, MMAD values obtained from the Handihaler were generally 
independent of the formulation.  The disparity between the MMAD values for formulations 
dispersed through the inhalers were greatest at the smaller carrier particle formulations, and 
eventually converged on a mutual value for the largest carrier size fractions. In our previous 
study, it was postulated that the reduction in MMAD obtained from larger carrier particles 
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dispersed through the Aerolizer may be attributed to the increased detachment of smaller drug 
particles from the carrier surface [80].  As the collision force between a particle and inhaler is 
dependent on the mass, and thus the volume, of the carrier particle, the momentum generated 
from a collision increases with the cube of the carrier particle diameter, assuming a relatively 
constant particle velocity (as volume   diameter3 )[8].  Thus, larger carrier particles can 
generate strong mechanical detachment forces, which can potentially exceed fluid-based forces 
[32, 87, 93].  
These strong mechanical forces may dislodge drug particles resistant to fluid-based 
detachment, including small aggregates and primary drug particles located within carrier 
particle surface asperities, inhibiting their interaction with the flow stream.  Accordingly, the size 
of drug particles depositing in the impactor would be expected to decrease with larger carrier 
particle populations, as observed in both the anhydrous and granulated formulations dispersed 
from the Aerolizer.  Comparing MMAD values obtained from the Aerolizer with the 
corresponding RF values, the carrier particle size fraction when the MMAD markedly declined 
matched the carrier size when aerosol performance exhibited a local improvement; this 
corresponded to the 180 - 212 µm size fraction for anhydrous carriers, and 90 - 125 µm for 
granulated lactose (p < 0.05). Conversely, MMAD values in the Handihaler were relatively 
consistent between carriers for both lactose grades, displaying no general trend with 
performance, although the MMAD from formulations dispersed through the Handihaler were 
consistently lower than from the Aerolizer, with the exception of the largest carrier sizes (> 180 
µm).  
In combination with the particle trajectory simulations, the aerosol performance data 
suggest the presence of an impaction-based mechanism of drug detachment in the Aerolizer 
whereby the relatively numerous and high energy collisions between large carriers and the 
inhaler wall generate a force sufficient in both magnitude and direction to detach smaller drug 
particles immune to detachment by the flow stream.  As discussed in detail elsewhere, this 
favors large carrier particles with extensive surface roughness, and accordingly the 
improvement in aerosol performance with larger carrier populations is more pronounced in 
 126 
granulated lactose formulations[80].  However, it is noted that while the present studies were 
performed at a fixed flow rate, the velocity, and hence momentum, of the carrier particles may 
significantly affect performance, particularly for larger carrier populations.  
5.4. CONCLUSION 
In this chapter, the influence of carrier particle size and surface roughness on inhaler 
performance was investigated.  Coupling the CFD particle trajectory simulations with the in vitro 
results, it is concluded that impaction-based forces are not a significant mechanism of 
detachment in the Handihaler, as reflected by both the absence of improved performance at the 
large carrier fractions and the minimal increase in simulated carrier particle-inhaler collisions 
with carrier diameter.  In contrast, the internal geometry of the Aerolizer is capable of 
generating a higher number of particle-inhaler collisions, with the frequency of the collisions 
increasing with carrier diameter.  Accordingly, aerosol performance from this DPI exhibited a 
dependence on the carrier particle size fraction which was not observed in the Handihaler to a 
similar extent.  Additionally, performance was also significantly influenced by carrier particle 
morphology, and although granulated lactose is not commonly employed in dry powder inhaler 
formulations, the use of this lactose grade afforded greater insight into distinctions in DPI 
performance than relatively smooth surfaced anhydrous lactose.   In conclusion, the results of 
this study suggest that matching the physical properties of the carrier population to the 
predominant detachment mechanism of the DPI may significantly influence aerosol 
performance.         
Up to this point, all the in vitro deposition studies have been performed at a fixed flow 
rate, specifically 60 L min-1.  It has been speculated that large carrier particles with extensive 
surface roughness promote drug detachment via mechanical forces that arise during collisions 
between the carrier particles and the inhaler walls, and that the greater mass of the larger 
particles increases their momentum relative to smaller carriers, inducing more forceful 
impactions.   
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Accordingly, as momentum is a function of both the mass and the velocity of the carrier 
particles, it is speculated that increasing the inhalation flow rate may prove more beneficial to 
particles that rely on mechanical detachment forces as opposed to particles that rely primarily 
on fluid forces, given that mechanical forces are thought to be more effective at particle 
detachment.  Studies investigating the influence of flow rate on dispersion as the size and 
surface roughness of the lactose carriers are altered will be the focus of the next chapter.   
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Figure 5.1.  SEM Images of Anhydrous and Granulated Lactose Carrier Particle 
Populations 
SEM micrographs of uncoated (A) 32 - 45 µm anhydrous lactose, (B) 90 – 125 µm 
anhydrous lactose, (C) 250 – 300 µm anhydrous lactose, (D) 32 - 45 µm granulated lactose, (E) 
90 – 125 µm granulated lactose, and (F) 250 – 300 µm granulated lactose sieve fractions.  Scale 
bars denote 200 µm. 
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Figure 5.2.  Schematic views of the Handihaler® (left) and Aerolizer® dry powder 
inhalers.   
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Figure 5.3.  Contour of Velocity Magnitude Inside Handihaler (left) and Aerolizer 
(right). 
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Figure 5.4.  Carrier particle trajectory inside the Aerolizer at 60 L min-1  
The particles were modeled as spherical, mono-disperse populations.  From left, article 
diameter = 32, 108, and 275 m. 
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Figure 5.5.  Carrier particle trajectory inside the Handihaler at 60 L min-1  
The particles were modeled as spherical, mono-disperse populations.  From left, particle 
diameter = 32, 108, and 275 m. 
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Figure 5.6.  Ratio of Fine Particle Fraction Values from the Aerolizer and 
Handihaler 
Ratio of the FPF values obtained from the Aerolizer over the Handihaler for both 
anhydrous and granulated lactose formulations as a function of carrier particle size.   
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Figure 5.7.  In vitro Performance of Anhydrous and Granulated Carrier 
Formulations 
Respirable fraction (RF) values of (A) anhydrous and (B) granulated lactose carrier 
particles dispersed from the Aerolizer and Handihaler at 60 L min-1.   Values are given as the 
mean of N = 3 replicates, with error bars representing the standard deviation for N = 3 
replicates. 
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Figure 5.8.  MMAD Values of Budesonide Dispersed from the Handihaler and 
Aerolizer 
Mass median aerodynamic (MMAD) of budesonide particles following dispersion of 2% 
(w/w) formulations with (A) anhydrous lactose, and (B) granulated lactose carrier particles at 60 
L min-1 from both the Aerolizer and Handihaler DPIs.   Values are given as the mean of N = 3 
replicates, with error bars representing the standard deviation for N = 3 replicates.   
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Table 5.1. Specific surface areas (SSA) of Anhydrous and Granulated lactose carrier particles by 
sieve fraction 
 
 
 
 
 
 
 
 
 
  
Carrier Sieve 
Fraction (µm) 
 
Anhydrous (AN) 
(m
2
/g) 
 
Granulated (GR) 
(m
2
/g) 
< 32 0.94 1.87 
32 – 45 0.48 1.71 
45 – 63 0.38 1.62 
63 – 75 0.43 1.64 
75 – 90 0.37 1.52 
90 – 125 0.41 1.56 
125 - 150 0.38 1.81 
150 – 180 0.38 1.73 
180 – 212 0.40 1.44 
212 - 250 0.42 1.67 
250 - 300 0.36 1.46 
 142 
 
 
 
 
 
Table 5.2. Average Simulated Collisions Experience by Carrier Particles in Aerolizer and 
Handihaler 
 
Carrier Particle 
Sieve Fraction (µm) 
 
Aerolizer  Handihaler 
32 (µm) 107.5 (µm) 275 (µm)  32 (µm) 107.5 (µm) 275 (µm) 
Inhaler-Carrier  
Collisions 
 
2.3 3.6 4.0 
 
1.7 2.2 2.3 
 
Average number of collisions between a carrier particle and the inhaler as it exits the device 
during actuation from the Aerolizer and Handihaler at 60 L min-1.   
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Table 5.3. In vitro Aerosol Performance Data from Anhydrous Lactose Carrier Particle 
Formulations 
Carrier Particle Sieve 
Fraction    (µm) 
Aerolizer® Handihaler® 
EF FPF RF EF FPF RF 
< 32 63.5  (1.6) 29.1  (1.4) 18.4  (0.7) 86.4  (1.1) 18.5  (0.7) 15.9  (0.4) 
32 – 45 64.5  (1.8) 21.3  (0.8) 13.7  (0.3) 79.0  (8.0) 15.5  (0.7) 12.2  (1.1) 
45 – 63 63.1  (2.2) 23.1  (1.8) 14.6  (1.4) 76.3  (1.2) 17.1  (1.2) 13.0  (0.9) 
63 – 75 68.9  (1.8) 15.1  (0.4) 10.4  (0.3) 79.2  (2.5) 13.7  (0.3) 10.8  (0.2) 
75 – 90 71.8  (2.4) 15.2  (0.3) 10.9  (0.5) 77.1  (1.3) 14.4  (0.7) 11.1  (0.4) 
90 - 125 62.3  (1.9) 13.7  (0.6) 8.5   (0.4) 80.0  (8.1) 15.9  (0.8) 12.4  (1.2) 
125 – 150 62.7  (2.1) 15.6  (1.4) 9.8   (1.2) 81.1  (4.7) 9.9   (0.5) 8.0   (0.8) 
150 – 180 62.3  (2.0) 12.1  (0.8) 7.5   (0.3) 82.3  (1.9) 9.5   (1.6) 7.8   (1.3) 
180 – 212 61.8  (1.9) 14.1  (1.1) 8.7   (0.5) 79.9  (1.8) 10.1  (0.2) 8.1   (0.2) 
212 – 250 63.4  (2.3) 15.5  (0.8) 9.9   (0.6) 82.3  (0.8) 8.7   (1.9) 7.1   (1.5) 
250 - 300 61.6  (1.7) 15.0  (1.1) 9.3   (0.9) 80.2  (0.4) 9.8   (0.3) 8.1   (0.6) 
 
Emitted fraction (EF), fine particle fraction (FPF), and respirable fraction (RF) for 2% 
(w/w) budesonide formulations with anhydrous lactose carrier particles characterized in vitro 
from the Aerolizer® and Handihaler® dry powder inhalers at 60 L min-1.  Values are given as the 
mean of N = 3 replicates, and values within parentheses represent the standard deviation for N 
= 3 replicates. 
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Table 5.4. In vitro Aerosol Performance Data from Granulated Lactose Carrier Particle 
Formulations. 
Carrier Particle Sieve 
Fraction    (µm) 
Aerolizer® Handihaler® 
EF FPF RF EF FPF RF 
< 32 57.0  (1.4) 18.5  (1.2) 11.1  (1.6) 76.9  (1.6) 17.1  (1.4) 13.1  (0.8) 
32 – 45 69.1  (3.7) 11.1  (0.6) 7.7   (0.1) 82.0  (0.5) 15.4  (1.0) 12.6  (0.8) 
45 – 63 74.4  (4.1) 8.9   (1.2) 6.6   (0.6) 82.1  (1.9) 12.8  (0.2) 10.5  (0.3) 
63 – 75 73.8  (3.7) 12.6  (1.4) 9.3   (0.6) 78.4  (2.7) 16.2  (0.7) 12.6  (0.2) 
75 – 90 73.9  (6.6) 9.7   (2.1) 7.2   (0.8) 78.7  (1.9) 19.4  (2.4) 15.3  (1.6) 
90 - 125 77.8  (1.8) 11.6  (0.9) 9.0   (0.5) 86.1  (2.0) 17.9  (0.8) 15.3  (0.4) 
125 – 150 71.3  (4.2) 18.9  (1.5) 13.4  (0.3) 84.3  (3.4) 20.5  (2.5) 17.2  (1.7) 
150 – 180 73.8  (2.5) 14.2  (1.3) 10.5  (0.7) 87.3  (1.4) 15.2  (1.5) 13.3  (1.1) 
180 – 212 72.6  (3.2) 20.8  (1.1) 15.1  (0.8) 87.1  (1.6) 16.1  (1.4) 14.0  (1.1) 
212 – 250 68.7  (5.4) 20.2  (1.5) 13.8  (0.7) 84.3  (1.1) 15.4  (2.8) 13.1  (2.3) 
250 - 300 68.5  (4.5) 20.1  (1.5) 14.5  (0.5) 85.5  (0.6) 18.4  (1.0) 15.7  (1.0) 
 
Emitted fraction (EF), fine particle fraction (FPF), and respirable fraction (RF) for 2% 
(w/w) budesonide formulations with granulated lactose carrier particles characterized in vitro 
from the Aerolizer® and Handihaler® dry powder inhalers at 60 L min-1.  Values are given as the 
mean of N = 3 replicates, and values within parentheses represent the standard deviation for N 
= 3 replicates. 
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CHAPTER 6 
6. Influence of Flow Rate on Binary DPI Formulations as a Function of 
Carrier Particle Diameter and Surface Roughness  
6.1. INTRODUCTION 
The studies detailed in the preceding three chapters have demonstrated that large 
diameter carrier particles may prove beneficial to aerosol performance by promoting drug 
detachment via mechanical forces. In chapter 4, it was speculated that drug detachment from 
carrier particles with extensive surface roughness would rely less on fluid forces and more on 
mechanical forces, as the rugosity of the carrier surface would inhibit the flow stream from 
direct interaction with the drug particles.  It was also theorized that the magnitude of the 
impaction forces generated by carrier particle-device collisions would be enhanced for larger 
diameter carriers relative to smaller particles due to their potentially higher momentum.  This 
was supported by the observed aerosol performance profiles of formulations prepared with 
granulated lactose carriers, where drug deposition improvements were observed as the size of 
the carrier particle increased [80]. This contrasts with the performance of carrier particles with 
less extensive surface roughness, as drug deposition generally diminished with increasing carrier 
particle diameter.       
To further examine the potential of carrier particle-device collisions to promote drug 
detachment, the performance of formulations prepared with carrier particle populations of 
varying size and surface roughness was examined through two commercial DPIs possessing 
markedly different internal geometries, and thus distinct powder de-agglomeration 
mechanisms. These studies were combined with computational fluid dynamics (CFD) to simulate 
the particle trajectories through the device as the diameter of the carrier particle was altered.  
The results indicated that coupling an inhaler that promotes particle-device collisions to carrier 
particle populations with physical properties that would most benefit from impactions (e.g. 
large carriers with high surface roughness), can yield improvements in performance relative to 
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carrier particle populations where collisions are less frequent.  Conversely, for inhalers with 
internal geometries that do not promote carrier particle-inhaler collisions, no significant 
improvements in drug deposition were observed as carrier diameter was increased.      
In the previous work, the flow rate was maintained at a constant value, specifically 60 L 
min-1.  In Chapter 4 it was speculated that the higher momentum arising from larger carriers 
(assuming comparable particle velocities) would induce more forceful collisions with the inner 
walls of the device as the particle travels through the inhaler during actuation.  As momentum is 
a function of both the mass and velocity of the carrier particle, it is speculated that increasing 
the flow rate through an inhaler may provide increased dispersion improvements from larger 
diameter carriers relative to their smaller counterparts.   
Specific Aim  
Accordingly, the specific aim of this chapter was to evaluate the influence of flow rate 
on the performance of binary DPI blends as the size and surface roughness of the carrier particle 
population is altered.  For this purpose, two morphologically distinct lactose grades were 
selected to serve as carriers, specifically α-lactose monohydrate and granulated lactose, and 
aerosol performance was evaluated in vitro via cascade impaction at 30, 60 and 90 L min-1.  As it 
is noted that increasing the flow rate through the device will enhance the magnitude of both the 
fluid forces and mechanical forces experienced by the powder, the use of lactose grades 
possessing either low or high surface roughness will allow discernment of which force plays a 
more significant role in improving performance, as the influence of fluid forces are expected to 
be mitigated for granulated carriers relative to α-lactose monohydrate. Additionally, to ensure 
that any observed performance differences were attributable to the carrier particles rather than 
the drug, the blends were prepared with both budesonide and salbutamol sulphate.    
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6.2. EXPERIMENTAL 
6.2.1. Materials 
Micronized salbutamol sulphate (USP grade) was purchased from Letco Medical (AL, 
USA) and used as received.  Budesonide was purchased in bulk (JinHuo Chemical Company, 
China) and micronized with a high energy jet mill (Aljet; Fluid Energy Processing and Equipment 
Co., PA, USA).  Analytical grade ethanol was purchased from Sigma (Sigma-Aldrich Chemical Co. 
MO, USA).  As carrier particle populations, α-lactose monohydrate (Pharmatose® 80 Mesh) and 
granulated lactose (SuperTab® 30GR) were provided by DMV-Fonterra (New Zealand).  Size-3 
HPMC capsules (VCaps®) were provided by Capsugel (NJ, USA).   
6.2.2. Carrier Particle Fractionation 
Samples of α-lactose monohydrate and granulated lactose were fractionated using an 
Autosiever® vibrating sieve shaker (Gilson Company Inc., OH, USA).  The sieving intensity 
(amplitude) was set to 40, and samples were fractionated for 5 minutes through sieves with the 
following mesh sizes: 300 µm, 250 µm, 150 µm, 125 µm, 63 µm, and 45 µm. Following the initial 
fractionation, the lactose carriers were sieved two additional times, at 3-minute sieving 
intervals, to obtain narrow particle size distributions.  
6.2.3. Preparation of Binary Blends 
1% (w/w) binary formulations were prepared by mixing 5 mg of drug with 495 mg of 
each lactose carrier particle population via geometric dilution.  The formulations were blended 
with a TurbulaTM orbital mixer (Glen Mills, NJ) for 40 minutes at 46 RPM.  The blend uniformity 
of each formulation was evaluated by randomly selecting eight 20-mg samples from each blend 
and assessing the drug content.  The blend uniformity is provided as the percent coefficient of 
variation for N = 8 replicates.   
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6.2.4. Physical Characterization 
The size distribution and surface roughness of the lactose carrier particle populations 
were visually examined by scanning electron microscopy (SEM; Supra 40VP, Zeiss, Germany). 
Prior to SEM, approximately 20 nm of a platinum::palladium (80::20) mixture was deposited 
onto the particles via sputter coating.  
Sizing of the drugs and the carrier particle populations were performed using laser 
diffraction with a Sympatec HELOS (Sympatec GmbH, Germany) apparatus equipped with a 6-mL 
cuvette dispersing system.  Mineral oil was used as the dispersing fluid, which included 1% Span 
85 to aid in particle de-aggregation.  The powders were suspended in the mineral oil and, if 
physically stable, sonicated for 60 seconds to disrupt aggregates.  Measurements were collected 
following elimination of all visible air bubbles.  The ‘forced stability’ option was used to ignore 
the signal from errant dust or residual air bubbles.   
The specific surface area of the lactose carrier particle populations was evaluated via 
nitrogen adsorption with a single-point BET method using a Monosorb® surface area analyzer 
(Quantrachrome Instruments; FL, USA).  Samples were outgassed under nitrogen at 40 °C for 24 
hours prior to each measurement.   
6.2.5. In Vitro Aerosol Performance 
20 (± 1) mg of powder were loaded into size-3 HPMC capsules and dispersed through an 
Aerolizer® (Plastiape S.p.A., Italy) DPI  into a next generation cascade impactor (MSP 
Corporation, MN, USA) at volumetric flow rates of 30, 60 and 90 L min-1.   The actuation time 
was adjusted to allow 4 L to flow through the inhaler.  To inhibit particle re-entrainment, the 
NGI stages were coated with a 2% (v/v) solution of silicon oil in hexane and allowed to air dry 
before each impaction.  Prior to each actuation, 15 mL of sample solvent (H2O for salbutamol 
sulphate and EtOH for budesonide) were added to the pre-separator and collected following 
powder dispersion from each capsule. Drug depositing in the capsule, inhaler, mouthpiece 
adaptor, and induction port were collected by rinsing each component with 10 mL of sample 
solvent, while the NGI stages were each rinsed with 5 mL.   
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The drug content was evaluated using UV-VIS absorption spectroscopy at 230 nm and 
244 nm for salbutamol sulphate and budesonide, respectively.  The emitted fraction was 
calculated as the ratio of the drug mass depositing in the mouthpiece, induction port, pre-
separator, and impactor stages over the cumulative drug mass collected following actuation 
(total drug deposited in the capsule, inhaler, mouthpiece, induction port, pre-separator and 
stages).  At 30 and 60 L min-1, the fine particle fraction (FPF) of each dose was the ratio of the 
drug mass depositing on stages 3 - 8 (corresponding to an aerodynamic diameter less than 6.4 
µm and 4.46 µm for 30 and 60 L min-1, respectively) of the impactor over the emitted dose [72].  
The respirable fraction (RF) was the ratio of the drug mass depositing on stages 3 – 8 over the 
entire dose recovered following each actuation.  At 90 L min-1, the same performance metrics 
were evaluated, with the exception that the drug collected from stages 2 - 8 was considered to 
be respirable as the cut-off diameter of stage 1 at 90 L min-1 is 6.48 µm.          
6.2.6. Statistics 
Statistical significance between performance values was determined with one-way 
ANOVA with Post Hoc tests between groups according to the Bonferroni method (P < 0.05). 
6.3. RESULTS AND DISCUSSION 
6.3.1. Physical Characterization 
The sizing data and specific surface area measurements for each carrier particle 
population are presented in Table 6.1.  For α-lactose monohydrate, increasing the diameter of 
the carrier particles resulted in a progressive reduction in SSA, with values declining from 0.39 to 
0.18 m2/g between the 45 – 63 µm carriers and the 250 – 300 µm fraction.  This contrasts with 
the granulated carriers, where the overall decline between the smallest (0.52 m2/g) and largest 
(0.43 m2/g) carrier fractions was only 17%, as compared to the 54% SSA reduction observed 
between lactose monohydrate carriers.   Additionally, the granulated carriers did not display a 
progressive SSA decline with larger particles, as the SSA measured from the largest size fraction 
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exceeded that of the 125 – 150 µm carriers.  The increasing disparity in surface roughness 
between the two grades as a function of carrier particle diameter is seen in Figure 6.1.   
6.3.2. In vitro Aerosol Performance 
The complete aerosol performance data for the salbutamol sulphate and budesonide 
formulations are presented in Tables 6.2 and 6.3, respectively.  Given that multiple parameters 
were altered throughout this study, the influence that carrier particle size and surface roughness 
had on performance as a function of flow rate will be examined separately.  It is noted that the 
Aerolizer is a relatively low resistance device, and 90 L min-1 corresponds to approximately a 4 
kPa pressure drop through this inhaler [34, 97, 102].  Accordingly, this is a flow rate that is 
readily achieved by most patients through this DPI [97].        
6.3.3. Influence of Carrier Particle Size (Salbutamol Sulphate) 
Figure 6.2 depicts the flow rate performance of the salbutamol sulphate formulations as 
a function of carrier particle size.  For α-lactose monohydrate, increasing the diameter of the 
carrier particle population inhibited performance for all flow rates examined.  At 30 L min-1, the 
disparity between the smallest and largest size fractions was most pronounced, with respective 
RF values of 22% and 8%.  As the flow is increased to 90 L min-1 the 45 – 63 µm formulation still 
outperformed its 250 – 300 µm counterpart, however the difference between them was less 
stark than at the lower flow rate, as the 250 – 300 µm carriers produced an RF value of 30% 
relative to 38% from the small carriers.   
For the granulated carriers, 30 L min-1 proved most detrimental to performance from 
the 250 – 300 µm, as RF was only 9% compared to 19% from the 45 – 63 µm carriers.  As with 
lactose monohydrate, the largest carriers exhibited the greatest relative improvement in 
performance with increasing flow rate. However, at 90 L min-1 the largest carrier size fraction 
demonstrated comparable performance to the 45 – 63 µm carriers.  Additionally, the 125 – 150 
µm carriers also exhibited performance comparable to the smaller size fraction at both               
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60 L min-1 and 90 L min-1, in contrast to lactose monohydrate, where the smallest size fraction 
continually produced higher RF values across the three flow rates.     
6.3.4. Influence of Carrier Particle Size (Budesonide) 
The flow rate performance of the budesonide formulations as a function of carrier 
particle size is provided in Figure 6.3.  For lactose monohydrate, performance was comparable 
across the carrier size ranges for the tested flow rates.  A slightly greater improvement in 
performance with flow rate was noted for the 250 – 300 µm carriers as RF values ranged from 9 
- 24% compared against 13 – 24% for the 45 – 63 µm particle size fraction.   
As with the lactose monohydrate carriers, the granulated lactose formulations exhibited 
comparable performance at the lower flow rate.  However, performance differed between the 
particle sizes as flow rate was increased.  Interestingly, it was the two largest size fractions that 
demonstrated both the greatest performance increase, and the highest RF values, while the 45 – 
63 µm carriers provided significantly lower performance at 60 and 90 L min-1.   For the 45 – 63 
µm size fraction, the respirable fraction doubled from 11% up to 22% as flow was increased 
from 30 to 90 L min-1.  In contrast, performance from the 250 – 300 µm carriers more than 
tripled across the same flow rate span, as RF values increased from 12% to 37%.   
6.3.5. Influence of Surface Roughness 
The flow rate performance of the formulations as a function of particle surface 
roughness is presented in Figure 6.4.  As was noted previously, the different APIs generally 
resulted in markedly different dispersion profiles for a given lactose grade-size fraction 
combination.  The exception to this was the 125 – 150 µm and 250 – 300 µm granulated carrier 
particles.   
However, when aerosol performance was evaluated comparing different lactose grades 
of the same carrier particle size fraction, it was observed that the overall performance trends 
were similar between APIs.  Performance was essentially comparable for the 45 – 63 µm carriers 
at all flow rates (with budesonide at 60 L min-1 being the lone exception).  For the two larger 
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carrier fractions, both lactose grades produced similar RF values at 30 L min-1.   However, as the 
flow rate was increased disparities were noted, as the granulated carriers outperformed their 
lactose monohydrate counterparts with the exception of the 125 – 150 µm/salbutamol 
formulations, where performance differences were slight but not significant (p < 0.05).  Overall, 
the greatest performance disparity between carriers was observed for the 250 – 300 
µm/budesonide blends, as the granulated carriers produced an average respirable fraction of 
37% compared to 24% for the lactose monohydrate carriers.   
6.3.6. Combined Influence of Size and Surface Roughness 
To assess the combined influence of carrier particle size and surface roughness on 
performance, the slope of the improvement in RF with increasing flow rate is shown for both 
drugs in Figure 6.5.  Of the three size fractions, the 45 – 63 µm exhibit the least flow rate 
dependent performance, as the performance improvements across the studied flow rates were 
not as stark relative to the larger carriers.  For the larger carriers, the typically lower 
performance at 30 L min-1 coupled to their greater overall improvement with increasing flow 
rate resulted in larger values for the RF slope.  It is noted that the relative values between 
carrier size fractions for a given lactose grade were similar as the drug was varied, indicating 
that despite producing significant differences in terms of absolute aerosol performance, the 
relative differences in performance were generally independent of the drug employed. Of the 
six carrier particle populations examined, the 250 – 300 µm granulated carriers produced the 
greatest performance improvement with flow rate.  Given that the high surface roughness 
would be expected to inhibit detachment by the flow stream, the enhanced performance of 
these carriers may be attributed to increased mechanical impaction forces.     
6.3.7. Influence of API 
The use of two APIs resulted in marked variations in aerosol performance among lactose 
grades. Overall, salbutamol sulphate formulations tended to produce significantly greater 
performance values relative to budesonide.  However, for the 125 -150 µm and 250 – 300 µm 
granulated carriers, RF values were comparable between drugs at 90 L min-1, indicating that in 
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contrast to the other tested carrier particle populations, performance from these carrier 
particles is relatively independent of the drug employed at the higher flow rate.  This may 
suggest that for these carrier particle populations, the detachment forces exceed adhesion 
forces at higher flow rates.   
The influence that the API material can impart to aerosol performance has been 
reported previously and is speculated to be due to the distinct physicochemical properties of the 
drug materials, specifically their respective adhesive and cohesive forces [17, 19]. Previous 
research examining these properties for salbutamol sulphate and budesonide concluded that 
budesonide possesses a high cohesive tendency while salbutamol sulphate is characterized as 
relatively adhesive, indicating that in a binary blend salbutamol particles may preferentially bind 
with lactose rather than form drug agglomerates via cohesive interactions, as would be 
predicted for budesonide [17].  It is noted that these adhesive and cohesive properties of the 
API described the relative affinity, or lack thereof, between the drug and lactose, and thus the 
described properties may differ as the frame of reference is altered.  However, as the carriers in 
the present study were also lactose, it was assumed that budesonide was cohesive and 
salbutamol sulphate was adhesive.     
The granulated lactose particles were selected in part for their potential to mitigate the 
role of fluid forces in drug detachment, thereby allowing the influence of mechanical 
detachment forces to be more clearly evaluated.  However, it is noted that the greater surface 
area of the granulated carriers relative to α-lactose monohydrate (especially for the 250 – 300 
µm fraction) may aid aerosol performance by inhibiting the formation of drug aggregates (for 
high drug concentrations), and also by sheltering drug particles within surface asperities and 
thus limiting the extent of the press-on forces between drug and carrier particles that arise 
during mixing.  This is expected to lower the adhesion force between the drug and carrier 
surface, as the press-on forces can increase the contact area, and thus the magnitude of the 
interaction, between particles. This has been discussed in great detail previously, particularly by 
de Boer and colleagues [9, 29].   
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To summarize the blending theory, it is noted that two distinct types of drug 
agglomerates are encountered during blending.  ‘Natural’ agglomerates are initially present in 
the drug powder, and during blending they may be broken up through abrasion as drug is 
continuously ground between coarse carrier particles.  In contrast, ‘blending’ agglomerates are 
formed during powder mixing due to cohesive interactions between the drug particles [9].  
Returning to the discussion of differing adhesive and cohesive APIs, it would be predicted that 
budesonide would prove most likely to form blending agglomerates, while salbutamol sulphate 
would be predicted to be distributed uniformly, given its reported high adhesive interaction 
with lactose [17].   
Accordingly, for budesonide thorough blending, particularly to induce abrasion of the 
drug between carrier particles, would be required to disrupt agglomerates [18].  However, the 
high surface rugosity of the larger granulated carrier particles would be expected to shelter the 
budesonide agglomerates within their surface asperities, inhibiting the ability of these carriers 
to both disrupt natural agglomerates and prevent formation of blending agglomerates [9].  This 
in turn could be expected to impair delivery of budesonide from large granulated carriers 
relative to lactose monohydrate, as drug agglomerates typically deposit in the induction port 
and pre-separator.     
Conversely, for an adhesive drug such as salbutamol sulphate, the opposite would be 
predicted as the formation of blending agglomerates would not be expected to be problematic, 
but large press-on forces could potentially augment the already strong adhesive interaction 
(relative to budesonide) between drug and carrier [29, 30].  These press-on forces would be 
larger for the lactose monohydrate carriers, as their low surface roughness would preclude drug 
sheltering in contrast to the granulated particles.  
Accordingly, for a given size fraction, particles with low and high surface rugosity could 
potentially improve or impair performance, dependent upon the properties of the drug.  Thus, 
two APIs with distinct adhesive and cohesive properties were selected to determine if the 
aerosol performance improvement previously observed from the large granulated carriers was 
due primarily to the drug or the carrier, as the primary benefit to performance imparted by 
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these carriers could potentially occur during blending rather than during dispersion. However, as 
noted above, while absolute performance values differed significantly between salbutamol and 
budesonide formulations, the relative differences as carrier particle size and surface roughness 
varied were independent of the API.      
6.4. CONCLUSION 
The present chapter evaluated the influence of the volumetric flow rate on the 
performance of binary DPI formulations prepared with multiple carrier particle size fractions 
possessing low and high surface roughness.  It was noted that although both the fluid forces and 
mechanical forces are increasing with the flow stream, the use of carrier particles with extensive 
surface roughness would mitigate the influence of flow detachment forces relative to particles 
with a lower degree of surface asperities.  The results from this study suggest that increasing 
flow is most beneficial to larger diameter carrier particles in general, and to large carrier 
particles with extensive surface roughness in particular.  Accordingly, as mechanical forces 
would predominate for these carriers, it was proposed that increasing the flow stream promotes 
forceful collisions between the carrier particle and inhaler due to the increased momentum of 
larger particles relative to smaller size fractions.   
The results of the present study, in combination with the previous three chapters, have 
demonstrated that under conditions where mechanical detachment forces are considerable, 
large carrier particles exhibit aerosol performance levels that deviate considerably from that 
predicted from many of the theories described in the literature.  Specifically, dispersing large 
diameter carrier particles with extensive surface roughness through a low resistance device 
designed to promote carrier particle-device collisions yields excellent drug dispersion 
performance.      
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Figure 6.1.  SEM Images of α-Lactose Monohydrate and Granulated Lactose 
Carrier Particles 
SEM images depicting both α-lactose monohydrate carrier particles fractionated into (A) 
45 – 63 µm, (B) 125 -150 µm and (C) 250 – 300 µm size ranges. Granulated lactose carrier 
particles fractionated into (D) 45 – 63 µm, (E) 125 -150 µm and (C) 250 – 300 µm size ranges are 
also shown. 
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Figure 6.2.  Aerosol Performance of Salbutamol Sulphate Blends with Increasing 
Flow Rate 
Respirable fractions (RF) from 1% (w/w) salbutamol sulphate formulations blended with 
45 – 63 µm, 125 – 150 µm, or 250 – 300 µm sieved size fractions of (A) α-lactose monohydrate 
or (B) granulated lactose carrier particles.  Data are presented as the mean (± standard 
deviation) for N = 3 replicates.   
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Figure 6.3.  Aerosol Performance of Budesonide Blends with Increasing Flow Rate  
Respirable fractions (RF) from 1% (w/w) budesonide formulations blended with 45 – 63 
µm, 125 – 150 µm, or   250 – 300 µm sieved size fractions of (A) α-lactose monohydrate or (B) 
granulated lactose carrier particles.  Data are presented as the mean (± standard deviation) for 
N = 3 replicates.   
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Figure 6.4.  Aerosol Performance as a Function of Carrier Particle Surface 
Roughness 
Respirable fractions (RF) from 1% (w/w) salbutamol sulphate formulations with either α-
lactose monohydrate or granulated lactose carrier particle populations with sieved size fractions 
of (A) 45 – 63 µm, (B) 125 – 150 µm, and (C) 250 – 300 µm. Also depicted are RF values from 1% 
(w/w) budesonide formulations with either α-lactose monohydrate or granulated lactose carrier 
particle populations with sieved size fractions of (D) 45 – 63 µm, (E) 125 – 150 µm, (F) 250 – 300 
µm.  Data are presented as the mean (± standard deviation) for N = 3 replicates.   
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Figure 6.5.  Slope of Respirable Fraction Improvement with Increasing Flow Rate  
Slope of the respirable fraction (%RF) between 30 L min-1 and 90 L min-1 for 1% binary 
formulations with 45 – 63 µm, 125 – 150 µm, and 250 – 300 µm size fractions of α-lactose 
monohydrate or granulated carriers with (A) salbutamol sulphate or (B) budesonide as the 
active pharmaceutical ingredient.   
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Table 6.1. Physical Properties of α-Lactose Monohydrate and Granulated Carrier Particle 
Populations 
 
Carrier Particle Sieve 
Fraction   (µm) 
d10 d50 d90 
% Fines 
(< 10 µm) 
Specific 
Surface Area  
(m2/g) 
 
 α-Lactose Monohydrate       
 45 – 63 41 65 91 5.0 0.39 
 
 125 – 150 116 184 250 2.9 0.25 
 
 250 – 300 230 353 480 2.4 0.18 
 
 Granulated Lactose      
 
 45 – 63 35 63 88 4.9 0.52 
 
 125 - 150 126 176 265 --- 0.37 
 
 250 - 300 230 304 365 ---- 0.43 
 
        
 
.   
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Table 6.2. Aerosol Performance Values of Salbutamol Sulphate Blends 
Carrier Particle  
Sieve Size Fraction  
(µm) 
30 L min-1 60 L min-1 90 L min-1 
EF (%) FPF (%) RF (%) EF (%) FPF (%) RF (%) EF (%) FPF (%) RF (%) 
α-Lactose Monohydrate          
45 – 63 µm 81.6 (1.6) 26.9 (1.7) 22.0 (1.6) 81.3 (2.0) 35.8 (1.8) 29.1 (1.9) 78.2 (3.7) 48.6 (1.1) 38.0 (2.6) 
125 – 150 µm 75.8 (1.9) 15.8 (2.1) 12.0 (1.8) 78.2 (1.3) 33.0 (1.7) 25.8 (1.4) 80.1 (1.8) 43.3 (2.1) 34.7 (2.3) 
250 – 300 µm 80.5 (4.6) 10.2 (1.6) 8.1 (0.8) 75.1 (2.2) 20.9 (1.8) 15.7 (0.9) 77.5 (1.6) 38.5 (3.4) 29.8 (2.4) 
Granulated Lactose          
45 – 63 µm 83.2 (1.9) 22.9 (1.0) 18.6 (1.9) 82.8 (3.8) 35.0 (2.1) 29.0 (0.9) 81.8 (0.5) 46.1 (0.5) 37.7 (0.2) 
125 – 150 µm 86.4 (2.1) 14.3 (1.1) 12.4 (1.2) 82.6 (0.8) 35.1 (1.7) 29.0 (1.3) 81.0 (0.8) 46.5 (2.2) 37.6 (2.1) 
250 – 300 µm 84.4 (2.6) 10.4 (1.6) 8.8 (1.3) 77.3 (3.6) 29.9 (1.7) 23.1 (0.3) 78.3 (1.6) 49.9 (0.9) 39.1 (1.5) 
 
The In vitro aerosol performance of 1% (w/w) salbutamol sulphate binary blends 
prepared with 45 – 63 µm, 125 – 150 µm, or 250 – 300 µm lactose monohydrate or granulated 
lactose carrier particle populations were evaluated at 30, 60 and 90 L min-1. Data are presented 
as the mean (± standard deviation) for N = 3 replicates. 
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Table 6.3. Aerosol Performance Values of Budesonide Blends 
Carrier Particle  
Sieve Size Fraction  
(µm) 
30 L min-1 60 L min-1 90 L min-1 
EF (%) FPF (%) RF (%) EF (%) FPF (%) RF (%) EF (%) FPF (%) RF (%) 
α-Lactose Monohydrate          
45 – 63 µm 69.4 (5.4) 19.3 (0.3) 13.4 (1.0) 73.4 (2.7) 28.0 (1.7) 20.6 (2.0) 73.3 (0.7) 32.6 (0.7) 23.9 (0.7) 
125 – 150 µm 72.7 (1.5) 14.5 (0.6) 10.5 (0.6) 70.4 (2.9) 28.3 (1.3) 19.9 (1.6) 70.8 (0.8) 36.8 (2.0) 26.0 (1.3) 
250 – 300 µm 73.9 (1.1) 12.2 (1.9) 9.0 (1.3) 69.8 (1.2) 22.6 (1.8) 15.8 (1.5) 71.9 (0.8) 33.5 (0.9) 24.1 (0.5) 
Granulated Lactose          
45 – 63 µm 72.0 (3.3) 14.9 (0.1) 10.8 (0.6) 75.4 (1.1) 20.2 (2.2) 15.2 (1.5) 79.5 (2.0) 28.1 (1.3) 22.3 (0.7) 
125 – 150 µm 82.7 (0.8) 15.8 (1.8) 13.1 (1.6) 79.2 (1.6) 33.3 (0.3) 26.4 (0.5) 79.6 (0.3) 44.0 (0.6) 35.0 (0.6) 
250 – 300 µm 81.0 (3.4) 14.7 (2.0) 11.9 (2.1) 74.2 (1.6) 30.6 (0.1) 22.7 (0.6) 77.3 (1.7) 48.3 (1.6) 37.3 (2.0) 
 
The in vitro aerosol performance of 1% (w/w) budesonide binary blends prepared with 
45 – 63 µm, 125 – 150 µm, or 250 – 300 µm lactose monohydrate or granulated lactose carrier 
particle populations were evaluated at 30, 60 and 90 L min-1. Data are presented as the mean (± 
standard deviation) for N = 3 replicates.   
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CHAPTER 7 
7. Development of a Novel Dry Powder Dispersion Mechanism for 
Pulmonary Drug Delivery  
Part 1: Carrier Particle Material Selection  
7.1. INTRODUCTION 
7.1.1. Lactose Carrier Particles 
In Chapter 1, the different mechanisms by which large carrier particles are perceived to 
be detrimental to the aerosol performance of DPI formulations were reviewed.  The unfavorable 
parameters of large diameter carrier particles include their relatively low surface area, the 
enhanced press-on forces during blending, their extensive surface roughness and the potential 
for increased van der Waals forces and higher surface energies relative to smaller carrier 
particles [1-12]. 
In Chapter 3, a comprehensive study was undertaken to evaluate the in vitro aerosol 
performance of binary DPI formulations with carrier particle populations derived from four 
grades of lactose fractionated into 13 narrow particle size ranges.  The results from this study 
indicate for a given particle size fraction, the performance of lactose carriers can vary 
considerably, and may deviate from the predicted trend that smaller carrier particle diameters 
will outperform their larger carrier diameter counterparts.  Specifically, it was observed that for 
lactose grades with relatively low surface roughness (α-lactose monohydrate and anhydrous 
lactose) the results generally followed the predicted trend that performance diminishes as the 
diameter of the carrier particle population is increased.  However, for lactose grades possessing 
extensive surface roughness, in vitro deposition deviated considerably from the predicted trend, 
especially for granulated carriers, as the performance of the largest fractions was comparable to 
the smallest carrier particle size fraction.     
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The mechanism governing drug particle detachment as the size and surface roughness 
of the carrier particle population varies was further investigated in Chapter 4 [13].  In vitro 
aerosol performance of multiple size fractions of anhydrous and granulated lactose carriers 
revealed a similar trend in deposition to that observed in Chapter 3, despite employing a 
different drug (budesonide) and concentration (2% (w/w)) than that employed in the initial 
comprehensive study (1% (w/w) salbutamol), indicating the deviation from the predicted trend 
observed with large carrier particles with extensive surface roughness was not an anomaly.  It 
was proposed that the surface roughness of granulated carrier particle populations induces a 
shift in the drug detachment mechanism, as their extensive rugosity inhibits detachment by the 
flow stream, thus making them more dependent on detachment by mechanical impactions.  
Accordingly, this would then favor larger carrier particle diameters, as their larger relative mass 
enables them to impact against the inner walls of the inhaler with greater force, accounting for 
the improved performance observed with large granulated carrier particle populations. 
In Chapter 5, the influence that the proposed carrier particle collisions with the inner 
walls of the inhaler have on aerosol performance was investigated by dispersing DPI 
formulations with carrier particle populations of diverging surface roughness through two 
commercial inhalers operating with different dispersion mechanisms.  The in vitro experiments 
were coupled with particle trajectory simulations using computation fluid dynamics (CFD). It was 
observed that in the Aerolizer, increasing the diameter of the carrier particles tended to 
increase the predicted number of collisions the particle has with the inhaler walls as it exits the 
device.  This was correlated to the improved aerosol performance observed in vitro with large 
granulated carrier particle formulations. Conversely, larger carrier particles did not increase the 
predicted number of carrier-inhaler collisions in the Handihaler to the same extent as seen in 
the Aerolizer.  This was supported by the in vitro deposition studies through the Handihaler, 
where there was no significant improvement in performance with increasing carrier particle 
diameter. These results suggest that carrier particle-inhaler collisions may be a significant source 
of drug detachment, and for carriers with high surface roughness, larger particle diameters 
would be beneficial for detachment via this mechanism.    
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Chapter 6 examined the influence that the inhalation flow rate on the performance of 
large granulated carrier particles.  As it was previously speculated that mechanical detachment 
forces predominate for these carriers, it is proposed that higher particle velocities, and hence 
momentums, would yield greater performance improvements with increasing flow rate relative 
to smaller carrier particle size fractions.  Binary formulations of budesonide and salbutamol 
sulphate were prepared using relatively smooth (α-lactose monohydrate), and rough 
(granulated) lactose grades as carrier particle populations.  As the flow rate was increased from 
30 to 60 L min-1, and then to 90 L min-1, the performance improvement from the largest carrier 
particle size, both lactose monohydrate and granulated, exceeded that of the smaller carriers, 
regardless of the API in the formulation.  Additionally, at 90 L min-1 the largest granulated carrier 
size fraction matched the performance of the smallest α-lactose monohydrate carriers for 
salbutamol sulphate, and outperformed all other size fractions, for both lactose grades, when 
budesonide was the API.  These results suggest that the improvement induced by larger flow 
rates is most beneficial for large carriers in general, and for large carriers with extensive surface 
roughness in particular, as would be expected if mechanical forces indeed played a significant 
role in drug detachment.        
Taken together, the results from Chapters 3 – 6 suggest that the role of large carrier 
particles is not as clearly defined as implied from the literature.  Specifically, carrier particles 
with large diameters and high surface roughness appear to deviate from the predicted trend, 
highlighting the incomplete nature of the proposed theories, while simultaneously illustrating 
the role of mechanical forces in the aerosol performance of dry powder formulations. 
Accordingly, we now examine the theory behind the hypothesis that larger carrier particles can 
enhance performance of DPI formulations.          
7.1.2. Large Carrier Particles: Theory    
The premise that larger carriers assist in drug dispersion is based on the observation 
that as larger carrier particles possess a greater mass compared to smaller carrier populations, 
they will collide with greater momentum against the inhaler walls as the exit the device during 
inhalation. This increased momentum will enhance the mechanical detachment forces 
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experienced by the drug particles adhered to the carriers.  The force, F, experienced during a 
collision is due to the change in particle momentum (  ) over the collision time,     (~100 
µs)[14].  Momentum is the mass of the carrier multiplied by its velocity: 
       
  
   
 
  
   
 
The mass of a spherical particle is the density, ρ, multiplied by its volume, V: 
      
Since the volume of a sphere is given by: 
   
   
 
 
The overall linear momentum of a spherical particle possessing diameter, d, composed 
of a material with density, ρ, traveling at a velocity, v, and undergoing a collision time, tc , would 
experience an impaction force: 
         
    
 (   )
 
As the mechanical forces vary with the cube of the carrier particle diameter, they have 
the potential to rapidly increase to values that can overwhelm the adhesive interaction between 
the drug and carrier.  To estimate the carrier particle size threshold when impaction forces could 
theoretically begin to overwhelm adhesive forces, a model was developed using Microsoft Excel® 
that allowed a range of factors, including drug and carrier diameters, densities, and inhalation 
flow rate to be adjusted.   The simplistic and rudimentary nature of the model is readily 
acknowledged, and limitations of the model include: 
1. The assumption of spherical and mono-disperse drug and carrier populations,  
2. The assumption that the carrier particle velocity equals that of the flow stream, 
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3. The interactions between the carrier and the inhaler are modeled as head-on 
collisions, where the trajectory of the carrier particle is perpendicular to that 
surface against which it collides, such that the entire momentum of the carrier 
particle is transferred to the drug particle. 
Adhesive forces were calculated using the theoretical van der Waals forces, with a 5 µm 
drug particle diameter [14]: 
 
      
 
    
(
    
     
) 
Given the limitations of the model, the generated values of adhesive and carrier particle 
impaction forces are far from exact, however the general trend is nevertheless interesting, 
where due to the reliance of the mechanical forces on the cube of the carrier particle diameter 
it is predicted that these detachment forces can potentially overwhelm adhesive interactions. 
7.1.3. Novel Large Carrier Particles 
As previously discussed, the results of Chapters 3 - 6 supported the hypothesis that large 
carrier particle diameters are not inherently deleterious to performance.  However, given that 
mechanical forces have the potential to rapidly exceed the strength of the adhesive interaction 
between drug and carrier, the ability to enhance the forces generated by the carrier-inhaler 
collisions may improve the performance already observed in the lactose studies.  Revisiting the 
limitations of the theory cited earlier, it was noted that in our initial calculations we assumed a 
direct, head-on collision between the carrier and inhaler.  However, glancing collisions would 
most likely be the norm, as the carrier particle caroms off the inhaler wall [15].  In this case, the 
mechanical forces would be a fraction of what was predicted when the model was developed 
assuming perpendicular trajectories and head-on collisions.  Accordingly, if carrier particles with 
diameters much greater than the mesh openings within an inhaler were employed, a direct 
collision would be guaranteed (Figure 7.1).  Furthermore, the use of carrier particles with large 
diameters ensures that they are retained within the device throughout inhalation, thus allowing 
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materials other than lactose to be explored, as the carrier itself will not be delivered to the 
patient.   
Specific Aim 
In this chapter, the potential for developing of a novel dispersion mechanism based 
upon macro carrier particles (> 500 µm) is explored.  The aerosol performance of drug-coated 
beads composed of multiple materials, including polystyrene, sucrose, silica, and glass, were 
screened for their potential to serve as large carrier particles. In addition to varying the bead 
material, multiple size ranges of each material were also employed to assess the influence of 
bead diameter on drug delivery. The selected beads were coated with budesonide using the 
traditional blending protocol employed for binary lactose formulations, and their performance 
was evaluated in vitro via cascade impaction through the Aerolizer.  Dispersion was performed 
at both 30 and 60 L min-1, to assess the flow rate dependence of the drug-coated beads.    
7.2. EXPERIMENTAL 
7.2.1. Materials 
Micronized budesonide (EP grade) was purchased from Spectrum Chemical (CA, USA) 
and used as received.  Porous polystyrene beads (Fairfield Processing Corp., CT, USA) were 
purchased locally. Samples of sucrose beads were provided by Colorcon (Colorcon, Inc., PA, USA) 
and silica beads were provided by Sud-Chemie (NM, USA).  Glass beads and analytical grade 
ethanol was purchased from Sigma (Sigma-Aldrich Corp., MO, USA).  For the blending additive 
studies, polypropylene and steel beads (Crosman Corporation, NY, USA) were purchased locally.   
7.2.2. Screening of Carrier Particle Size 
The carrier particles were sorted using 12” diameter ASTM test sieves with the following 
mesh sizes:  0.595 mm (No. 30), 0.84 mm (No. 20), 1.17 mm (No. 16), 1.44 mm (No. 14), 2.36 
mm (No. 8), 3.38 mm (No. 6), 4.38 mm (No. 5), and 5.38 mm (No. 3 1/2).    
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7.2.3. Blending of Beads and Drug Powder 
Approximately 5 mg of budesonide were weighed into a 30 mL glass vial, to which were 
added 5 beads (for diameters > 3.38 mm), or 10 beads (for diameters < 3.38 mm).  The drug and 
beads were blended with a TurbulaTM orbital mixer (Glen Mills, NJ) at 46 RPM for 40 minutes.  
Following blending, the beads were removed from the coating vial and stored in a desiccator for 
72 hours prior to use.    
7.2.4. Density  
The densities of the sucrose, silica, and glass beads were measured using a helium 
pycnometer (Quantachrome, FL, USA).  The density of the porous polystyrene beads was 
obtained by weighing the beads individually, and then measuring the diameters of the beads 
with calipers and assuming the volume of sphere.  The densities of 10 replicates were measured 
for the porous polystyrene beads.      
7.2.5. In vitro Aerosol Performance 
 The aerosol performance of the drug-coated polystyrene beads was evaluated in vitro 
using a next generation cascade impactor (NGI; MSP Corp., MN, USA) at 30 and 60 L min-1.  To 
accommodate the beads within the inhaler, a capsule-based device was required, and 
accordingly the Aerolizer DPI (Plastiape S.p.A, Italy) was selected as the capsule chamber was 
sufficiently large to allow the beads adequate space to move within during inhalation. The 
actuation time was adjusted to allow 4 L of air to flow through the device at each flow rate.  For 
bead diameters > 3.38 mm, a single bead was used per cascade impaction run.  For smaller 
diameters, 3 beads were placed into the capsule chamber of the Aerolizer for each actuation.  
15 mL of EtOH was added to the pre-separator prior to every run and collected following each 
impaction.  The capsule, dispersion chamber, mouthpiece, mouthpiece adaptor, and induction 
port were each rinsed with 10 mL of EtOH, and the stages of the NGI were each rinsed with 5 
mL.   
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Drug mass was quantified by UV-VIS spectroscopy at 244 nm using an Infinite M200 
microplate reader equipped with a cuvette port (Tecan US, Inc., NC, USA).  For each cascade 
impaction, the recovered dose is the cumulative drug mass collected from the bead, inhaler, 
mouthpiece adaptor, induction port, pre-separator, and NGI stages.  The emitted fraction (EF) is 
provided as the percentage of the recovered dose collected from the mouthpiece adaptor, 
induction port, pre-separator, and NGI stages.  The fine particle fraction (FPF) is the percentage 
of the emitted dose collected from stages 3 – 8 of the NGI, while the respirable fraction (RF) is 
the percentage of the recovered dose collected from stages 3 – 8. As the flow rate varies 
through the NGI, the particle cut-off diameters for each stage also varies.  At 60 L min-1 the cut-
off diameter of stage 2 is 4.46 µm, shifting to 6.40 µm at 30 L min-1 [16].         
7.3.  RESULTS AND DISCUSSION 
7.3.1. Physical Characterization 
The sieve fractions collected for each material are presented in Table 7.1.  For each 
material, at least two size fractions were obtained, allowing for the influence of particle size in 
addition to density to be assessed.  The measured densities of all beads (those that will be drug-
coated and those to be employed as blending additives in subsequent studies) are provided in 
Table 7.2.  The polystyrene beads possessed a very low average density (0.027 g /cm3) by 
comparison to the sucrose (1.51 g /cm3), silica (1.84 g /cm3) and glass beads (2.48 g /cm3)  
7.3.2. Aerosol Performance of Drug-Coated Beads 
The in vitro performance of drug-coated polystyrene, sucrose, silica, and glass beads are 
presented in Figure 7.2 to Figure 7.5.  The parameters evaluated were the ability of the bead to 
deliver the dose from the device (EF), coupled to the efficiency of powder dispersion (FPF).  This 
first parameter is a combination of the effectiveness of the bead-inhaler collisions to detach the 
drug from the carrier; the latter assesses both the carrier’s ability to prevent the formation of 
stable drug agglomerates during blending, coupled to the inhaler’s capacity to de-aggregate the 
powder that is detached from the bead. It is noted that both EF and FPF will also be heavily 
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influenced by the blending process of the drug and carrier, and this will be discussed in detail 
below. Furthermore, the effectiveness of the collisions between the bead and device to detach 
the drug are specifically examined, and the fraction of the total dose that was retained on the 
beads following dispersion was evaluated, as was the fraction of the total dose retained on the 
inner walls of the inhaler.       
For the polystyrene beads (Figure 7.2), diverging trends in bead and device retention 
were observed as the diameters of the carrier particle populations were enlarged.  Bead 
retention increased significantly (p < 0.05) from 4% with the 0.84 – 1.12 mm size fraction, up to 
approximately 14% of the total dose for the 4.38 – 5.38 mm carrier beads.  In combination, the 
polystyrene beads yielded emitted fractions that were relatively constant for all bead size 
ranges examined, with 45 – 50% of the total dose delivered from the device.  FPF exhibited a 
slight improvement with carrier diameter, increasing from an average of 55% (0.84 – 1.12 mm) 
up to 66% (3.38 – 4.38 mm) and 64% (4.38 – 5.38 mm).    
For the sucrose, silica, and glass beads (Figure 7.3 to Figure 7.5), significantly lower dose 
emission was observed relative to the polystyrene, with EF values between 20 – 30% for silica, 
and 10 – 20% for the sucrose and glass beads.  Interestingly, the dose retained on the bead 
decreased with larger bead sizes, despite the much greater press-on forces between the drug 
and carrier that could be expected during blending with larger, and thus heavier, beads.  This 
suggests that collisions between the bead and device generated greater detachment forces with 
increasing bead size for a given material.  As with the polystyrene, there was observed a trade-
off between bead and device retention, with the drug mass collected from the device generally 
increasing with carrier particle size for the three denser materials.  It was observed that bead 
retention was not directly related to bead density, as the silica material retained between 37 – 
45%  of the dose on the bead following dispersion, in contrast to the sucrose particles, which 
despite a lower density retained 45 – 60% for the 0.84 – 1.17 mm and 1.17 – 1.44 mm size 
ranges, indicating that the bead material plays a role in modulating the adhesive force between 
drug and carrier, which is likely a function of the physicochemical properties of both the drug 
and the bead. Overall, FPF values ranged from approximately 45% for the sucrose beads up to 
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69% for the glass beads, indicating that the powder emitted from the device is likely to be well 
dispersed.        
The pattern of dose retention differed between the polystyrene carriers and the denser 
materials, as most of the retained dose was collected from the inner walls of the device for the 
former, while the majority of the non-emitted dose remained adhered to the bead surface 
following dispersion for the sucrose, silica, and glass beads.  It is speculated that the retained 
dose from the polystyrene carriers was due to the collisions between the bead and inner surface 
of the device, causing powder to rub-off onto the inhaler walls with each collision.  This 
indicates that the detachment forces of the polystyrene carriers are sufficient to remove 
upwards of 85% of the dose from the bead surface.  In contrast, for the heavier beads the force 
of the collisions between the bead and inhaler appeared to be insufficient to effectively detach 
most of the dose, as observed with the polystyrene beads.  Accordingly, while the denser beads 
exhibited FPF values comparable to, if not greater than, the polystyrene carriers, overall drug 
deposition was higher for the low density beads.   
7.3.3. Flow Rate Dependent Performance 
To assess the flow rate dependent performance of the drug-coated beads, the 
volumetric flow rate was reduced by half, and dispersion performance of the different bead 
materials was evaluated at 30 L min-1 (Figure 7.6).  Polystyrene beads demonstrated excellent 
flow rate independent performance with no significant difference in RF values for the 0.84 – 
1.17 mm size fraction, and only a slight decline for the larger 4.38 – 5.38 mm carriers, as the 
mean respirable fraction decreased from 28% to 24%.    For silica, sucrose, and glass beads, the 
performance was significantly inhibited at the lower flow rate for all size fractions examined.  
Similar to the performance at 60 L min-1, the silica beads exhibited the best performance of the 
three remaining materials at 30 L min-1, but RF values were only 5%, a decline of approximately 
60% from the performance at the higher flow rates.  For the sucrose beads, performance was 
halved at 30 L min-1, while glass beads essentially ceased to function at the lower flow rate, 
delivering less than 2% of the dose to the ‘deep lung’ region of the NGI.    
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The flow rate independent performance of the polystyrene beads is likely due to the 
very low density of these particles, allowing these beads to be readily entrained at 30 L min-1, 
and thus producing sufficient momentums to yield effective collision/detachment forces.  By 
comparison, for the much heavier sucrose, silica, and glass beads, the reduction in flow rate 
appeared to have adversely affected the velocity, and hence linear momentum, of the particles, 
resulting in diminished collision forces and thus significantly reducing the percentage of the 
dose detached from the bead surface.  
7.3.4. Blending Studies 
The beads were blended with the drug powder according the protocol employed to 
prepare traditional lactose-based binary DPI formulations.  However, given the extremely low 
surface area of the beads relative to 20 mg of inhalation-grade lactose, coupled with the 
reported cohesive nature of budesonide, it was speculated that longer blending times may 
adversely affect aerosol performance by inducing the formation of drug agglomerates that 
typically deposit in the induction port and pre-separator. 
As noted by De Boer and coworkers, during powder blending there are two competing 
processes that promote either excellent or poor drug content uniformity in the formulation[1, 
3].  In one instance, the repeated abrasion of the drug particles by the coarse carriers can break-
up agglomerates of drug that were initially present in the powder prior to blending.  These are 
termed ‘natural agglomerates,’ and their disruption has long been noted to be an advantage of 
thorough powder blending.  However, the repeated physical contact between drug particles 
may also induce formation of ‘blending’ agglomerates, which arise if the cohesive tendency of 
the drug particles exceeds the adhesive tendency between the drug and carrier material [17, 
18].  Accordingly, to produce a blend with excellent drug content uniformity, natural 
agglomerates must be broken-down while the formation of agglomerates during blending must 
be prevented.  The process that dominates for a given formulation depends on the 
physicochemical properties of both the drug and carrier, the overall concentration (% w/w) of 
each component, and the blending parameters employed, including blending speed, mixing 
time, and batch size.   
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Budesonide was selected as the model drug for these screening studies due in part to its 
cohesive nature, as the affinity between budesonide particles was reportedly much stronger 
than the adhesive interaction between budesonide and lactose, in contrast to salbutamol 
sulphate, which displayed the opposite trend, and adhered readily to the surface of the lactose.  
At the outset of these studies, it was recognized that one of the challenges of using large beads 
as carriers for pulmonary delivery would be to overcome the diminished surface area available 
for drug binding; a limitation of large diameter carrier particle populations that was discussed in 
Chapter 1.  Accordingly, if the process could be optimized for budesonide, it is expected that 
performance from other API materials would be at least comparable to that of this cohesive 
powder.  
7.3.5. Blending Time 
To examine the influence of blending time, 0.84 – 1.17 mm beads of polystyrene, silica, 
and glass were mixed for short (8 minutes) or long (40 minutes) time intervals.  Following 
blending, their aerosol performance was tested at 60 L min-1 (Figure 7.7).  From the theory 
describing blending of binary formulations, it was speculated that heavier particles could break-
up drug agglomerates, thereby potentially improving dispersion.  Conversely, denser beads 
could potentially also increase bead retention, as the press-on forces between the drug and 
carrier surface would be enhanced by the higher momentum of the heavier particles during 
blending.   
The resulting RF values indicate that blending time and performance are not related 
solely by the density of the material, as increased mixing times improved performance from the 
heavier glass beads, while reducing overall drug deposition from the lighter silica beads.   The 
observed improvement in performance with longer coating times for the glass beads contrasted 
with our initial hypothesis, as it was expected that these heavy particles would enhance the 
adhesive forces between drug and carriers by providing large press-on forces during blending. It 
was speculated that prolonged mixing times may cause the beads to detach drug from their 
surface due to the repeated collisions occurring during blending.  As larger particles, especially 
agglomerates would be most susceptible to detachment due to their higher mass, a greater 
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concentration of fine particles may remain on the surface of the glass beads following blending 
at 40 minutes compared to 8 minutes.  This was supported by the lower recovered doses 
observed from this these carriers at 40 minutes relative to the 8-minute blending period, 
indicating that a lower drug mass remains adhered to the bead, potentially due to the 
detachment of the larger aggregates.  In contrast to the silica and the glass material, the low 
density polystyrene beads exhibited no significant change in performance between the two 
blending periods.     
7.3.6. Blending Additives 
During the blending-time studies, it was noted that the low mass of the polystyrene 
beads may be incapable of either disrupting natural agglomerates or preventing the formation 
of blending agglomerates. It was thus speculated that performance may be improved if higher 
density materials were incorporated into the formulation during blending, thereby providing the 
requisite abrasion to limit the extent of drug aggregates coating the bead surface.  To test this 
theory, polystyrene beads were blended with budesonide alone, or with five polypropylene (ρ = 
1.0 g/cm3) or steel (ρ = 7.8 g/cm3) beads included in the vial.  The polypropylene and steel beads 
were monodisperse with 6 mm diameters.  Following blending, the polystyrene beads were 
tested through the Aerolizer at 60 L min-1 and the resulting aerosol performance is presented in 
Figure 7.8.   
While the inclusion of heavier beads was expected to disrupt drug agglomerates, the 
increased momentum of the denser particles during blending could potentially augment the 
press-on forces between the drug and carrier, increasing bead retention and lowering emitted 
fraction. However, the amount of the nominal dose that remained adhered to the bead surface 
following dispersion was not significantly different between the three samples, and emitted 
fraction was noted to improve with the inclusion of the polypropylene and steel blending 
additives.   The addition of both the polypropylene and steel beads also yielded increased 
respirable fractions compared to polystyrene beads alone, although only the RF increase from 
the formulation with steel bead additives was found to be significant (p < 0.05). For both EF and 
RF, the observed improvements correlated with the denser, and thus heavier, additive.   
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Accordingly, the inclusion of dense beads during blending could be a potential strategy to 
improve aerosol performance from low-density polystyrene carriers by providing a sufficient 
energy source to disrupt drug agglomerates.   
7.4. CONCLUSION 
In this chapter, the aerosol performance of large, drug-coated beads was evaluated to 
determine the potential of developing a novel dry powder dispersion mechanism based on the 
mechanical forces that occur when large carrier particles impact with the inner walls and mesh 
of a DPI.  In contrast to the predicted theory, the low surface area of the large carriers did not 
cause extensive ‘throat’ deposition.  Indeed, all materials and size fractions produced FPF values 
ranging from 45 - 70% at 60 L min-1.  However, the ability of the beads to deliver the dose to the 
patient was rather low.  For the sucrose, silica, and glass materials, a large fraction of the dose 
remained adhered to the bead surface following actuation, suggesting that the collisions forces 
generated by these materials were not sufficient in magnitude to detach the drug from the 
carriers.  Consequently, when the flow rate was halved to 30 L min-1, these materials essentially 
ceased to function, delivering less than 5% of the total dose.   
Similar to sucrose, silica, and glass beads, the low-density polystyrene were plagued by 
low dose emission, with EF values typically below 50%.  However, in contrast to the denser 
materials, the majority of the retained dose was collected from the inner walls of the device 
rather than from the bead, indicating effective drug detachment.  Additionally, of the tested 
materials only polystyrene demonstrated flow rate independent performance and thus 
polystyrene beads were selected for future studies.   
The following chapter will focus on improving performance from the drug-coated beads 
by increasing the fraction of the dose that is delivered from the device.  As it is speculated that 
the physical impactions between the carrier and inhaler are primarily responsible for the 
retained dose, an alternative dispersion mechanism will be investigated to limit the physical 
contact between the drug and carrier while maintaining their excellent drug detachment 
potential.  Additionally, the blending studies indicated that due to their low mass, polystyrene 
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beads are ineffective at disrupting agglomerates, and mild improvements were observed when 
high density additives were included during blending.  However, a more effective method to 
inhibit drug agglomerates is desired, and accordingly this will also be addressed in the following 
chapter.        
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Figure 7.1.  Predicted Mesh Interactions for Small and Large Carrier Particles 
The smaller carrier particle will generally pass through perforations in the mesh, or 
experience glancing collisions.  By contrast, the large carriers will experience direct collisions, 
maximizing the resulting impaction force.   
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Figure 7.2.  In vitro Aerosol Performance of Budesonide-Coated Polystyrene Beads 
The in vitro aerosol performance of budesonide-coated polystyrene beads was 
evaluated through the Aerolizer at 60 L min-1. The performance metrics evaluated were the (A) 
percentage of the recovered dose that remained adhered to the bead or device following 
actuation and (B) the emitted fractions (% emitted) and fine particle fractions (FPF). Values are 
provided as the mean (± standard deviation) for N = 3 replicates.   
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Figure 7.3.  In vitro Aerosol Performance of Budesonide-Coated Sucrose Beads 
The in vitro aerosol performance of budesonide-coated sucrose beads was evaluated 
through the Aerolizer at 60 L min-1. The performance metrics evaluated were the (A) percentage 
of the recovered dose that remained adhered to the bead or device following actuation and (B) 
the emitted fractions (% emitted) and fine particle fractions (FPF). Values are provided as the 
mean (± standard deviation) for N = 3 replicates.   
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Figure 7.4.  In vitro Aerosol Performance of Budesonide-Coated Silica Beads 
The in vitro aerosol performance of budesonide-coated silica beads was evaluated 
through the Aerolizer at 60 L min-1. The performance metrics evaluated were the (A) percentage 
of the recovered dose that remained adhered to the bead or device following actuation and (B) 
the emitted fractions (% emitted) and fine particle fractions (FPF). Values are provided as the 
mean (± standard deviation) for N = 3 replicates.   
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Figure 7.5.  In vitro Aerosol Performance of Budesonide-Coated Glass Beads 
The in vitro aerosol performance of budesonide-coated glass beads was evaluated 
through the Aerolizer at 60 L min-1. The performance metrics evaluated were the (A) percentage 
of the recovered dose that remained adhered to the bead or device following actuation and (B) 
the emitted fractions (% emitted) and fine particle fractions (FPF). Values are provided as the 
mean (± standard deviation) for N = 3 replicates.   
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Figure 7.6.  Influence of Flow Rate on the Performance of Drug-Coated Beads 
To assess the relative flow rate dependence of the drug-coated beads, the in vitro 
aerosol performance was evaluated through the Aerolizer at 30 L min-1 using beads of the 
different materials.  The respirable fractions (RF) were compared against their respective values 
at 60 L min-1.  Values are provided as the mean (± standard deviation) for N = 3 replicates.   
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Figure 7.7.  Blending-Time Studies of Budesonide-Coated Polystyrene, Silica, and 
Glass Beads 
Polystyrene, silica, and glass beads with diameters between 0.84 – 1.17 mm were 
blended with budesonide for either 8 minutes or 40 minutes.  Following blending they were 
dispersed at 60 L min-1  through the Aerolizer.  The performance metrics evaluated are (A) the 
percentage of the recovered dose that was retained on the beads following dispersion and (B) 
the respirable fractions from each formulation.  Values are provided as the mean (± standard 
deviation) for N = 3 replicates.       
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Figure 7.8.  Blending Additive Studies of Budesonide-Coated Polystyrene Beads 
Polystyrene beads (0.84 – 1.17 mm) were blended with budesonide either alone, or with 
polypropylene or steel beads added to the formulation during mixing to evaluate the ability of 
the denser beads to disrupt drug agglomerates.  The formulations were blended for 40 minutes, 
and their aerosol performance was assessed at 60 L min-1.  The emitted fractions (EF) and 
respirable fractions (RF) are reported as the mean (± standard deviation) for N = 3 replicates.       
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Table 7.1. Collected Bead Size Ranges Following Fractionation 
 Bead Size Ranges (mm)  
 Polystyrene Sucrose Silica Glass  
 0.84 – 1.17 0.84 – 1.17 0.60 – 0.84 0.60 – 0.84  
 1.17 – 1.44 1.17 – 1.44 0.84 – 1.17 0.84 – 1.17  
 1.44 – 2.36 1.44 - 2.36 1.17 – 1.44   
 3.38 – 4.38     
 4.38 – 5.38     
 
For each of the materials at least two size fractions were collected, allowing for the 
evaluation of both density and carrier particle diameter on aerosol performance.   
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Table 7.2. Measured Densities of Bead Materials 
 Material 
Density 
(g/cm
3
) 
 
    
Carriers    
 Polystyrene   0.027  
 Sucrose 1.51  
 Silica 1.84  
 Glass 2.48  
Additives    
 Polypropylene 1.04  
 Steel 7.65  
    
 
 
 
 
 
 
  
 194 
CHAPTER 8 
8. Development of a Novel Dry Powder Dispersion Mechanism for 
Pulmonary Drug Delivery, Part 2: Optimization of the Dispersion 
Mechanism and Coating Method 
8.1. INTRODUCTION 
In the previous chapter, a novel dry powder dispersion mechanism based upon collisions 
of large diameter drug-coated beads was introduced, and bead materials of various size ranges 
screened for their potential to serve in this capacity.  Of the tested materials, the low density 
(0.027 g/cm3) polystyrene beads demonstrated drug deposition levels comparable to the 
reported values from many commercial devices, coupled with excellent flow rate independent 
performance.  Therefore, this material was selected as the most suitable candidate for future 
studies. 
With the selection of the carrier particle material complete, the focus of this chapter will 
be to address the performance issues encountered during the initial screening studies.  
Particularly, the high fraction of the total dose retained within the device following actuation 
and the extensive formation of drug particle aggregates during blending will be addressed as a 
means to improve the aerosol performance of the drug-coated polystyrene beads.         
8.1.1. Device Retention 
As discussed in Chapter 5, efficient delivery from dry powder inhalers requires high dose 
emission coupled with effective powder dispersion.  Accordingly, devices that perform well at 
only one of these tasks will yield only moderate drug deposition levels relative to an inhaler that 
excels at both emission and dispersion. Many studies examining the performance of commercial 
DPIs have noted that there is generally a trade-off between dose emission and powder 
dispersion, as the design features that optimize one parameter typically do so to the detriment 
of the other.  For example, DPIs that produce high emitted fractions tend to have very straight 
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flow paths that minimize the surface area of the powder flow channel through the inhaler.  
Alternatively, inhalers that employ more complex internal geometries to increase turbulence of 
the powder-laden flow stream and/or promote particle-particle and particle-device collisions, 
are more susceptible to higher levels of mouthpiece retention [1-4].   
Examples of these opposing characteristics of DPI performance are illustrated in the 
Diskhaler and Turbuhaler, two marketed DPIs that have enjoyed considerable commercial 
success [5].  At comparable volumetric flow rates, the percentage of the nominal dose retained 
in the mouthpiece of the Diskhaler was typically below 5%, and tended to remain constant as 
flow rate was varied. In contrast, mouthpiece deposition was strongly dependent on flow rate 
through the Turbuhaler, as higher flow rates corresponded to lower device retention, with 
values ranging between 20 – 40% of the nominal dose.  However, despite the greater emitted 
fraction values obtained through the Diskhaler, overall performance from the Turbuhaler was 
superior, with RF values of approximately 35% compared to an average of 23% from the 
Diskhaler.  
Referring to the earlier discussion regarding the trade-off between device emission and 
powder dispersion, it is clear that the Diskhaler is superior at delivering the dose from the 
device, while the Turbuhaler excels at de-aggregation.  Examining the internal geometries of 
these devices, it is noted that in contrast to the relatively simple internal mouthpiece geometry 
of the Diskhaler (essentially a straight channel from the powder bed to the exit of the device), 
the Turbuhaler incorporates a spiraling flow path in the mouthpiece to aid in drug dispersion   
[6, 7].  However, this design induces more drug particles to deposit in this region for the 
Turbuhaler.  Accordingly, while the powder dispersion from this device is relatively high, with 
FPF values in excess of 50%, the lower emitted fractions result in RF values of 35%, as opposed 
to the higher deposition levels that could be achieved if the emitted fraction from the 
Turbuhaler matched that of the Diskhaler. However, it is noted that these inhalers employ 
different formulations, as the Diskhaler delivers a binary blend of coarse lactose carriers and 
micronized drug, while the Turbuhaler generally employs spheronized pellets of pure drug, and 
accordingly differences in performance may not be solely attributable to device design features.         
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In Chapter 7, in vitro aerosol performance studies from the drug-coated polystyrene 
beads actuated through the Aerolizer exhibited good powder dispersion, with FPF values of up 
to 70%. However, dose delivery was relatively low, as over 50% of the total dose was retained in 
the inhaler following actuation, yielding low emitted fractions and overall RF values between 25 
– 30%.  In contrast to the heavier sucrose, silica, and glass beads, where upwards of 80% of the 
dose remained adhered to the bead following dispersion, the majority of the retained dose from 
the polystyrene beads was collected from the inner walls and mesh of the device.  Thus, it was 
speculated that the repeated collisions between the drug-coated beads and the inhaler induces 
a large fraction of the drug to rub-off onto the walls, where it remains adhered. Accordingly, 
despite the excellent powder dispersion profiles exhibited by the Aerolizer, an alternative 
dispersion mechanism using the Handihaler® DPI was explored as a means to enhance the dose 
emitted from the device.        
8.1.2. Drug Powder Aggregates 
In the previous chapter, coating of drug on the carrier beads was performed using the 
standard method employed in preparing lactose-based binary blends.  Specifically, the drug and 
beads were mixed together for an extended period of time (typically 40 minutes) using a 
Turbula® oribital mixer where the vial containing the formulation is continuously rotated, 
causing the powder to tumble back-and-forth from one end to the other throughout the 
blending period (Figure 8.1).  For traditional binary formulations with lactose carrier particles, 
the continuous tumbling allows coarse carriers to break down drug aggregates, producing a 
stable blend with excellent uniformity, as the drug particles are well distributed over the surface 
of the carriers.  However, in order to perform this function, the carrier particles must be 
sufficiently heavy to disrupt drug aggregates via abrasion. As seen in chapter 3, despite the 
extremely large surface area available in the LMH < 20 µm carrier particle population, the blend 
uniformity was relatively poor, with a coefficient of variation above 10%.  It was proposed that 
this resulted from the very low mass of these small carrier particles, rendering them ineffective 
at disrupting either the natural agglomerates initially present in the drug powder, or the 
blending agglomerates  that form during mixing [6, 8-10].                
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Similarly, as was discussed in Chapter 7, the low mass of polystyrene beads inhibits their 
ability to break down drug agglomerates.  Moreover, the much lower available surface area for 
drug binding of the beads relative to traditional lactose carrier particles would be expected to 
promote the formation of blending agglomerates.   In addition to the carrier particle parameters 
that could induce aggregate formation, the adhesive and cohesive properties of drugs can vary 
extensively, as noted by Begat and coworkers, who developed an cohesive-adhesive balance 
(CAB) approach to characterizing the relative affinity of drug particle for lactose interface.  In 
their study, it was noted that budesonide is a relatively cohesive material, and it would be 
expected that during blending agglomerates may be produced [11, 12].  Indeed, an investigation 
on the blending dynamics of a budesonide-lactose binary system indicated that content 
homogeneity does not increase with blending time, as might be expected with an adhesive drug. 
Instead, the system exhibits a erratic blend uniformity profile, where the coefficient of variation 
declines as drug particles are distributed over the carrier particle surface, only to increase as 
drug segregates from the carriers.  Combined, the low mass and reduced surface area would 
result in considerable drug particle agglomerate formation during blending in a traditional 
orbital mixer. Consequently, when these drug particle aggregates are emitted from an inhaler 
possessing a powder dispersion mechanism incapable of disrupting the agglomerates, extensive 
‘throat’ deposition would be expected to occur. 
One possible method to combat the formation of agglomerates is to include high 
density additives to supply the requisite abrasion mechanism that the low density polystyrene 
beads cannot provide.  This approach was examined in the previous chapter, where 
polypropylene (density = 1.0 g/cm3) and steel (density = 7.6 g/cm3) beads were added to the 
formulation prior to blending. Significant improvements in aerosol performance were observed 
for the steel bead additives relative to a control formulation that did not include any blending 
additives, as RF values increased from 28% to 34%.  However, the performance enhancement 
was minimal, and a more effective approach was sought.  Specifically, the potential of a novel 
coating method to deposit the micronized drug particles onto the surface of the bead in their 
primary particle size (1 – 5 µm) was explored.              
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8.2. EXPERIMENTAL 
8.2.1. Materials 
Micronized budesonide (EP grade) was purchased from Spectrum Chemical (CA, USA) 
and used as received.  Porous polystyrene beads (Fairfield Processing Corp., CT, USA) were 
purchased locally. As described in Chapter 7, the polystyrene carriers were manually sieved to 
collect beads with diameters between 4.38 mm and 5.38 mm.  Analytical grade ethanol was 
purchased from Sigma (Sigma-Aldrich Corp., MO, USA).   
8.2.2. Traditional Coating of Polystyrene Beads 
Individual batches consisted of three polystyrene beads placed into a 30 mL glass vial 
following the addition of 5 mg of micronized drug powder. The vial was sealed and blended with 
a Turbula® orbital mixer (Glen Mills, NJ, USA) for 40 minutes at 46 RPM.  These parameters are 
identical to those employed in the lactose formulation studies of Chapters 3 – 6.  Following 
blending, the beads were dropped approximately 30 cm onto an aluminum mesh to remove any 
loosely adhered powder. The beads were stored in a desiccator for 3 days prior to use.     
8.2.3. Piezo-Assisted Coating of Polystyrene Beads 
To coat the polystyrene beads, 5 mg of micronized drug powder was added to a 30 mL 
scintillation vial.  For each coating ‘batch,’ three polystyrene beads with diameters between 4.38 
– 5.38 mm were added to the vial containing the drug powder.  The vial was sealed and the 
bottom half was submerged in an ultra-sonicating water bath (Fisher Scientific, NH, USA).  When 
the vial is placed in the water bath, the energy imparted to the powder by the sonics serves to 
aerosolize a fraction of the powder bed, creating a sustained plume as powder is continuously 
aerosolized, then slowly deposits back to the powder bed via gravitational settling, and then is 
aerosolized once more. Throughout the coating period the beads are continuously exposed to 
the aerosol cloud, and as the aerosolized drug particles deposit, some will land on the bead 
surface where initially they adhere directly to the bead via van der Waals interactions. With 
continued drug deposition, particles will begin to deposit on top of other drug particles, 
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adhering directly to them rather than to the surface of the polystyrene.  Accordingly, initial 
coating of the drug is an adhesive-driven process, as coating is governed by the affinity between 
the drug and bead surface.  By contrast, subsequent coating is influenced by cohesive 
interactions between the drug particles.   
Unless otherwise specified, the beads were coated for 2 minutes. During coating, the 
vial was rotated slowly from side-to-side, allowing the beads to roll across the powder, thereby 
exposing the entire surface to the emitted drug particles.  Following coating, the beads were 
removed from the scintillation vial and dropped approximately 12 inches onto an aluminum 
mesh to remove any loosely adhered drug particles and agglomerates.  The drug-coated 
polystyrene beads were then stored in a desiccator for 3 days prior to use.    
8.2.4. Scanning Electron Microscopy (SEM) 
Drug coating of the carrier particles was assessed using scanning electron microscopy 
(SEM; Supra 40VP, Zeiss, Germany).  To accommodate the large beads, following initial bead 
placement onto a stage covered with double-sided conductive tape, the sides of the tape were 
folded against the bead and then transfixed with a metal pin, piercing both the tape and the 
bead to allow adequate conduction. Prior to imaging, approximately 20 nm of a 
platinum::palladium (80::20) mixture was deposited onto the beads via sputter coating. 
8.2.5. In vitro Aerosol Performance 
  The aerosol performance of the drug-coated polystyrene beads was evaluated 
in vitro using a next generation cascade impactor (NGI; MSP Corp., MN, USA) at 60 L min-1, with 
a 4-second actuation time.  For each actuation, a single bead (diameter 4.38 – 5.38 mm)       was 
placed into the capsule chamber of either the AerolizerTM (Plastiape S.p.A., Italy) or the 
HandihalerTM (Boehringer Ingelheim, CT, USA).  Following actuation, the capsule, dispersion 
chamber, mouthpiece, mouthpiece adaptor, and induction port were each rinsed with 10 mL of 
EtOH, and the stages of the NGI were each rinsed with 5 mL.  The amount of budesonide 
depositing on each component was quantified by UV-VIS spectroscopy using an Infinite M200 
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microplate reader equipped with a cuvette port (Tecan US, Inc., NC, USA) at 244 nm.  For each 
impaction, the total amount of drug collected from the bead, inhaler, mouthpiece adaptor, 
induction port, pre-separator, and NGI stages is defined as the recovered dose. The emitted 
fraction (EF) is the percentage of the recovered dose collected from the mouthpiece adaptor, 
induction port, pre-separator, and NGI stages.  The fine particle fraction (FPF) is provided as the 
percentage of the emitted dose collected from stage 3 – 8 of the NGI.  The respirable fraction 
(RF) is the ratio of the drug collected from stages 3 – 8 of the NGI, over the recovered dose.     
8.3. RESULTS AND DISCUSSION 
8.3.1. Influence of Device on Performance 
The in vitro performance of drug-coated polystyrene beads dispersed through either the 
Aerolizer or Handihaler at 60 L min-1 is shown in Figure 8.2. As mentioned in the previous 
chapter, the device retention in the Aerolizer typically exceeds 50% of the total dose. This 
performance is repeated in the present study, as only 42% of the dose was emitted from this 
inhaler. By contrast, device emission from the Handihaler was very efficient, with 85% of the 
total dose emitted from this device.  To explain this disparity in delivery efficiency, a closer 
examination of the respective mechanism governing bead motion within the two devices is 
required.   
The operating mechanism of the Aerolizer was discussed in detail previously in chapter 
7.  In this device, the drug-coated beads collide repeatedly with the mesh and inner walls of 
device due to the tangential air inlets located on opposite sides of the dispersion chamber [13].  
Throughout device actuation, the bead continuously rattles as it collides with multiple sections 
of the inner device geometry, and with the combined influence of the flow stream, detaches the 
drug particles from the surface of the bead.  However, these physical collisions between the 
drug-coated beads and the device causes drug to rub-off onto the inhaler walls, where it 
remains adhered.    
In contrast to the dual tangential inlets of the Aerolizer, the Handihaler employs a single 
cylindrical air inlet, 3.5 mm in diameter [14].  The air inlet opens into the dispersion chamber 
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(diameter = 7.6 mm) where the capsule is located.  While the geometry is more straightforward 
than that of the Aerolizer, a unique fluid phenomena known as sudden flow stream expansion 
arises from this configuration.  
Sudden expansion of a flow stream occurs when a small volume channel abruptly opens 
to a larger volume chamber (Figure 8.3).  When this happens the flow stream decelerates as it 
enters the larger volume, detaching from the inner walls of the channel at the corner of the 
expansion, and reattaching downstream of this transition region [15].  However, a portion of the 
flow is detached, and rather than proceeding downstream with the bulk of the flow, recirculates 
as a turbulent eddy at the corner of the abrupt volume expansion, causing a pressure loss. 
Figure 8.4 depicts the static pressure profile through the dispersion chamber of the Handihaler 
as the volumetric flow rate is varied.  It is noted that the pressure gradient that develops across 
the dispersion chamber increases with the volumetric flow rate.   For example, pressure values 
range from approximately -2.5 x 102 to 6 x 101 Pa at 30 L min-1.  When the flow rate is raised to 
60 L min-1 the disparity in static pressure across the dispersion chamber also increases, ranging 
from -8 x 102 to 3 x 102 Pa. As depicted in Figure 8.4, the low pressure region is located at the 
corner of the volume expansion.    
In contrast to the Aerolizer, where the motion of the beads is similar regardless of bead 
diameter, the dynamic profile varies considerably with diameter in the Handihaler.  When a 
small bead (diameter < 4.5 mm) is placed in the dispersion chamber of the Handihaler, the 
incoming flow carries the bead forward and pushes it against the mesh, where it is held 
stationary for the duration of the flow stream. Conversely, when a large bead (diameter > 6 mm) 
is employed, it is confined primarily to the rear of the dispersion chamber, where it oscillates 
weakly, repeatedly colliding against the base of the dispersion chamber adjacent to the inlet.   
Based on the fluid profile that develops in the Handihaler as the inlet transitions 
abruptly into the dispersion chamber, it is speculated that the small diameter beads are not 
influenced by the low pressure region in the corner of the expansion.  Accordingly, they 
primarily, if not exclusively, experience the force of the incoming flow stream, which carries 
them toward the mesh located opposite the inlet.  Alternatively, the motion of the large 
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diameter beads in the dispersion chamber is greatly influenced by the low pressure region, to 
the extent that despite the incoming flow stream pushing the bead toward the mesh, the bead 
is retained in the region adjacent to the inlet, oscillating weakly as it is simultaneously acted 
upon by the two forces, though the backward force of the low pressure regions appears to be 
predominate.          
This is supported by the observation that when a polystyrene bead with an approximate 
diameter between 4.5 – 5.5 mm is placed in the Handihaler, it oscillates rapidly near the center 
of dispersion chamber.  In this case, the diameter of the bead allows it to be influenced nearly 
equally by the incoming flow stream, which carries it forward, and the low pressure region, 
which pulls it in the opposite direction.  During inhalation, the forces act in unison to rapidly 
oscillate the low density bead.   For the specific geometry of the Handihaler, the bead diameter 
that functions best is fixed between 4.5 – 5.5 mm.  This diameter will vary according to both the 
diameter of the dispersion chamber, and the ratio of the dispersion chamber diameter to the 
diameter of the air inlet.   
In light of these observations, the high emitted fraction from the Handihaler relative to 
the Aerolizer is better understood, as in the latter device the bead undergoes repeated physical 
impactions with the inhaler walls, while in the Handihaler the bead oscillates primarily in the 
center of the dispersion chamber, and physical collisions with the device are minimal.  However, 
the higher emitted fractions obtained from the Handihaler did not translate into improved 
aerosol performance from this device relative to the Aerolizer.  The fine particle fraction from 
beads dispersed from the Handihaler was only 40%, while the Aerolizer produced significantly 
higher FPF values of 64%.  In contrast to the Aerolizer, where the majority of the emitted dose 
reaches the lower stages of the cascade impactor, approximately 48% of the emitted dose from 
the Handihaler deposits in the induction port. Accordingly, overall performance in terms of 
respirable fraction was comparable between drug-coated beads actuated from the Aerolizer and 
Handihaler.   
The tangential inlets of the Aerolizer have been shown to produce rather large 
turbulence levels within the dispersion chamber, specifically in the absence of a capsule [16]. 
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This may explain the greater powder dispersion observed from this device, where FPF values 
exceeded 60%.  In contrast to the Aerolizer, which has been extensively studied by 
computational fluid dynamics, published studies examining the turbulence levels within the 
Handihaler are not available [16 - 19].  However, from the data it is clear that that ability of the 
Handihaler to detach and emit drug from the device is superior to the Aerolizer, while the 
Aerolizer provides more extensive powder dispersion. This trend is not exclusive to the drug-
coated polystyrene beads, as similar results were observed in Chapter 5, when lactose carrier 
DPI formulations were dispersed from both inhalers. 
While the overall drug deposition was not significantly greater through the Handihaler, 
the extremely high emitted fraction made it a more ideal device for the drug-coated polystyrene 
beads compared to the Aerolizer.  As it was speculated that the high induction port deposition 
was primarily due to agglomerated drug particles that were not effectively dispersed following 
detachment, a novel method to coat drug onto the bead surface as primary particles was 
investigated.         
8.3.2. Influence of Coating Method 
As previously mentioned, the very low surface area of the polystyrene beads ensures 
that drug particles will interact extensively during blending, and coupled with the low mass of 
these carriers, the aggregates that form will not be effectively disrupted.  Accordingly, an 
alternative approach to coating the beads would be to modulate the nature of the interaction 
between drug particles, preventing the formation of large, stable agglomerates.  To achieve this, 
it was proposed to coat the bead by initially aerosolizing the drug powder into primary particles, 
then allowing the particles to deposit onto the surface of the polystyrene bead where they may 
remain adhered via Van der Waals forces.  In this way, the drug particles will deposit on top of 
each other through a random process.  This contrasts with traditional blending, where repeated 
contact occurs between drug particles as the powder continuously cascades within the vial, 
allowing the drug particles repeated opportunities to encounter other particles with 
orientations that may yield a strong cohesive interaction.     
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8.4. PIEZO-ASSISTED COATING (PAC) 
To compensate for the diminished surface area of the polystyrene beads and decrease 
the extent of drug agglomerates coating the bead surface, a novel coating method was 
developed that employed piezoelectric energy to aerosolize micronized drug powder onto the 
polystyrene beads.  An overview of the method is depicted in Figure 8.5, and the coating process 
is described in detail in the ‘Experimental’ section of this chapter.   
As seen in the SEM micrographs in Figure 8.6, traditional coating produced patches of 
drug powder distributed sporadically over the bead surface.  Closer examination indicated these 
were composed primarily of dense powder aggregates. During actuation these powder 
compacts may be released largely intact, and in the absence of effective particle dispersion 
deposit in the induction port and pre-separator.  By contrast, the PAC method yielded a more 
uniform distribution of powder on the bead surface, where the powder appeared as distinct 
primary particles as opposed to the dense aggregates observed during standard blending.  It is 
noted that the mass of budesonide coated by the PAC method (200 – 300 mcg) was on average 
much lower than that produced by standard blending (600 – 900 mcg).  However, the coating 
masses from the PAC method were comparable to those found in commercial products for the 
pulmonary delivery of a budesonide powder, where the nominal dose can range between 100 – 
400 mcg [20, 21]. 
The in vitro performance from polystyrene beads coated by either standard blending or 
PAC is shown in Figure 8.7.  As speculated, while the EF values were similar between the two 
coating methods, significantly lower induction port deposition occurred using the PAC method, 
resulting in greater overall performance as FPF and RF was significantly higher (p < 0.05) relative 
to the standard coating method.  The combination of powder dispersion through the Handihaler 
with the PAC method improved overall drug deposition (as measured by RF) from 28% up to 
45%.        
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8.5. MODULATING DRUG COATING 
While the coating levels of budesonide observed with the PAC method are within the 
range typically delivered by commercial devices, the ability to accurately control the dose 
coated onto the beads is essential. Accordingly, the potential parameters that influence overall 
coating mass were investigated.  For the initial studies the coating time was altered, and beads 
were coated with budesonide for 1, 2, 5 and 10 minutes and the drug depositing on their 
surface quantified following the standard drop from a short distance to remove any loosely 
adhered powder.  As the beads ranged in size from 4.38 – 5.38 mm, the dose was normalized to 
the bead diameter, yielding a strong relationship (R2 = 0.992) between coating time and drug 
deposition (in terms of mcg of drug per bead diameter in millimeters) (Figure 8.8). It is noted 
that the relationship it not linear, as doubling the coating time does not double the dose.  
However, as coating time was increased so too did the amount of drug coated on the bead 
surface, with the 1-minute coating time providing the lowest overall coating levels (64 mcg/mm) 
and the 10 minute time the highest (128 mcg/mm), demonstrating that moderately high doses 
of budesonide, in excess of 500 mcg, are achievable by the PAC method when the coating time 
is prolonged. 
In the preceding PAC examples, the beads were placed directly in the powder bed, 
resulting in hundreds of micrograms of drug being coated onto their surface.  For situations 
requiring low drug doses, a different approach was examined where the beads were removed 
from the micronized drug and coated while being held a fixed distance above the powder bed.  
During the PAC method the coating vial is filled by an aerosol cloud, as the powder is 
continuously fluidized by the piezoelectric energy provided by the sonicating water bath.  It was 
speculated that holding the bead above the powder bed would still allow drug deposition onto 
the bead surface (as the bead will be located within the aerosol cloud), but to a lesser extent 
relative to when the bead is directly in the powder.   Examples of the low dosing ranges that are 
targeted include the SPIRIVA® (22 mcg of tiotropium bromide per dose) and FORADIL (12 mcg of 
formoterol fumarate) formulations, delivered from the Handihaler and Aerolizer, respectively 
[22, 23].     
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For this study, the beads were held either 10 mm or 25 mm above the powder bed, and 
compared against the coating masses attained when the bead is placed directly in the powder.  
As with the coating-time study, due to the minor variations in bead size the drug mass 
depositing on the bead surface was normalized to bead diameter (Table 8.1).  When the bead is 
held 10 mm above the powder bed, coating levels ranged between 27 – 31 mcg, as an average 
of 5.6 mcg/mm were coated compared to 65 mcg/mm when the bead is directly in the powder.  
Elevating the bead further to 25 mm above the powder reduces drug coating to approximately 
half that of the 10 mm distance, with coating levels of 2.4 mcg/mm, yielding 11 – 13 mcg total 
per bead, comparable to the nominal dose delivered by the Aerolizer [22].   
8.6. CONCLUSIONS 
In this chapter, the potential of an alternative dispersion mechanism to improve the 
emitted fraction from drug-coated polystyrene beads was evaluated.  During the screening 
study described in Chapter 7, large drug-coated beads were dispersed in the Aerolizer DPI 
resulting in repeated, physical collisions between the bead and inner walls of the device.  For 
low-density polystyrene beads, over half the dose remained adhered to the inhaler following 
actuation such that despite the good powder dispersion levels exhibited from this device overall 
drug delivery remained below 30% of the nominal dose.  In contrast to the physical collisions 
between the bead and device in the Aerolizer, when the bead was actuated from the Handihaler 
it oscillated rapidly within the center of the dispersion chamber and physical collisions between 
the device and bead were infrequently observed.  However, despite the absence of physical 
collisions between the bead and inhaler, it is speculated that the momentum transfers that arise 
due to the rapid and continuous acceleration changes of the bead as it oscillates provide 
sufficient detachment forces to promote effective drug delivery.  This was supported by the high 
emitted fraction exhibited by the Handihaler, where EF values were approximately double those 
obtained through the Aerolizer.      
Although the delivered dose obtained from the Handihaler made it better suited to 
optimize performance of the drug-coated polystyrene beads, the higher EF values did not yield 
improved overall performance, as extensive induction port deposition from the Handihaler 
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resulted in RF values comparable to those from the Aerolizer.  To improve performance by 
lowering the ‘throat’ deposition, a coating method was developed to inhibit the extensive drug 
agglomerates that were formed during traditional blending of drug with the beads.  The novel 
PAC method employed piezoelectric energy from a sonicating water bath to aerosolize the drug 
powder into primary particles, which were then able to deposit on the bead surface and adhere 
via van der Waals forces.     Combined with the dispersion mechanism of the Handihaler, the 
PAC method produced RF values of 45%.  Additionally, the ability to modulate the dose by 
adjusting the coating time and the bead distance from the powder bed was demonstrated, 
permitting a range of drug masses of approximately 10 – 500 mcg to be coated onto the bead. In 
the following chapter, the precise bead size to maximize oscillations and optimize performance 
will be assessed.  Additionally, the potential of the drug-coated beads to provide flow rate 
independent performance through the Handihaler will be evaluated.   
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Figure 8.1.  Illustration of Powder Motion during Blending in a Turbula® Orbital 
Mixer. 
For standard blending of lactose carrier particles with micronized drug, the powders are 
mixed using a Turbula® orbital blender.  In this method, the vial is continuously rotated, inducing 
the powder to cascade from one end of the vial to the other.  This blending process typically 
exhibits excellent drug content uniformity, as the repeated abrasion of the drug powder by the 
coarse carriers effectively disrupts drug agglomerates.     
  
 212 
 
 
 
 
Figure 8.2.  Aerosol Performance of Budesonide-Coated Polystyrene Beads from 
the Aerolizer and Handihaler DPIs 
The in vitro aerosol performance of budesonide-coated polystyrene beads (diameters 
between 4.38 - 5.38 mm) was evaluated at 60 L min-1 through the AerolizerTM and HandihalerTM 
DPIs.  Opposing trends in emitted fraction (EF) and fine particle fraction (FPF) yielded 
comparable respirable fractions (RF) from the two inhalers.  Values are provided as the mean (± 
standard deviation) for N = 3 replicates.     
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Figure 8.3.  Sudden Expansion of a Flow Stream (Adapted from Gupta, et al, 1984). 
In the Handihaler, the 3.5 mm diameter inlet opens abruptly to the 7.6 mm diameter 
dispersion chamber.  When a flow stream travels through such a volume expansion, it 
decelerates as it flows into the larger chamber, and the boundary layer that forms in the narrow 
chamber detaches at the corner of the expansion.  This results in an annular region developing 
at the corner of the volume expansion, where the fluid does not continue downstream, but 
recirculates as an eddy.  These eddies induce a pressure loss, causing a reduction in the 
mechanical energy carried by the flow, and are generally avoided.   
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Figure 8.4.  Static Pressure Contours Across the Handihaler Dispersion Chamber at 
30, 45, and 60 L min-1.   
When a flow stream passes from the inlet to the dispersion chamber of the Handihaler, 
it encounters a sudden volume expansion.  This phenomenon results in a pressure gradient 
developing across the dispersion chamber, where the low pressure region is located at the 
corner of the expansion.  The pressure gradient increases with increasing flow rate through the 
device. This image was produced using the computational fluid dynamic (CFD) software Fluent® 
(Fluent Inc. (2006), NH, USA).  Image courtesy of Shaun Kim.   
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Figure 8.5.  Illustration of Piezo-Assisted Coating (PAC) Process for Coating 
Polystyrene Beads   
To limit the extent of drug agglomerates, a piezo-assisted coating (PAC) method was 
developed to aerosolize the drug particles and then allow them to settle onto the bead surface 
and remain adhered through van der Waals interactions.  A vial containing the beads and 
micronized powder is placed within a sonicating water bath, where the energy of the sonics 
fluidizes a portion of the powder bed, creating a sustained aerosol plume of dispersed drug 
particles.      
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Figure 8.6.  SEM Images of Uncoated Polystyrene Beads, and Beads Coated with 
Budesonide via Standard Blending or with the PAC Method.     
Budesonide-coated polystyrene beads were imaged via SEM to evaluate the potential of 
the two coating methods to minimize the formation of stable drug agglomerates. SEM images of 
uncoated polystyrene carriers (Figures A – B) indicate that the beads are not perfectly spherical 
as assumed, but possess a degree of surface roughness. The beads were coated using standard 
blending in a Turbula® orbital mixer (Figures C – D) or via the piezo-assisted coating method 
(Figures E – F). To accommodate the polystyrene carriers, the beads were lightly pressed down 
onto a stage covered with double-sided conductive tape, and then the sides of the tape were 
folded against the bead and transfixed with a metal pin, piercing both the tape and the bead to 
permit adequate conduction.   
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Figure 8.7.  In Vitro Aerosol Performance of the PAC Method. 
The in vitro aerosol performance of budesonide-coated polystyrene beads (diameters 
between 4.38 - 5.38 mm) at 60 L min-1 through the Handihaler DPI.  The beads were coated 
either with the standard method in a Turbula® orbital blender, or using the piezo-assisted 
coating (PAC) method.  Values are provided as the mean (± standard deviation) for N = 3 
replicates.  While both methods produced comparable emitted fractions (EF), the fine particle 
fraction (FPF) and respirable fraction (RF) values were significantly improved by the PAC 
method.  
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Figure 8.8.  Coating Time Studies using the PAC Method     
To evaluate influence of coating time using the PAC method, polystyrene beads were 
coated for 1, 2, 5, or 10 minutes.  To normalize for bead diameter, the total drug mass 
recovered following coating was divided by the bead diameter as measured using calipers. 
Values are provided as the mean (± standard deviation) for N = 3 replicates.   
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Table 8.1. Drug Coating as a Function of Bead Distance 
 Bead Distance from Powder Bead (mm) 
 
 0 10 25  
Total drug mass per  
bead diameter  
(mcg/mm) 
65.2  (1.9) 5.6  (0.3) 2.4  (0.2) 
 
     
Total Drug Mass  
per Bead  
(mcg) 
327 - 333 27 – 31 11 – 13 
 
     
 
Previous studies have coated the beads while they were directly in the powder bed.  To 
evaluate the potential to coat lower drug masses, the beads were held either 10 mm or 25 mm 
above the powder bed during the 2-minute coating period.  The coating levels are compared to 
beads that were coated while directly in the powder bed.  To normalize for bead diameter, the 
total drug mass recovered following coating was divided by the bead diameter as measured 
using calipers. Values are provided as the mean (± standard deviation) for N = 3 replicates.   
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CHAPTER 9 
9. Refinement and Optimization of Large Carrier Particle Dispersion 
Technology 
9.1. INTRODUCTION 
Passive dry powder inhalers are completely dependent on the inspiratory effort 
generated by the patient to aerosolize and disperse the dose.  However, due to marked 
differences between patients, particularly with regards to age and disease state, there is 
considerable variation in the inspiratory effort that a patient can produce through a given 
device.  Consequently, aerosol performance varies considerably between patients. For example, 
patients with severe COPD were reported to inhale through the Handihaler with a median flow 
rate of 35 L min-1, in  contrast to patients with mild COPD, who generated a median flow of 45 L 
min-1 through this inhaler [1]. An additional study examining patient flow rates through the 
Handihaler noted that approximately one-quarter of COPD patients with a severe condition 
were unable to achieve a flow rate of 20 L min-1[2].  In vitro deposition studies of tiotropium 
delivered from the Handihaler reported that at 20 L min-1 only 16% of the nominal dose is 
delivered, as opposed to 22% at 28.3 L min-1.  Accordingly, many of the patients who would 
most benefit from inhalation therapy are those least capable of producing sufficient flow rates 
to adequately disperse the powder.   
In the two preceding chapters, a candidate carrier bead material was selected and 
matched to a dispersion mechanism that demonstrated high dose delivery from a commercial 
dry powder inhaler.  When the beads are placed in dispersion chamber of a Handihaler, they can 
oscillate rapidly due to the opposing fluid forces that simultaneously act upon them.  The 
extremely low density of the polystyrene beads could potentially enable them to oscillate at 
very low rates, where traditional lactose carrier particles have been shown to perform poorly, 
thus allowing the drug-coated bead to provide efficient drug dispersion performance 
independent of inspiratory effort. 
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Specific Aim 
The specific aim of this chapter is to obtain a thorough mechanistic understanding of the 
parameters that govern the performance of the drug-coated bead through the Handihaler.  
Beads were photographed during actuation within the Handihaler, and their dynamic profiles 
compared to that of standard capsules. In addition, as the beads emit a loud ‘rattling’ sound 
during actuation, their acoustic signals were recorded to assess the frequency of their 
oscillations. To evaluate the potential for the large carriers to function effectively independent 
of flow rate, the aerosol performance of the drug-coated polystyrene beads are compared to 
that of traditional binary blends using both a corticosteroid and a β-agonist at 15, 30 and 45 L 
min-1. 
9.2. EXPERIMENTAL 
9.2.1. Materials 
Budesonide and salbutamol were both purchased in bulk (Jinhuo Chemical Company, 
China) and micronized with a high energy jet-mill with respective pusher and grinding  pressures 
of 80 and 110 PSI (Aljet; Fluid Energy Processing and Equipment Co., PA, USA). Respitose® 
ML006 inhalation-grade lactose was generously provided by DMV-Fonterra (New Zealand) and 
used as received.  Size-3 gelatin capsules were provided by Capsugel (NJ, USA).  
9.2.2. Physical Characterization of Carrier Particles 
The size distribution and drug coating on the lactose carrier particles was visually 
assessed by scanning electron microscopy (SEM; Supra 40VP, Zeiss, Germany). Prior to SEM, 
approximately 20 nm of a platinum::palladium (80::20) mixture was deposited onto the particles 
via sputter coating. SEM was also performed on both uncoated and drug-coated polystyrene 
beads. To accommodate the polystyrene carriers, the beads were lightly pressed down onto a 
stage covered with double-sided conductive tape. The sides of the tape were then folded 
against the bead and transfixed with a metal pin, piercing both the tape and the bead to permit 
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adequate conduction. As with the lactose particles, prior to imaging approximately 20 nm of a 
platinum::palladium (80::20) mixture was deposited onto the beads via sputter coating.  
Powders were sized via laser diffraction using a Sympatec HELOS (Sympatec GmbH, 
Germany) apparatus equipped with a 6-mL cuvette dispersing system.  Mineral oil was used as 
the dispersing fluid, which included 1% Span 85 to aid in particle de-aggregation.  The powders 
were suspended in the mineral oil and, if physically stable, sonicated for 60 seconds to disrupt 
aggregates.  Measurements were collected following elimination of all visible air bubbles.  The 
‘forced stability’ option was used to ignore the signal from errant dust or residual air bubbles. 
The specific surface area of the lactose carrier particles was determined via nitrogen 
adsorption with a single-point BET method using a Monosorb® surface area analyzer 
(Quantrachrome Instruments; FL, USA).  Samples were outgassed under nitrogen at 40 °C for 24 
hours prior to each measurement.  The surface area of the polystyrene beads was approximated 
using the equation for the surface area of a smooth sphere. 
The density of the lactose carrier particles was evaluated by helium pycnometry 
(Quantachrome, FL, USA).  For the porous polystyrene, 10 beads were weighed individually and 
their respective diameters measured with calipers.  The volume was assumed equal to that of a 
sphere. 
9.2.3. Preparation of Binary Lactose Formulations 
Budesonide and salbutamol were each mixed in a ratio of 1:50 (w/w) with ML006 
inhalation-grade lactose via geometric dilution to obtain 500 mg of a 2% binary blend. The 
formulations were blended with a Turbula® orbital mixer (Glen Mills, NJ, USA) for 40 min at 46 
RPM. Samples were stored in a desiccator at least 5 days prior to use. Blend uniformity was 
determined by assessing the drug content in eight 20-mg samples selected at random from each 
mixture. The formulations exhibited high content uniformity, with coefficients of variation 
between the samples for both blends below 3%. 
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9.2.4. Drug Coating of Polystyrene Beads 
To coat the polystyrene beads, 2 mg of micronized drug powder were weighed into a 
30-mL scintillation vial, followed by three 5.2 mm polystyrene beads.  The vial was sealed and 
the bottom half was submerged in a sonicating water bath (Fisher Scientific, NH, USA) for 2 
minutes.  When the vial is placed in the water bath, the energy imparted to the powder by the 
sonics aerosolizes a fraction of the powder bed, creating a sustained plume as powder is 
continuously aerosolized, then deposits by gravitational settling, and then is aerosolized once 
more. Throughout the coating period, the beads are continuously exposed to the aerosol cloud, 
and as the aerosolized drug particles deposit some land on the bead surface where initially they 
adhere directly to the surface of the bead, and then once a monolayer has been formed, 
subsequent drug particles adhere directly to other drug particles via van der Waals and 
electrostatic interactions.  Due to the small size, and thus negligible mass, of the primary drug 
particles, van der Waals interactions overwhelm other types of forces, including gravitational 
forces. During coating, the vial was rotated slowly from side-to-side, permitting the bead to roll 
across the powder and thereby expose the entire surface to the emitted drug particles.  
Following coating, the bead was removed from the scintillation vial and dropped approximately 
12 inches onto an aluminum mesh to remove any loosely adhered drug particles and 
agglomerates.  The drug-coated polystyrene beads were then stored in a desiccator for 3 days 
prior to use.    
9.2.5. Measurement of Device Resistance 
To evaluate the resistance of the DPI, the pressure drop (cmH2O) across the Handihaler 
at multiple volumetric flow rates (20, 30, 40, 50, 60, and 70 L min-1) was measured using a digital 
manometer (SPER Scientific; AZ, USA). The device resistance was determined by plotting the 
square root of the pressure drop (∆P) against the flow rate (Q), with the slope of the 
relationship equaling the device resistance (R), as described by Clark and Hollingworth [3]: 
√         
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The pressure drop across the device was initially assessed with an empty dispersion 
chamber, and then with either a size-3 gelatin capsule (perforated with the Handihaler’s 
piercing mechanism), or with a 5.2 mm polystyrene bead placed within the dispersion chamber.   
Additionally, the flow rate corresponding to a pressure drop of 4 kPa through the inhaler was 
also determined for each of the three configurations.  
9.2.6. Bead Imaging 
Images of the beads during device actuation were shot at f/22 with a 1/8 second 
exposure using a strobe flash (Canon Speedlite 500EX) for the solitary light source firing five 
times at a rate of 199 Hz.  The strobe captured the position of the gelatin capsule or polystyrene 
bead at five distinct locations (ca. 5 x 10-3 seconds between each flash) within the inhaler during 
actuation.   Long exposure photographs were captured at f/14 and 4 s to allow the imaging of 
both the beads and the capsules over the course of a normal inhalation profile.  This method 
allowed the visualization of the average location of either the bead or the capsule throughout 
the duration of the inhalation event. 
9.2.7. Acoustic Characterization of the Oscillating Polystyrene Beads 
The audio data of an oscillating bead in the HandihalerTM was recorded using a BOSS BR-
600 Digital Recorder (Roland Instruments).  The inhaler and microphone were placed inside a 
noise-isolating box which was lined with extra foam padding, to reduce the pickup of vacuum 
pump or other laboratory noise.  The inhaler was then connected, via a USP induction port, to 
an NGI set outside of the box.  The desired flow rate was attained, and then 300 s of audio data 
were captured at 44.1 kHz.  The open-source software Audacity was used to visualize the 
waveform of the collected audio data.  The distance (in time) from one peak (an audio event) to 
the next was measured, and 128 such measurements were performed on each recording to 
determine the average frequency of an audio event.  One audio event was assumed to 
represent one virtual impaction, with two impactions occurring in one full bead oscillation cycle. 
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9.2.8. In vitro Aerosol Performance 
The respective aerosol performance profiles of the binary blends and drug-coated large 
polystyrene carrier particles were evaluated in vitro with a next generation cascade impactor 
(NGI; MSP Corporation, MN, USA) at 15, 30, and 45 L min-1. The actuation times at 30 and 45 L 
min-1 were adjusted to provide a 4 L volume through the inhaler (8 and 5.3 seconds, 
respectively).  However, at 15 L min-1, the device was actuated for 8 seconds, corresponding to a 
2 L volume.  The volumetric flow rates were measured with a digital flowmeter (TSI Performance 
Measurement Tools, MN, USA) connected in series with the NGI, and a home-built solenoid-
valve timer box ensured that the actuation times were consistent between runs.  For the binary 
blends, 20 (±1) mg of powder were placed into size 3 gelatin capsules and punctured via the 
piercing mechanism of the DPI.  For the drug-coated polystyrene carriers, a single bead was 
placed into the dispersion chamber for each impaction.  To prevent particle re-entrainment, the 
NGI stages were coated with a 2% (v/v) solution of silicon oil in hexane and allowed to air dry 
prior to each impaction.   
For the cascade impactions of the binary formulations at 30 and 45 L min-1, 15 mL of 
EtOH were added to the pre-separator prior to every run and collected following each 
impaction. The capsule, dispersion chamber, mouthpiece, mouthpiece adaptor, and induction 
port were each rinsed with 10 mL of EtOH, and the stages of the NGI were each rinsed with 5 
mL.  At 15 L min-1 a pre-separator was not included, as recommended by the archival calibration 
study. Additionally, an external filter was attached downstream of the impactor as at this flow 
rate the MOC is not an effective final stage particle collector [4]. For the NGI experiments with 
the polystyrene beads, a pre-separator was not included at any flow rate, and similar to the 2% 
formulations an external filter was included downstream of the impactor at 15 L min-1.  
Following each impaction, the polystyrene bead was rinsed with 10 mL of EtOH, with the 
remaining rinsing volumes identical between the binary blends and polystyrene beads.        
The drug content was assessed by UV-VIS spectroscopy using an Infinite M200 
microplate reader equipped with a cuvette port (Tecan US, Inc., NC, USA) at 230 nm and 244 nm 
for salbutamol and budesonide, respectively.  The emitted fraction (EF) is given as the 
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percentage of the total recovered dose depositing on the mouthpiece adaptor, induction port, 
pre-separator (for binary blends) and NGI stages; at 15 L min-1 the drug depositing on the 
external filter was also included.  The fine particle fraction (FPF) is given as the percentage of the 
emitted fraction depositing on stage 3 and below at 30 and 45 L min-1, and stage 4 and below 
(including the external filter) at 15 L min-1.  The respirable fraction (RF) is calculated as the 
percentage of the total recovered dose depositing on stage 3 and below at 30 and 45 L min-1, 
and stage 4 and below (including the external filter) at 15 L min-1.  For 15 and 30 L min-1, the cut-
off sizes for the stages of the NGI were obtained from the literature, while at 45 L min-1 the 
stage cut-off sizes were calculated in accordance with the guidelines described in the U.S. 
Pharmacopeia [4, 5]. The respective cut-off diameters of stage 2 at 30 and 45 L min-1 are 6.40 
µm and 5.18 µm, while that of stage 3 at 15 L min-1 is 5.39 µm (Table 9.1).  
9.2.9. Statistics 
Statistical significance between performance values was determined with one-way 
ANOVA with Post Hoc tests between groups according to the Bonferroni method (P < 0.05). 
9.3. RESULTS AND DISCUSSION 
9.3.1. Physical Characterization of Drug and Carriers 
The measured physical properties for the lactose carriers and polystyrene beads are 
presented in Table 9.2.  The lactose population is characterized by small particle sizes and a high 
percentage of fine particles (diameters < 10 µm).  Previous studies in our laboratory evaluating 
the aerosol performance of binary blends with multiple inhalation-grade lactose populations 
(Respitose grades: ML006, ML001, SV003 and SV010) concluded that ML006 provides the 
highest performance levels of the tested carriers.  Accordingly, it was selected as a comparator 
to the drug-coated polystyrene beads.    
For a 20-mg sample of ML006 lactose, the total surface area of the carrier population is 
approximately 0.021 m2, and thus the surface area available for drug binding in a 20-mg sample 
is approximately 250 times greater than the surface area available for drug attachment on a 
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single 5.2 mm polystyrene bead.  Accordingly, for comparable drug masses, interactions 
between drug particles will be more extensive for the polystyrene beads.  In Figure 9.1, the low 
concentration of drug (2% w/w) coupled with the large SSA of the lactose carriers resulted in 
very low surface coverage of the carrier particles.  In contrast, the polystyrene beads were 
coated with multiple layers of drug particles (Figure 9.2). Both budesonide and salbutamol 
provided nearly uniform coatings on the surface of the bead, and the drug particles were 
observed largely as discreet particles rather than dense agglomerates. 
9.3.2. Device Resistance 
The Handihaler is a high-resistance device, with a measured resistance of approximately 
0.173 ((cmH2O)
0.5 / L min-1) when a perforated, size 3 gelatin capsule is in the dispersion 
chamber (Table 9.3).  This value matched the device resistance of the Handihaler reported in the 
literature, where a 39 L min-1 flow rate was found to correspond with a 4 kPa pressure drop [1].  
When a capsule is placed within the device, the resistance increases approximately 31%, from 
0.132 to 0.173 ((cmH2O)
0.5 / L min-1).  By comparison, a lower increase in device resistance (9%) 
was observed upon addition of a polystyrene bead to the dispersion chamber of the Handihaler, 
with a measured value of 0.144 ((cmH2O)
0.5 / L min-1)(Figure 9.3).  Due to the lower overall 
resistance upon addition of the bead, the flow rate corresponding to a 4 kPa pressure drop is 
approximately 44 L min-1, compared to 39 L min-1 when a capsule occupies the dispersion 
chamber. 
Devices with resistances below 0.07 (cmH2O)
0.5 / L min-1 are classified as low resistance 
devices, while the demarcating value traditionally cited to distinguish intermediate and high 
resistance devices is 0.12 (cmH2O)
0.5 / L min-1 [6].  Accordingly, the Handihaler is a high 
resistance device, and aerosol performance was thus evaluated at volumetric flow rates 
between 15 L min-1 and 45 L min-1 to encompass the range of inspiratory efforts achievable by 
patients through the Handihaler [1, 2].  
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9.3.3. In vitro Aerosol Performance 
The in vitro aerosol performance for both binary blends and polystyrene beads are 
presented in Tables 9.4 and 9.5.  Studies examining the in vitro deposition of tiotropium from 
the Handihaler have reported relatively low emitted fractions, with 56 – 60% of the nominal 
dose delivered from the device between 20 and 60 L min-1 [1].   This contrasts with the values 
obtained in the present study for the binary lactose blends, where the Handihaler exhibited very 
high emitted fractions of 84 – 90% for both drug formulations at 30 and 45 L min-1.  By 
comparison, the emitted fractions from the polystyrene carriers at 45 L min-1 were comparable 
to the binary formulations for both drugs, though salbutamol was slightly higher than 
budesonide.  When the flow rate was reduced to 30 L min-1, the performance was diminished 
for both drugs, though the difference was only significantly (p < 0.05) lower for budesonide.  
This is potentially due to the greater adhesive interaction between the budesonide particles and 
the polystyrene beads, as will be discussed in detail below. 
Despite the high EF values for the binary lactose blends at these flow rates, much of the 
emitted dose was deposited in the induction port and pre-separator, particularly for 
budesonide, as noted by the FPF values.  By comparison, the majority of the dose emitted from 
the device by the polystyrene beads was well dispersed, with FPF values between 66 – 68% and 
76 – 82% for budesonide and salbutamol, respectively.   
Although the FPF and RF values were significantly greater from salbutamol, the 
improvement in aerosol performance from the drug-coated beads relative to the binary blends 
was greater for the budesonide formulations, where the maximum disparity between RF values 
for the lactose blend (26%) and drug-coated-bead (58%) occurred at 45 L min-1. By comparison, 
performance differences between the lactose blend and the bead were less stark, as deposition 
increased to 69% for the latter relative to 47% from the former.  These differences suggest that 
the ability to coat the drug onto the bead surface largely as primary particle is more 
advantageous for a highly cohesive powder such as budesonide.  By comparison, the observed 
aerosol performance of salbutamol indicates it is readily dispersible powder, with FPF and RF 
values approximately 50% greater than those observed for the budesonide blend.   
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9.3.4. Performance at 15 L min-1 
When a capsule is placed within the dispersion chamber of the Handihaler, it vibrates 
and rattles during actuation, and this motion is believed to aid in ejecting powder from the 
capsule (Figure 9.4).  By comparison, the opposing fluid forces acting on the bead cause it to 
oscillate rapidly within the dispersion chamber, and it is noted that the bead also spins while it 
oscillates. As seen in Figure 9.5, the bead does not typically collide with the mesh or extensively 
contact the walls of the dispersion chamber.  Rather, the bead oscillates rapidly near the center, 
which as discussed in the previous chapter, limits the amount of drug retained in the device and 
promotes a high emitted fraction. 
Figure 9.6 depicts long-exposure photographs of both the capsule and beads within the 
dispersion chamber of the Handihaler during actuation at 30 and 15 L min-1.  At 30 L min-1 the 
capsule vibrates and rattles extensively, as indicated by the blurred image representing the 
motion of capsule during the 4-second exposure. When the flow rate is reduced to 15 L min-1, 
the capsule no longer rotates or rattles, but rather rests against the mesh of the inhaler 
throughout actuation, as this flow rate is not sufficiently high to induce capsule vibrations, 
which is believed to aid in powder emission.  Additionally, the low flow rate is insufficient to pull 
the powder through the perforations in the capsule wall, and consequently the majority of the 
formulation is retained in the device, specifically still within the capsule. EF values of 9% and 
15% were observed for budesonide and salbutamol, respectively.  For the low-density 
polystyrene beads, 15 L min-1 reduced, but did not prevent, oscillation, as frequencies of 110 Hz 
were generated at this flow rate.  Additionally, at 30 L min-1 the bead appeared to travel a 
slightly greater distance within the dispersion chamber relative to the lower flow rate.  
However, despite the lower frequency and shorter distance traveled between oscillations, the 
detachment forces produced at this flow rate were sufficient to yield emitted fractions of 65% 
for salbutamol and 45% for budesonide.   
Overall, the lactose-based formulations yielded respirable fractions below 10% for both 
drugs.  For the drug-coated polystyrene beads, deposition of salbutamol remained significantly 
higher than for budesonide, with RF values of 44% and 24%, respectively.  Nevertheless, for 
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both drugs the respirable fractions produced from the polystyrene bead carriers at 15 L min-1 
were comparable to those obtained from the lactose formulations at 30 and 45 L min-1 (Figure 
9.7) 
9.3.5. Drug Coating 
The overall drug mass coating the surface of the polystyrene beads is governed initially 
by the strength of the adhesive interaction between the drug and bead to form the initial 
monolayer, followed by the cohesive interaction between drug particles during the formation of 
subsequent layers.  The affinity of the drugs to the polystyrene beads was not identical, with 
budesonide yielding higher coating masses than salbutamol for the 2-minute coating period.  
This disparity may arise from the differences in the lipophilic nature of the drugs, with 
respective log P values of 2.18 and 0.015 for budesonide and salbutamol, which may result in 
greater adhesion to the hydrophobic polystyrene surface [7, 8].  Additionally, budesonide has 
been noted to be a relatively cohesive drug, and in combination with its greater lipophilicity, 
may result in the significantly higher coating masses observed for this API.   This higher affinity 
of budesonide for the polystyrene bead surface is noted in the overall fraction of the nominal 
dose that is retained on the bead following actuation.   
9.3.6. Bead Oscillations and Detachment Forces 
During actuation, the bead generates a very loud rattling sound as it oscillates within the 
dispersion chamber.  For every oscillation of the bead, it was speculated that two ‘impaction’ 
events occur, where each ‘impaction’ signals an abrupt acceleration change as the bead rapidly 
comes to a stop and then proceeds to reverse direction, accelerate, and stop; the process is 
repeated for the entirety of the actuation period. The continuous nature of these ‘impaction’ 
events results in the characteristic rattling of the bead.  The frequency of the ‘impaction’ events 
arising from the oscillations of the polystyrene beads ranged from 110 Hz at a flow rate of 15 L 
min-1, up to 225 Hz at 45 L min-1 (Table 9.6).  The oscillation frequency of the beads was not 
constant, but varied slightly as the amplitude of the oscillations varied.   
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9.3.6.1. Influence of Oscillations 
To assess the role of the oscillations in drug detachment, a polystyrene bead was held 
stationary within the dispersion chamber of a Handihaler during actuation at 30 L min-1.  A small 
hole was drilled into the side of the dispersion chamber to allow a pin to enter the chamber and 
pierce the budesonide-coated polystyrene bead (Figure 9.8).  The bead was held in the center of 
the chamber, approximately 2 mm from the opening of the inlet into the chamber, with a flow 
rate of 30 L min-1 for 8 seconds. During actuation, the pin was slowly rotated to allow the entire 
surface area of the bead to be exposed directly to the incoming flow stream.  
The performance of the stationary and oscillating beads at 30 L min-1 is shown in Figure 
9.9. With the bead held stationary by the pin, 72.0% of the dose remained on the bead following 
actuation. By comparison, when the polystyrene bead oscillates, only 5.4% remains adhered to 
the carrier.  Overall, the respirable fraction from the stationary polystyrene bead was 8.3%, a 
significant decline in performance when compared to the oscillating bead, where 52.6% of the 
coated dose deposited in the lower stages of the cascade impactor.   While the incoming flow 
stream does detach drug particles from the polystyrene bead, the detachment forces are not as 
effective as when the flow stream is coupled with the momentum transfers arising from the 
rapidly oscillating bead.    
9.4. CONCLUSION 
This chapter compared the performance of traditional lactose-based binary blends with 
that of 5.2 mm drug-coated polystyrene beads using budesonide and salbutamol as model APIs.  
To evaluate the relative flow rate dependence of the formulations, dispersion performance was 
assessed at flow rates ranging from 15 to 45 L min-1, encompassing the range of inhalation 
efforts observed in COPD patients for whom the Handihaler is commonly prescribed.  Overall 
performance for salbutamol exceeded that of budesonide for all flow rates, and is likely due to a 
difference in the cohesive and adhesive properties between the two drugs, as this API 
performance disparity was noted from both the drug-coated beads and the lactose binary 
blends.   
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At 30 and 45 L min-1, the polystyrene beads significantly outperformed the lactose 
blends, with bead RF values ranging from 53 – 58% for budesonide, and 67 – 69% for 
salbutamol.  At 15 L min-1, the performance of the lactose blends was extensively inhibited, as 
the flow rate is too low to induce capsule vibrations, and over 80% of the dose was retained in 
the device.  By contrast, though the frequency of the bead oscillations declined with the 
decreasing flow rate, they remained sufficiently high at 15 L min-1 to generate detachment 
forces capable of emitting between 45% - 65% of the dose from the DPI.  Additionally, it was 
observed that the respirable fractions of the polystyrene bead carriers at 15 L min-1 were 
comparable to those obtained from the lactose formulations at 30 and 45 L min-1 for both drugs.   
The oscillations of the polystyrene bead during actuation appeared to play a significant 
role in drug detachment, as overall performance when the bead was held stationary in the 
dispersion chamber was approximately 16% of that when the bead oscillated.  Thus, the 
polystyrene carriers function initially as a scaffold onto which drug particles attach in their 
primary particle size via the piezo-assisted coating method.  During actuation, the forces 
generated by the rapid oscillations of the polystyrene bead within the dispersion chamber 
effectively detach the drug from the bead surface, producing high drug deposition levels relative 
to traditional lactose-based binary formulations.   
In Chapters 7 – 9 the in vitro aerosol performance of the polystyrene beads was 
evaluated through a commercial DPI.  However, these inhalers are not designed to optimize the 
performance of the drug-coated polystyrene beads, and in the previous studies the dispersion 
mechanism was designed around the device.  Accordingly, in the last chapter of this thesis, 
inhaler prototypes will be designed to optimize the aerosol performance of the large, drug-
coated polystyrene beads.      
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Figure 9.1.  SEM Images of ML006 Lactose Binary Blends 
SEM images of ML006 lactose carrier particles blended with micronized (A - B) 
budesonide or   (C - D) salbutamol to prepare 2% (w/w) binary DPI formulations.  Scale bars for 
images A and C denote 100 µm, while scale bars for images B and D equal 20 µm.         
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Figure 9.2.  SEM Images of Drug Coated Polystyrene Beads 
SEM micrographs of polystyrene beads following 2-minutes of piezo-assisted coating 
with either miconized (A - C) budesonide or (D – F) salbutamol.  As seen in figures A and D, the 
double-sided tape was folded against opposite sides of the polystyrene bead and transfixed with 
a metal pin to hold it in place during sputter-coating and provide adequate conduction for 
imaging.         
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Figure 9.3.  Device Resistance Measurement of the Handihaler with a Capsule or 
Bead  
The device resistance was measured by plotting the square root of the pressure drop 
across the inhaler at multiple volumetric flow rates.  The measurements were recorded either 
with an empty dispersion chamber, or with a perforated size-3 gelatin capsule or 5.2 mm 
polystyrene bead in the dispersion chamber.  The inclusion of the capsule yielded a higher 
increase in device resistance relative to the bead as noted by the steeper slope of the (pressure 
drop)0.5-flow rate relationship.  
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Figure 9.4.  Illustration Depicting Relative Capsule and Bead Motions in the 
Handihaler  
During actuation, the capsule will travel the length of the dispersion chamber until it 
contacts the mesh, where the flow stream induces it to spin and vibrate rapidly as it rattles 
against the walls of the devices.  In contrast, the polystyrene bead oscillates rapidly near the 
center of the dispersion chamber, with infrequent contact against the inner walls of the DPI. 
Additionally, though only a single arrow is provided depicting the rotation of the polystyrene 
carrier, during actuation the bead may spin in three dimensions. 
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Figure 9.5.  Image Series of Polystyrene Bead Oscillations.  
The images depict the oscillating motion of an uncoated, 5.2 mm polystyrene bead in 
the dispersion chamber of the Handihaler at 30 L min-1. The images were captured with a 1/8 
second exposure using a strobe flash for the solitary light source firing five times at a rate of 199 
Hz.  The strobe captured the position of the polystyrene bead at five distinct locations (ca. 5 
milliseconds between flashes) within the inhaler during actuation. The above images were all 
captured during a single, 8-second actuation period.   
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Figure 9.6.  Long Exposure Photographs of Capsule and Bead Motion. 
Bead and capsule motion at 15 and 30 L min-1 were imaged using long exposure 
photographs.  The images were captured at f/14 and 4-s to allow the imaging of both the beads 
and the capsules over the course of a typical inhalation profile.  This method allowed the 
visualization of the average location of either the bead or the capsule throughout the duration 
of the inhalation event.  At 15 L min-1 the image of the capsule (A) is not blurred because it 
remained stationary throughout the 4 second exposure.  By contrast, the capsule at 30 L min-1 
(B) produced a blurred image as it vibrated rapidly in the dispersion chamber.  The polystyrene 
beads oscillated at both 15 L min-1 (C) and 30 L min-1 (D), though their respective frequencies and 
amplitudes differed.  
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Figure 9.7.  In Vitro Performance of Salbutamol and Budesonide Formulations   
The in vitro aerosol performance values (RF) of (A) salbutamol sulphate and (B) 
budesonide formulations prepared either with lactose carrier particles or coated directly onto 
polystyrene beads are provided.  Values are given as mean (± standard deviation) for N = 3 
replicates.  For both drugs, the polystyrene beads outperform the binary blends at all tested 
flow rates.  Performance at 15 L min-1 from the polystyrene carriers is comparable to that of the 
lactose blends at 30 and 45 L min-1.   
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Figure 9.8.  Illustration Depicting a Stationary Bead Configuration. 
A small hole was drilled into the side of a Handihaler capsule chamber to allow a metal 
pin to transfix a budesonide-coated polystyrene bead, preventing it from oscillating. During 
actuation the pin was slowly rotated, turning the bead and allowing the entire surface to be 
directly exposed to the incoming flow stream.  As noted previously, the polystyrene bead 
oscillates rapidly near the center of the dispersion chamber, with infrequent contact with the 
inner walls of the DPI. Though only a single arrow is provided depicting the rotation of the 
polystyrene bead, during actuation the bead spins in three dimensions. 
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Figure 9.9.  In vitro Performance of Stationary and Oscillating Budesonide-Coated 
Polystyrene Beads 
The performance disparity of the stationary and oscillating beads is provided by the 
percentage of the nominal dose retained on the bead carrier, and the respirable fraction (RF) 
following a single 8-second actuation at 30 L min-1.  The bead was either held stationary within 
the dispersion chamber using a metal pin that was rotated during the 8-second actuation period 
to allow the entire surface of the bead to be directly exposed to the incoming flow stream.  The 
impaired drug dispersion from the stationary bead suggests the oscillations of the bead are 
effective at detaching drug.  The values are given as mean (± standard deviation) for N = 3 
replicates.   
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Table 9.1. Stage Cut-off Sizes for the NGI at 15, 30 and 45 L min-1 
 D50 (µm) for each volumetric flow rate (L min
-1
)  
 15 30 45  
     
Stage 1 14.1 11.7 9.41  
Stage 2  8.61 6.40 5.18  
Stage 3 5.39 3.99 3.26  
Stage 4 3.30 2.30 1.90  
Stage 5 2.08 1.36 1.09  
Stage 6 1.36 0.83 0.65  
Stage 7 0.98 0.54 0.41  
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Table 9.2. Physical Characterization of ML006 Lactose Carrier Particles and Large Porous 
Polystyrene Beads 
 
Particle sizing, specific surface area, and density measurements for Respitose® ML006 
lactose carrier particles and polystyrene beads are provided.  In contrast to the lactose carriers, 
where specific surface area is a population measurement and provided as m2/g, the surface area 
reported for the polystyrene carrier is that of a single polystyrene carrier (assuming a spherical 
bead) and is provided in units of m2.    
  
 Diameter (µm)    
 d10 d50 d90 
SSA 
(m
2
/g) 
Density 
(g/cm
3
)  
 
LACTOSE 3.5 14.3 41.0 1.04 1.54  
       
 Diameter (mm) 
Surface Area  
(m
2
) 
Density  
(g/cm
3
) 
 
POLYSTYRENE 5.2 (± 0.1) 8.5 x 10
-5
 0.027  
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Table 9.3. Device Resistance of Handihaler with the Inclusion of a Capsule or Bead 
Dispersion Chamber  
Configuration 
 
Device Resistance 
((cmH2O)
0.5
 / L min
-1
) 
 
Flow Rate at 4 kPa 
(L min
-1
) 
Empty 0.132 49 
Size 3 Gelatin Capsule 0.173 39 
5.2 mm Polystyrene Bead 0.144 44 
 
The bead provides a smaller increase in device resistance relative to the capsule, and 
accordingly the flow rate corresponding to a 4 kPa pressure drop is higher when a bead is in the 
dispersion chamber     
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Table 9.4. In vitro Aerosol Performance of Budesonide Formulations 
Flow Rate                        
(L min-1) 
Lactose Carrier Particles  Macro Carrier Particles  
EF (%) FPF (%) RF (%) FPD (mcg)  EF (%) FPF (%) RF (%) FPD (mcg)  
           
15 8.9  (4.1)   52.7  (4.3)   5.2  (2.3) 11 – 24  44.8  (4.6) 55.3  (1.9) 23.8  (3.0) 64 – 78  
30 84.4 (1.9) 35.3  (4.0) 29.7  (2.7) 95 – 122  78.9  (2.1) 66.7  (1.6) 52.6  (1.2) 133 – 168  
45 84.1 (2.6) 30.7  (1.4) 25.8  (0.4) 97 - 114  85.9  (1.5) 67.8  (2.0) 58.2  (1.3) 142 - 172  
           
 
The in vitro aerosol performance of 2% (w/w) formulations and budesonide-coated 
polystyrene beads evaluated through the Handihaler at 15, 30 and 45 L min-1.   Values are given 
as mean (± standard deviation) for N = 3 replicates.   
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Table 9.5. In vitro Aerosol Performance of Salbutamol Formulations 
Flow Rate                        
(L min-1) 
Lactose Carrier Particles  Macro Carrier Particles  
EF (%) FPF (%) RF (%) FPD (mcg)  EF (%) FPF (%) RF (%) FPD (mcg)  
           
15 15.1  (3.8) 52.4  (7.9) 7.8  (1.6) 35 – 48  65.4  (2.5) 68.2  (2.7) 44.4  (1.5) 67 – 86  
30 87.6  (1.5) 53.0  (1.7) 46.5  (2.2) 181 – 209  84.9  (4.1) 81.4  (2.9) 69.2  (5.7) 108 – 128  
45 90.4  (0.4) 51.7  (2.7) 46.7  (2.6) 202 - 223  89.4  (3.2) 74.6  (1.3) 66.7  (2.6) 103 - 152  
           
 
The in vitro aerosol performance of 2% (w/w) formulations and salbutamol-coated 
polystyrene beads evaluated through the Handihaler at 15, 30 and 45 L min-1.   Values are given 
as mean (± standard deviation) for N = 3 replicates.   
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Table 9.6. Acoustic Profile Data of Polystyrene Beads 
 Volumetric Flow Rate (L min
-1
)  
 15 30 45  
Time Between  
Audio Events  
(ms) 
18.3  (0.8) 10.9 (0.9) 9.2 (0.8)  
Bead Oscillation  
Frequency  
(Hz) 
55 (4) 95 (16) 112  (20)  
 
During actuation, the polystyrene beads generate a strong audible signal in the form of 
a loud rattle. The acoustic profiles at different flow rates were measured and analyzed to assess 
the time between ‘rattles’ (the audio events) and obtain the frequency at which the beads 
oscillate.  One audio event was assumed to represent one virtual impaction, with two 
impactions occurring in one full bead oscillation cycle. 
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CHAPTER 10 
10. Design, Development, and Testing of Prototype Inhaler Devices to 
Optimize Aerosol Performance from Drug-Coated Polystyrene Carrier 
Particles 
10.1. INTRODUCTION 
Passive dry powder inhalers rely solely on the inspiratory effort provided by the patient 
to fluidize, entrain and disperse the powder formulation.  However, particle engineering 
technologies notwithstanding, simply passing the flow stream across the powder bed is 
insufficient to promote effective powder dispersion from standard binary formulations.  As a 
result, DPIs incorporate a diverse array of design features to enhance particle dispersion and 
improve performance.  Many of these features are designed to induce turbulent flow, typically 
just prior to where the flow stream encounters the dose.   Additional device geometries 
including baffles, grids and spiraling flow channels are incorporated to promote particle-particle 
and particle-device collisions. The various mechanisms of DPI dispersion were discussed in detail 
in Chapter 1. 
The diverse inner geometries of commercial DPIs have given rise to devices possessing a 
wide spectrum of resistance levels (Table 10.1).  Low resistance devices are typically more 
comfortable for patients to use, as for two DPIs with disparate resistance values patients must 
exert a greater inhalation effort through the higher resistance device to achieve a sufficiently 
strong flow rate for adequate particle dispersion.  However, it has been extensively reported 
that there is generally a trade-off between resistance and performance, as higher resistance 
devices will emit a greater fraction of fine particles, provided that a sufficient airflow can be 
generated by the patient through the inhaler.  Accordingly, relatively high resistance devices, 
such as the Turbuhaler, exhibit marked flow rate dependence as many patients are incapable of 
producing a sufficient flow rate to adequately operate the device.  By comparison, low 
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resistance devices offer more consistent dispersion over a wider range of flow rates, though on 
average performance is significantly lower relative to their high-resistance counterparts.     
The relationship between device resistance and the energy passing through a DPI can be 
approximated as [1]: 
   (  )  
where Q is the volumetric flow rate (L min-1),    is the pressure drop across the device 
(Pa), and t is the dose emptying time (seconds).  The pressure drop across the device is related 
to the device resistance (R) as [2]: 
√      
An alternative approach to characterize inhaler performance is described by Dunbar and 
colleagues [116]. This approach is based on the power supplied by the inhalation flow stream, 
where power is defined as the rate at which work is done by the air flow (alternatively described 
as the rate of inspiratory effort): 
       (  )  
As power is the rate at which work is performed, it is noted that the above two methods 
are essentially identical.  Accordingly, for a comparable flow rate, the energy/power that flows 
through a device and interacts with the dose is proportional to the device resistance.  High flow 
rates through high resistance devices generally provide the greatest dispersion performance.  
Unfortunately, many patients cannot produce a sufficient flow stream through a high resistance 
inhaler, and performance is inhibited.   
Specific Aim 
As reported in Chapter 9, the drug-coated polystyrene beads provide effective powder 
dispersion even at very low flow rates where traditional binary blends essentially cease to 
function.  The in vitro aerosol studies were performed using the Handihaler, a capsule-based DPI 
that is not designed to optimize performance of the drug-coated polystyrene beads.  
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Additionally, the Handihaler is a very high resistance device that many patients have reported 
difficulty using, and therefore the ability to lower device resistance while maintaining the high 
performance levels previously noted is highly desirable.   Accordingly, the specific aim of this 
chapter is focused on the design, development and testing of inhaler prototypes to optimize the 
performance of the large, drug-coated polystyrene beads described in Chapters 7 through 9. To 
this end, prospective inhaler geometries will be designed and produced via rapid prototyping, 
and performance will be evaluated in vitro using cascade impaction.   
In addition to the prototypes designed for a single bead, a DPI with two dispersion 
chambers in parallel will also be developed.  This configuration allows the simultaneous 
actuation of two drug-coated beads for combination drug therapy. Additionally, a dual-chamber 
configuration may be employed for high doses of a single drug, such as for the delivery of 
vaccines or antibiotics.   
Rapid Prototyping 
Rapid prototyping is a solid freeform fabrication (SFF) process, and is a collection of 
techniques, including selective laser sintering (SLS) and stereolithography (SLA) that are 
employed to manufacture solid objects initially modeled with computer aided design (CAD) 
software [4, 5].  SLS employs a CO2 laser that traces a pattern onto a hot bed of thermoplastic 
powder, thereby solidifying the powder where it passes.  Following the completion of each 
individual layer, a fresh layer of powder is placed on top of the bed, repeating the process.  By 
contrast, SLA polymerization of the resin occurs through crosslinking by a UV laser to produce a 
solid.  As with SLS, a three-dimensional object is formed from the successive layering of thin, 
two-dimensional cross-sections. Generally the material properties produced by SLA are inferior 
to those developed by SLS, as the latter process employs actual engineering thermoplastics.  
However, the higher level of detail, lower cost, and faster production times of the SLA process 
made it well-suited to the present studies.   
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10.2. EXPERIMENTAL 
10.2.1. Materials 
Budesonide was purchased in bulk (Jinhuo Chemical Company, China) and micronized 
under nitrogen using a high energy jet-mill with respective pusher and grinding pressures of 80 
and 110 PSI (Aljet; Fluid Energy Processing and Equipment Co., PA, USA).  Two micronization 
cycles were performed to produce a narrow particle size distribution of drug.  Micronized 
salbutamol sulphate was purchased from Letco Medical (AL, USA) and used as received.  Low 
density (0.027 g/cm3) polystyrene beads were generously provided by Styrochem® (TX, USA) and 
sorted to obtain particle diameters between 5.1 and 5.3 mm.   
10.2.2. Prototype Design 
The device geometries were modeled using the 3D CAD software package, Inventor® 
(Autodesk, CA, USA).  The final designs were saved in the STL file format and submitted to the 
RP manufacturer.     
10.2.3. Rapid Prototyping 
The completed prototype CAD designs were submitted to the rapid prototyping 
company, FineLine Prototyping (NC, USA). As discussed above, the relatively low cost, excellent 
dimensional accuracy and rapid development times of the SLA technology made it the ideal 
choice for production of the device prototypes.  While numerous materials may be employed in 
stereolithography, DSM SOMOS 9120 was selected for our application as it most closely 
resembles the physical properties of a stiff polypropylene material, providing robust, durable 
prototypes with excellent chemical resistance and accurate features. It is noted that this 
material does not meet USP Class VI testing requirements for biocompatibility and cytotoxicity.  
However, these prototypes were not designed for clinical studies, but rather to obtain a 
mechanistic understanding of the geometries that would most optimize dispersion performance 
from the polystyrene carrier particles, and thus the selected material is well-suited for the study 
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objectives. The prototypes were manufactured using normal resolution stereolithography, 
where building proceeds in 0.004” (0.10 mm) layers.       
10.2.4. Measurement of Device Resistance 
To assess the resistance of the DPI, the pressure drop (cmH2O) across the Handihaler at 
multiple volumetric flow rates (20, 30, 40, 50, 60, and 70 L min-1) was measured using a digital 
manometer (SPER Scientific; AZ, USA).  The base of the inhaler was kept constant through the 
measurements (3.5 mm inlet diameter, 8 mm inlet length, with a 15 degree taper), and only the 
mouthpiece designs were varied.  Unless specified, each dispersion chamber contained a 5.2 
mm, uncoated polystyrene bead during the pressure drop measurements.  The device resistance 
was determined by plotting the square root of the pressure drop against the volumetric flow 
rate, with the slope of the relationship equaling the device resistance, as described by Clark and 
Hollingworth [2].   The flow rate (L min-1) corresponding to a 4 kPa pressure drop across the 
device was also measured for the single dispersion chamber model, the configurations 
incorporating flow bypass channels, and also for the dual dispersion chamber design.      
10.2.5. Drug Coating of Polystyrene Beads 
The polystyrene beads were coated according to the protocol detailed in Chapter 9.  
Briefly, 2 mg of micronized drug (either budesonide or salbutamol sulphate) were weighed into 
a 30-mL glass scintillation vial. Three 5.2 mm polystyrene beads were added to the vial, which 
was then sealed and the bottom half submerged in a sonicating water bath (Fisher Scientific, 
NH, USA) for 2 minutes.  During coating, the vial was slowly rotated side-to-side to enable the 
bead to roll across the powder bed. Following coating, the bead was removed from the 
scintillation vial and dropped approximately 30 cm onto an aluminum mesh to remove any 
loosely adhered drug particles and agglomerates.  The drug-coated polystyrene beads were then 
stored in a desiccator for 3 days prior to use.    
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10.2.6. In vitro Aerosol Performance 
The aerosol performance profiles of the drug-coated large polystyrene carrier particles 
were evaluated in vitro with a next generation cascade impactor (NGI; MSP Corporation, MN, 
USA). For the Handihaler (Boehringer Ingelheim, Germany) and single chamber prototype 
devices, the flow rate was set to 39 L min-1, with a 4-second actuation time.  For the dual 
chamber devices, and models incorporating flow bypass channels, the flow rate was set to 
correspond to a 4 kPa pressure drop across the inhaler.  The volumetric flow rates were 
measured with a digital flowmeter (TSI Performance Measurement Tools, MN, USA).  For each 
actuation, a single bead was placed into the dispersion chamber of the device.  To prevent 
particle re-entrainment, the NGI stages were coated with a 2% (v/v) solution of silicon oil in 
hexane and allowed to air dry prior to each impaction.  Following each impaction, the capsule, 
dispersion chamber, mouthpiece, mouthpiece adaptor, and induction port were each rinsed 
with 10 mL of EtOH, and the stages of the NGI were each rinsed with 5 mL.  For the dual 
chamber studies, the individual components of the device apparatus were rinsed with the same 
volumes but with a mobile phase of 50 mM sodium acetate buffer. 
The drug content was assessed by UV-VIS spectroscopy with an Infinite M200 
microplate reader equipped with a cuvette port (Tecan US, Inc., NC, USA) at 244 nm for 
budesonide.  Quantification of simultaneous drug deposition from the dual chamber device in 
vitro studies was performed according to a published protocol [6].  Briefly, analysis was 
performed using gradient elution with a 2 mL/min flow rate with an HPLC equipped with a C18 
column (150 x 3.9 mm, 5 µm particle size; Waters Corp., MA, USA), and a detection wavelength 
of 240 nm.   
The emitted fraction (EF) is the percentage of the total recovered dose depositing on 
the mouthpiece adaptor, induction port, and NGI stages.  The fine particle fraction (FPF) is given 
as the percentage of the delivered dose possessing an aerodynamic diameter less than 5 µm. 
The respirable fraction (RF) is calculated as the percentage of the total recovered dose with an 
aerodynamic diameter below 5 µm. As discussed in detail below, an additional performance 
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metric assessed was the percentage of the emitted dose collected from the USP induction port 
(%IP).  
10.3. RESULTS AND DISCUSSION 
10.3.1. Particle Deposition in the USP Induction Port 
In Chapter 8, the fluid flow phenomenon that occurs when a relatively narrow volume 
abruptly opens to a larger volume was discussed.  At the corners of the volume expansion, the 
flow stream detaches from the inner walls, re-attaching a distance downstream of the transition 
region.  However, a portion of the flow stream is entrapped at the corners of the expansion 
producing a pressure drop.  It is believed that this phenomenon is responsible for the rapid bead 
oscillations that occur during actuation, which effectively detach drug particles from the surface 
of the polystyrene carrier particles.   
However, similar to the abrupt volume expansion found in the transition region 
between the inlet (3.5 mm) and the dispersion chamber (7.6 mm) of the device, a second 
volume expansion occurs when the mouthpiece of the device (5 mm) transitions into the 
comparatively larger USP induction port (22 mm).  Particle deposition in the induction port of 
the cascade impactor corresponds to extrathoracic particle deposition in vivo, and accordingly in 
vitro particle deposition in this region is commonly referred to as ‘throat’ deposition.     
Particle deposition in the induction port is speculated to occur by inertial impaction, as 
coarse carrier particles and agglomerated drug particles are unable to follow the flow stream as 
it navigates the 90° bend in the induction port, thus colliding into the walls of this region where 
they remain adhered.  Additionally, as the volumetric flow rate is augmented, the amount of 
particles that deposit in this area is also increased, as larger primary drug particles will be 
collected from this region due to the increased inertia resulting from their higher velocity.  
Accordingly, while the performance through DPIs is often classified as being flow rate 
dependent, particle deposition does not continually improve with flow rate until 100% FPF has 
been achieved.  For example, a previous study examining the influence of flow rate on 
performance through the Aerolizer has reported that overall performance is optimized at 
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approximately 65 L min-1, corresponding to a pressure drop well below 4 kPa through this device 
[7]. When the flow rate is increased from this value, any improvements to particle emission and 
dispersion that occur are offset by enhanced ‘throat’ deposition, resulting in no overall change 
in total drug deposition. An additional study of extrathoracic deposition from DPIs concluded 
that particles above 10 µm in aerodynamic diameter may be expected to deposit in the 
extrathoracic region, either in the oral cavity or the larynx, while particles with aerodynamic 
diameters below 2 µm (e.g. primary drug particles) would not be extensively influenced by 
inertial impaction [8].   
Accordingly, while ‘throat’ deposition by impaction is problematic for particles 
possessing relatively high inertia, such as coarse carriers and agglomerated drug particles, this 
does not apply to the same extent for primary drug particles with comparatively lower masses. 
However, while primary particles possess relative immunity to deposition in the induction port 
by inertial impaction, they may be more susceptible to deposition in this region by an 
alternative mechanism.  As discussed above, when the mouthpiece of the inhaler transitions 
into the induction port, an abrupt volume expansion is encountered resulting in recirculating 
eddies at the corner of the expansion. It is speculated that this recirculating region would most 
likely influence primary drug particles, as the relatively low inertias that enable them to 
accurately follow the flow stream through the induction port may also serve to render them 
more readily susceptible to deposition in this region due to the turbulent flow in this region.    
We have performed dispersion studies from drug-coated polystyrene beads where drug 
particle collection from the induction port was separated into two fractions, corresponding to 
regions either adjacent to the mouthpiece or adjacent to the NGI.  It was noted that upwards of 
50% of the drug mass that deposits in the induction port is collected from the half of the 
induction port adjacent to the mouthpiece, indicating that an extensive number of fine particles 
deposit in this region.  Indeed, following each cascade impaction a dusting of fine powder is 
observed in this transition area, while large drug particle aggregates are observed in the region 
of the induction port proximal to the NGI.  It is speculated that the drug particles collected from 
the inhaler-induction port transition region would otherwise contribute to FPF and RF values.  
 258 
Accordingly, the prototypes were designed with the primary purpose of minimizing drug loss in 
this region, and the two metrics primarily employed to report the performance of a given design 
are the %IP (percentage of the emitted dose that deposits in the induction port) and FPF 
(percentage of the emitted dose with an aerodynamic diameter < 5 µm).     
10.3.2. In vitro Aerosol Performance from the Handihaler DPI 
For comparative purposes, three budesonide-coated beads were dispersed through the 
Handihaler at 39 L min-1, corresponding to a 4 kPa pressure drop through the device.  The 
resulting %IP and FPF values are 21.3 % and 72.1 %, respectively.   
10.3.3. Prototype Design 
The archetypal design of the prototype inhalers is shown in Figure 10.1.  Overall, the 
base of the inhaler remained unchanged through the experiments, with a constant 15-degree 
taper throughout the 8 mm inlet, and a 3.5 mm exit diameter.  Previous work in our laboratory 
has shown that this design reduces the device resistance relative to the straight air inlet 
configuration employed in the Handihaler while maintaining the high bead oscillation 
frequencies responsible for effective particle detachment from the bead surface.  The measured 
resistance of this design (including a 5.2 mm bead in the dispersion chamber) is 0.140 (cmH2O)
0.5 
/ L min-1 .  Although this value falls into the category of a high-resistance device, it is only 80% 
the resistance  value of the Handihaler [3, 9].  Accordingly, the flow rate corresponding to a 4 
kPa pressure drop through the prototype is 46 L min-1 as compared to 39 L min-1 for the 
commercial device (Table 10.2).      
10.3.4. Mouthpiece Length 
The diameter of the flow passage through the mouthpiece was kept constant at 7.6 mm 
(corresponding to the diameter of the dispersion chamber) as the length of the mouthpiece was 
varied between 20 mm, 30 mm, and 40 mm (Figure 10.2). The influence of mouthpiece length is 
depicted in Figure 10.3.  As the length is increased from 20 mm to 30 and 40 mm a slight but 
significant (p < 0.05) decrease was noted in the induction port deposition, as the 20.0% from the 
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20 mm length was reduced to 16.3% and 15.2% for the 30 and 40 mm configurations, 
respectively. This corresponded to a significant improvement in FPF for both 30 and 40 mm 
mouthpiece lengths relative to the 20 mm design, with values increasing from 69.4% up to 
76.5% (30 mm) and 75.4% (mm).  Performance between the 30 and 40 mm mouthpiece lengths 
were comparable, and no significant differences were observed.   
These results generally match those obtained by Coates and colleagues, who examined 
the influence of varying the mouthpiece length of the Aerolizer DPI from 47 mm down to three-
quarters and one-half the standard length [10]. CFD studies indicated that the full-length 
mouthpiece produces a well distributed velocity profile.  By contrast, the three-quarters length 
mouthpiece produced a slightly greater velocity difference while the half-length mouthpiece 
produced a non-uniform flow profile, where high-velocity regions were observed together with 
lower velocity regions.  It was speculated by the authors that the high velocity regions observed 
in the shorter mouthpiece could potentially increase throat deposition.  However, no 
significantly increased induction port deposition was observed in vitro, and the authors 
concluded that high velocity regions may dissipate in the throat prior to particle impaction. 
These conclusions match those of the present study, with the exception that the 20 mm 
mouthpiece length was shown to significantly lower performance (FPF), though overall 
differences were slight.  By comparison with drug-coated beads from the Handihaler, where 
mouthpiece length is approximately 28 mm (5 mm diameter), overall performance was 
comparable with all three tested lengths, as the slightly higher performance levels from the 30 
and 40 mm designs were not found to be significant.       
10.3.5. Mouthpiece Exit Diameter 
To evaluate the influence of the exit diameter, mouthpiece designs with tapered flow 
channels such that the exit diameter was twice that of diameter at the base of the mouthpiece, 
were compared against the standard straight channel geometry, where the flow channel 
diameter is constant throughout the length of the mouthpiece (Figure 10.4).  The in vitro 
performance data is presented in Figure 10.5.  For both mouthpiece lengths, doubling the exit 
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diameter significantly lowered %IP and improved FPF.  At 20 mm, % IP declined from 20.0% to 
11.8%, with a corresponding improvement in FPF from 69.4%  to 79.7%.  Likewise, %IP from the 
30 mm tapered design declined from 16.3% down to 10.0%, while FPF improved from 76.5% up 
to 84.1%.    
Interestingly, there was no significant difference between the different mouthpiece 
lengths of the tapered configurations. As described above for the straight flow channel designs, 
decreasing the mouthpiece length from 30 to 20 mm was found to significantly reduce 
performance by increasing the %IP and lowering FPF.  However, for the tapered designs, 
performance was observed to be comparable between both mouthpiece lengths. A previous 
study by Coates and colleagues through the Aerolizer also examined performance as the exit 
diameter was increased.  Two of the configurations included in their study were tapered to 
provide exit diameters 1.5 times (16 mm) and 2 times (21 mm) greater than that of the standard 
design (10.5 mm). The authors observed that while overall drug deposition differences between 
the designs were not found to be significant, a significant decline in deposition in the induction 
port was noted for the tapered designs.  Using CFD, the authors concluded that the tapered 
design significantly reduces the axial component of the air flow velocity exiting the mouthpiece, 
thus corresponding to lower particle deposition in this region.  Additionally, the study indicated 
that it is the axial motion of the particles that is primarily responsible for induction port 
deposition, and that the radial motion of the emitted aerosol was not found have a significant 
influence on in vitro ‘throat’ deposition.  These results matched those of the present study, 
where reduced induction port deposition was observed when the exit diameter was doubled.  
However, in the present study, significant FPF values were noted for the tapered geometries 
with both mouthpiece lengths.  Additionally, compared against the performance of the drug-
coated polystyrene beads through the Handihaler, the tapered design significantly lowered % IP 
and improved FPF for both mouthpiece lengths.   
In the Aerolizer® study, the authors concluded that the design of the mouthpiece 
influences ‘throat’ deposition by controlling the axial component of the air flow velocity exiting 
the mouthpiece, and lower values for this parameter were correlated with decreased throat 
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deposition.  As noted previously, the mouthpiece transitions into the induction port, there is a 
sudden volume expansion.  It was speculated that the flow profile in this region may be 
responsible for the deposition of fine particles. However, for the tapered designs, the particle-
laden flow stream is expanding as it enters the induction port, and it was speculated that this 
may reduce the overall pressure drop in the transition region, as there is no longer the same 
abrupt volume expansion as with the straight-channel design.  Unfortunately, in the present 
studies CFD simulations were not coupled with the in vitro performance data, and thus the 
precise mechanism of how the tapered designs influence performance has not been fully 
elucidated.   
10.3.6. Powder Channel Diameter 
To evaluate the influence of the diameter of the powder channel through the 
mouthpiece, designs were developed where the channel diameter was varied from 4, 5, 6, and 
7.6 mm (Figure 10.6).  The length of the mouthpiece was kept constant at 40 mm.  The in vitro 
aerosol performance results are shown in Figure 10.7.   As noted by Coates and colleagues in 
their studies of aerosol performance in the Aerolizer, the mouthpiece geometry exerts its 
influence on ‘throat’ deposition by modulating the axial velocity of the aerosol cloud emitted 
from the device.  Specifically, reduced axial velocities were correlated with significantly lower 
levels of induction port deposition.  
For a constant volumetric flow rate, decreasing the diameter of the powder channel 
through the mouthpiece would be expected to increase the velocity of the emitted aerosol 
cloud. According to the previous theory, smaller diameter devices would be expected to 
produce the higher %IP values.  This was observed for the 4 mm design, which exhibited 
significantly higher deposition in the induction port (%IP = 34%), and lower FPF values (56%) 
compared to the 5 mm, 6 mm, and 7.6 mm channel diameter mouthpieces, where induction 
port deposition ranged from 23 – 26% and FPFs were between 64 – 66%.  Accordingly, none of 
these designs provided significantly improved performance relative to that observed from the 
Handihaler.           
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10.3.7. Flow Bypass Channels and Sheath Flow 
The mouthpiece designs incorporated flow bypass channels to lower the overall 
resistance of the device while providing a sheath of air flow around the powder-laden flow 
stream exiting the mouthpiece (Figure 10.8).  For the bypass channels, eight circular inlets 
(diameter = 1.5 mm) were arranged circumferentially around the mouthpiece, entering 
perpendicular to the central axis of the powder flow channel, and connecting with the sheath 
flow channel; a distance of 2 mm separated the sheath flow channel from the powder flow 
channel.  The distance between the inner and outer edge of the sheath flow channel was varied 
from 1.5 mm to 3 mm.  A final design included a 3-mm gap between the inner and outer edge of 
the sheath flow channel, with a 5 mm fillet applied to the outer edge of the device, yielding a 
sheath flow passage that diverges from the central powder channel as it transitions into the 
induction port.  For the sheath-flow designs, the length of the mouthpiece was kept constant 
(40 mm) as was the diameter of the powder flow channel (5 mm). 
The measured resistances of these prototypes are listed in Table 10.3. The inclusion of 
flow bypass channels markedly lowered device resistance relative to the single chamber design, 
increasing the flow rate at a 4 kPa pressure drop from 46 L min-1 up to 108 L min-1.  When the 
distance between the inner and outer edge of the sheath flow channel is increased from the 1.5 
mm to 3.0 mm, the device resistance is reduced by 30%, from 0.079 to 0.061 (cmH2O)
0.5 / L min-
1, thus transitioning from an intermediate resistance device to a low resistance device [3]. The 
inclusion of a filleted outer edge with a 3.0 mm does not appreciably alter resistance, and the 4 
kPa flow rate is only marginally increased, from 105 to 110 L min-1.     
The in vitro performance of the flow bypass designs was compared against a 
mouthpiece without flow bypass channels, with a 5-mm powder flow channel diameter and 40-
mm mouthpiece length at 39 L min-1 (Figure 10.9).  The inclusion of flow channels is not 
sufficient to effect induction port deposition, as the %IP values are not significantly different 
between the design without bypass channels and the mouthpieces with the 1.5 and 3.0 mm 
sheath flow channels.  However, when the outer edge of the channel is filleted, %IP declined 
significantly from 26% to 18% compared to the design without flow bypass channels.   
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In contrast to %IP, where only the filleted 3.0 mm flow bypass design exhibited 
significant differences, FPF values were significantly higher for all flow bypass designs relative 
the control design.  FPF values for the flow bypass channels ranged from 70 – 77%, with the 
filleted design demonstrating the highest performance values.  However, when compared to 
performance from the Handihaler, only the filleted design displayed significantly improved 
performance in terms of both lower %IP and higher FPF.       
10.3.8. Performance of Dual Chamber Prototype 
The design of the dual chamber device is shown in Figure 10.10. To accommodate both 
dispersion chambers while keeping the overall device diameter fixed at 22 mm, the two 
channels were separated by only 1 mm.  Due to the close proximity of the dispersion chambers, 
it was not possible to use the tapered air inlet employed in the single dispersion chamber 
prototypes as overlap would have occurred between the adjacent inlets. Accordingly, this design 
used straight air inlets similar to the Handihaler®.  
The device resistance of the inhaler is provided in Table 10.4. Due to the two air inlets, 
the overall resistance is only 0.079 (cmH2O)
0.5 / L min-1 when two beads are included in the 
dispersion chamber, and is categorized as an intermediate resistance device [3].  The flow rate 
corresponding to a 4 kPa pressure drop across the device is 81 L min-1, approximately twice that 
of the Handihaler.  The inclusion of the polystyrene beads into each dispersion chamber 
produces a minimal increase in device resistance relative to the empty chambers (Figure 10.11).              
In vitro deposition performance from the dual chamber device incorporating two beads, 
each coated with either budesonide or salbutamol and simultaneously actuated in parallel is 
shown in Figure 10.12.  As discussed above, the plastics and surface finishing of the prototype 
devices were not optimized to maximize the emitted dose, and the device retention values were 
29% for budesonide and 30% for salbutamol, compared to 20% and 13% observed when 
dispersion was evaluated through the Handihaler. As a result, the emitted fractions were 
diminished 16% (budesonide) and 21% (salbutamol) relative to the EF values obtained from the 
commercial device at approximately the same overall pressure drop. While it is noted that the 
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dispersion through the Handihaler was performed with a single bead, the device retention 
values through the dual chamber device are comparable to those observed with the single 
chamber prototypes, indicating that retention was due primarily to the prototype material as 
opposed to being attributable to the simultaneous actuation of two beads and a corresponding 
lower flow rate through each chamber.   The two drugs exhibited similar deposition profiles 
through the NGI and aerodynamic diameters of 2.76 µm and 2.91 µm were calculated for 
budesonide and salbutamol, respectively (Figure 10.13).   
As noted in the previous chapter, budesonide displayed a higher affinity for the bead 
relative to salbutamol, as recovered doses ranged from 230 – 280 µg for the corticosteroid, and 
100 – 180 µg for the β-agonist.  Additionally, bead retention for the former was between 6 – 9 % 
of the total dose, compared to 2 – 4% for the latter.   By comparison, for the commercial 
combination DPI products ADVAIR® Diskus® and SYMBICORT® Turbuhaler®, in vitro drug delivery 
has been reported to range between 10 – 25% of the metered dose [11-13].  
10.4. CONCLUSION 
This chapter examined variations in mouthpiece design performance with the purpose 
of developing a prototype device to improve the aerosol performance of drug-coated 
polystyrene beads.  To that end, designs were developed using CAD software and manufactured 
via stereolithography.  The designs incorporated variations in mouthpiece length, mouthpiece 
exit diameter, and powder channel diameter, in addition to flow bypass and sheath flow 
configurations.  Of the different designs evaluated in vitro, only the tapered mouthpieces and 
filleted sheath flow channel design significantly outperformed dispersion from the Handihaler, 
with FPF values ranging up to 84%, and %IP as low as 10%.  Additionally, the inclusion of flow 
bypass channels reduced overall device resistance to approximately half the value of the 
Handihaler, enabling flow rates in excess of 100 L min-1 at 4 kPa, demonstrating the 
development of a low resistance device capable of highly efficient drug delivery.     
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Figure 10.1.  Archetypal Design of a Single Dispersion Chamber Prototype Inhaler 
The inner diameters of the dispersion chamber and powder flow channel through the 
mouthpiece were both 7.6 mm.  Providing the flow stream to the dispersion chamber was a 
conical inlet (8 mm length with a 15 degree taper angle) with a 3.5 mm diameter inlet.  The 
mouthpiece contains a mesh situated directly above the dispersion chamber to prevent escape 
of the bead from the device.  A locking mechanism on each side of the inhaler allows the 
mouthpiece and dispersion chambers to be sealed during actuation. 
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Figure 10.2.  Prototype Designs with Varying Mouthpiece Length 
The overall dimensions were kept constant relative to the archetype, with only the 
length of the mouthpiece varying to provide powder channels of 20 mm, 30 mm, and 40 mm.    
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Figure 10.3.  Performance of Prototypes with Varying Mouthpiece Length 
In vitro aerosol performance was evaluated at 39 L min-1 as mouthpiece length was 
varied from 20, 30, and 40 mm. Values are provided as the mean (± standard deviation) for N = 3 
replicates.   
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Figure 10.4.  Prototype Designs with Tapered Device Outlet Channels 
The diameter of the channel was tapered to be 15.2 mm at the exit, corresponding to 
the twice the diameter at the base of the mouthpiece (7.6 mm). The length of the mouthpiece 
was also varied to provide powder channels of 20 mm, 30 mm and compared against straight-
channel mouthpieces of similar lengths.   
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Figure 10.5.  Performance of Tapered Mouthpiece Channel Prototypes 
In vitro aerosol performance was evaluated at 39 L min-1 as the diameter of the 
mouthpiece outlet was varied from 7.6 mm to 15.2 mm for (A) 20 mm and (B) 30 mm 
mouthpiece lengths. Values are provided as the mean (± standard deviation) for N = 3 replicates.   
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Figure 10.6.  Prototype Designs with Varying Mouthpiece Channel Diameters 
The length of the mouthpiece was maintained at 40 mm while the diameter of the 
channel was altered from 4 mm, 5 mm, 6 mm and 7.6 mm. 
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Figure 10.7.  Performance of Varying Mouthpiece Channel Diameters 
In vitro aerosol performance was evaluated at 39 L min-1 as the diameter of the 
mouthpiece outlet was varied between 4 mm, 5 mm, 6 mm, and 7.6 mm. The overall length of 
the channel was 40 mm.  Values are provided as the mean (± standard deviation) for N = 3 
replicates.   
  
0
10
20
30
40
50
60
70
% Induction Port FPF
P
e
rc
e
n
ta
g
e
 (
%
)
4 mm
5 mm
6 mm
7.6 mm
 275 
 
 
 
Flow Bypass Channel Configuration 
None 1.5 mm 3 mm 
3 mm                  
Filleted Edge 
 
 
 
   
 
Figure 10.8.  Designs Possessing Flow Bypass and Sheath Flow Channels 
The length of the mouthpiece was maintained at 40 mm, and the diameter of the 
powder flow channel was 5 mm for all designs.  Eight circular inlets (1.5 mm diameter) were 
arranged circumferentially around the mouthpiece.  The inlets connected to a sheath flow 
channel whose inner edge was separated from the outer edge of the powder flow channel by a 
2 mm distance.  The distance between the inner and outer edge of the sheath flow channel was 
varied between 1.5 mm and 3.0 mm.  In the latter configuration, the outer edge of the sheath 
flow channel was filleted by 5 mm.   
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Figure 10.9.  Performance of Flow Bypass and Sheath Flow Mouthpiece Designs 
In vitro aerosol performance for the various flow bypass channel (FBC) configurations. 
The performance of these designs was compared against a prototype with similar mouthpiece 
and channel diameters (40 mm and 5 mm, respectively) but without flow bypass channels (No 
FBC).  The designed tested included a distance between the inner and outer edge of the sheath 
flow channel of 1.5 mm (1.5 mm (FBC)) and 3.0 mm (3.0 mm (FBC)).  Additionally, a design 
similar to the latter prototype but with a filleted outer edge of the sheath flow channel (3.0 mm 
(FBC) F) was evaluated.  Values are provided as the mean (± standard deviation) for N = 3 
replicates.   
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Figure 10.10.  Design of a Dual Dispersion Chamber Prototype Inhaler 
The inner diameters of the dispersion chamber and mouthpiece were 7.6-mm for both 
channels.  Providing the flow stream to the dispersion chamber was a straight inlet, 8-mm in 
length and 3.5-mm in diameter.  The mouthpiece contains two meshes, each situated directly 
above a dispersion chamber to prevent escape of the beads from the device.  A locking 
mechanism on each side of the inhaler allows the mouthpiece and dispersion chambers to be 
maintained closed during actuation.   
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Figure 10.11.  Pressure Drop Across the Dual Chamber Prototype at Various Flow 
Rates 
The square root of the pressure drop was evaluated with both dispersion chambers 
empty, or with a 5.2 mm polystyrene bead included in each chamber.    
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Figure 10.12.  Performance of Dual Chamber Prototype Inhaler 
In vitro aerosol performance of budesonide- and salbutamol-coated polystyrene beads 
dispersed simultaneously from the dual chamber prototype design. The volumetric flow rate 
was set to correspond to a 4 kPa pressure drop across the device (81 L min-1) and the actuation 
time adjusted to provide 4 L of air flow through the device. Values are reported as the mean      
(± standard deviation) for N = 3 replicates.   
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Figure 10.13.  Stage Deposition from Dual Chamber Prototype 
The deposition values are reported for each stage as a fraction of the cumulative dose 
collected from all eight NGI stages following each cascade impaction. The similarity of the stage 
deposition profiles indicates comparable aerosol performance, as reflected by their similar 
aerodynamic diameters. Values are reported as the mean (± standard deviation) for N = 3 
replicates.   
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Table 10.1. Resistances of Marketed DPIs and Devices Presently in Development 
Dry Powder 
Inhaler 
 
Device Resistanc 
(cmH2O)
0.5
 / L min
-1 
Flow Rate      
@ 4 kPa 
( L min
-1 
) 
REF 
    
Rotahaler 0.040 160 [2] 
Spinhaler 0.051 125 [2] 
Diskus 0.066 96 [13] 
Diskhaler 0.067 95 [2] 
Aerolizer 0.070 91 [15] 
Breezhaler 0.070 91 [18] 
Turbuhaler 
(Mark III) 
0.086 74 [13] 
Turbuhaler 0.100 64 [2] 
AIR 0.140 46 [17] 
Easyhaler 0.156 41 [19] 
Handihaler 0.164 39 [9] 
Inhalator 0.180 36 [2] 
Taifun 0.182 35 [16] 
Pulvinal 0.190 34 [14] 
MedTone 0.374 17 [20] 
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Table 10.2. Device Resistances of Handihaler and Single Chamber Prototype 
Device 
Device Resistance 
((cmH2O)
0.5
 / L min
-1
) 
Flow Rate @ 4 kPa 
(L min
-1
) 
Handihaler 0.173 39 
Prototype 0.140 46 
 
Prior to resistance measurements, an empty size-3 gelatin capsule was placed into the 
dispersion chamber of the Handihaler and punctured via the piercing mechanism of the DPI.  For 
the prototype, a 5.2 mm polystyrene bead (uncoated) was likewise placed into the dispersion 
chamber before measuring the resistance.     
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Table 10.3. Resistances for Flow Bypass and Sheath Flow Channel Configurations 
Device 
 
Device Resistance 
((cmH2O)
0.5
 / L min
-1
) 
 
Flow Rate @ 4 kPa 
(L min
-1
) 
   
1.5 mm 0.079 81 
3.0 mm 0.061 105 
3.0 mm, Filleted 0.058 110 
 
Prior to resistance measurements, a 5.2 mm polystyrene bead (uncoated) was placed 
into the dispersion chamber of the prototype inhaler.      
  
 284 
 
 
 
 
 
 
Table 10.4. Measured Device Resistance for Dual Chamber Prototype Device 
Dispersion Chamber 
Configuration 
 
Device Resistance 
((cmH2O)
0.5
 / L min
-1
) 
 
Flow Rate at 4 kPa 
(L min
-1
) 
   
Empty 0.073 90 
5.2 mm Polystyrene Beads 0.079 81 
   
 
Resistance of a prototype device with dual dispersion chambers was initially measured 
with both dispersion chambers empty and with each chamber containing a 5.2 mm polystyrene 
bead.     
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CHAPTER 11 
11.  Final Conclusions 
This thesis has examined the influence that the physical properties, specifically the 
diameter and surface roughness, of the carrier particle population can impart to the aerosol 
performance of binary DPI formulations.   
In chapter 3, a comprehensive in vitro study was undertaken, examining the aerosol 
performance of 4 grades of lactose fractionated into 13 narrow and contiguous size fractions.  In 
addition to the in vitro drug deposition profiles from these 52 formulations, many of the 
physicochemical parameters that have been reported to be important for the performance of 
binary blends, including the lactose fines concentration, specific surface area, and surface 
energy of the carrier particles were examined.  It was noted that while the overall performance 
of the α-lactose monohydrate carrier populations followed the expected trend where increasing 
the diameter of the carrier particle resulted in diminishing overall drug deposition, the 
performance from many of the formulations deviated from that predicted in the literature.  
Specifically, spray dried and granulated lactose carriers, both possessing extensive surface 
roughness, exhibited performance improvements with large carrier particle diameters.   
Chapter 4 more closely examined the influence of carrier particle diameter and surface 
roughness, while simultaneously using a distinct drug and concentration than that employed in 
the previous chapter. Though the absolute values differed between studies, the overall trends 
were similar as the larger granulated carrier particles outperformed smaller size fractions. It was 
speculated that this may occur due to a shift in the predominant drug detachment mechanism 
for these larger granulated particles, as their surface roughness would diminish the influence of 
fluid-based drug detachment from the flow stream, thus causing them to rely more on 
mechanical detachment forces derived from particle collisions.  Accordingly, this would favor 
larger carrier particles capable of producing sufficient momentum transfers between the drug 
and carriers during collisions.     
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In chapter 5 the performance of a DPI as a function of carrier particle size and surface 
roughness was evaluated.  Specifically, formulations were delivered from two commercial 
inhalers (Aerolizer® and Handihaler®) and computational fluid dynamics was used to model the 
carrier particle trajectories within the devices.  The results indicated that in the Aerolizer, carrier 
particles undergo more collisions with the inner walls of the DPI as their diameter increases.  In 
contrast, the Handihaler exhibited no marked change in the frequency of particle collisions as 
their diameter was altered.  These disparate trends were reflected in the in vitro studies from 
the granulated carriers, where increasing particle diameter improved performance from the 
Aerolizer but not in the Handihaler, suggesting that particle-device collisions could indeed 
promote drug delivery.     
Chapter 6 examined the influence of flow rate on the performance of lactose carrier 
particles as a function of diameter and surface roughness.  These studies revealed that larger 
diameter carrier particles benefit most from increases in flow rate. Additionally, granulated 
carrier particles exhibited both the greatest performance improvement as flow was increased 
from 30 min-1 to 90 L min-1, and the best overall performance at the higher flow rate.  These 
results suggest that mechanical detachment forces can dominate fluid forces, and carrier 
particles that are designed to optimize the influence of the former can yield excellent drug 
dispersion.     
  From these observations, a novel dry powder dispersion mechanism was developed 
based on drug detachment due to mechanical forces.  Specifically, large carrier particles (> 500 
µm) were employed to increase the collision forces between particle and device.  These particles 
were designed to be much larger than the pore sizes of the meshes found in DPIs, ensuring that 
the particle is retained and thus allowing the use of materials other than FDA-approved lactose.   
Chapter 7 focused on the selection of an appropriate carrier particle material, with low-
density polystyrene beads emerging as the optimal candidate. Chapter 8 addressed the 
development of both a dispersion mechanism to minimize the dose retained within the device, 
and a novel coating method to limit the extent of drug agglomeration and optimize performance 
of these particles.    
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In Chapter 9, drug-coated polystyrene beads were compared against the performance of 
traditional binary formulations at multiple flow rates.  At all flow rates, for both budesonide and 
salbutamol, the beads significantly outperformed the lactose carrier particle-based 
formulations.  Specifically, the performance of the beads at 15 L min-1 was comparable to the 
performance of the binary lactose blends at 30 and 45 L min-1.  Additionally, the oscillating 
frequency of these beads as a function of flow rate was measured, enabling a better 
understanding of the mechanism governing their performance. 
In Chapter 10, the potential of a prototype device to further improve the performance 
of the large, drug-coated polystyrene beads was investigated.  Using rapid prototyping, diverse 
inhaler designs were manufactured and tested.  Specifically, the inclusion of flow bypass 
channels enabled the production of a low resistance device demonstrating FPF values of 
approximately 80%.  Additionally, a dual-chamber prototype was designed and tested for use in 
combination therapy (e.g. for delivery of a corticosteroid and a β-agonist), and FPF values of 
approximately 70% for both drugs were observed at a flow rate corresponding to a 4 kPa 
pressure drop across the device.      
In conclusion, this project has demonstrated that large carrier particle diameters are not 
as detrimental to performance as initially theorized. Coupling large diameter particles 
possessing extensive surface roughness to both a device and flow rate that promotes 
mechanical detachment forces can yield excellent dispersion performance.   These observations 
then led to the development of a novel dispersion mechanism that has reproducibly 
demonstrated superior performance to commercially employed formulations.   
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APPENDIX 
1. Reported Literature Values of DPI Performance 
The following table lists the in vitro and in vivo aerosol performance data reported in the 
literature for various dry powder inhalers.  For commercial devices, such as the DiskusTM and 
TurbuhalerTM, only the dispersion performance of each DPI’s marketed formulation is provided, 
as opposed to experimental formulations that were dispersed through a commercial device.    
For clarity, the table is sorted by inhaler, then by whether the study occurred in vitro or 
in vivo, and then according to the API delivered.  Multiple flow rates that were investigated in 
the same study are reported together.  The values reported represent the lung deposition of the 
metered dose, except where only the deposition of the emitted dose was provided, which is 
denoted by an asterisk (*).  For the in vivo studies, the mean volumetric flow rate measured for 
the patient population was reported.   
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Inhaler Study REF 
API /  
Formulation 
Flow Rate 
(L min-1) 
FPF 
Mean (StDev) 
       
AEROLIZER       
 In vitro      
   Formoterol    
  (1)  28.3 ~  17    %  
    40 ~ 23    %  
    60 ~ 27    %  
    80 ~ 27    %  
       
  (2)  30 ~ 13    %  
    60 ~ 15    %  
    90 ~ 31    %  
    120 ~ 31    %  
       
  (3)  28.3   ~ 18     %  
    80 ~ 19     %  
       
  (4)  60 25.7 %  
       
 In vivo      
   Formoterol    
  (3)   20    % (4) 
       
AIR       
 In vitro      
   
Placebo Large Porous 
Particles 
   
  (5)  20 67    % (4) 
    28.3 71    % (3) 
    60 74    % (4) 
       
 In vivo      
   
Placebo Large Porous 
Particles 
   
  (5)  38* 51   %  
       
AIRMAX       
 In vitro      
   Budesonide    
  (6)  60 – 70 47    %  
    60 – 70 48    %  
    60 - 70 61    %  
       
  (7)  70 42.7 % (1.9) 
       
 In vivo      
   Budesonide    
  (7)  37* 28.3 % (5.6) 
    71* 25.8 % (6.5) 
       
ASPIRAIR       
 In vitro      
   Neuro-active Compound    
  (8)  60 77    %  
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BREEZHALER       
 In vitro      
   Indacaterol    
  (9)  30 18.0 % (1.4) 
    40 22.7 % (1.1) 
    50 25.3 % (0.9) 
    60 28.0 % (0.6) 
    70 28.7 % (0.5) 
    80 30.0 % (0.5) 
    90 31.3 % (1.1) 
    100 32.0 % (0.7) 
       
  (9)  30 18.0 % (1.1) 
    40 24.0 % (1.2) 
    50 28.3 % (1.3) 
    60 30.0 % (2.0) 
    70 31.0 % (2.2) 
    80 33.7 % (1.8) 
    90 35.3 % (1.5) 
    100 34.3 % (1.2) 
       
CERTIHALER       
 In vitro      
   
Novel Anti-inflammatory 
Agent 
   
  (10)  60 45.0 %  
    60 53.9 %  
       
  (11) Formoterol 60 32 – 49%   
       
       
CLICKHALER       
 In vitro      
   Beclomethasone    
  (12)  60 24.2 % (3.6) 
       
   Budesonide    
  (13)  60 34.6 % (2.5) 
       
   Salbutamol Sulphate    
  (14)  28.3 31.4 %  
  (12)  60 40.7 % (4.5) 
       
 In vivo      
   Budesonide    
  (13)  60 26.8 % (6.8) 
       
DISKHALER       
 In vitro      
   Beclomethasone    
  (15)  60 23.0 %  
       
   Salbutamol Sulphate    
  (16)  30 14.4 % (2.3) 
    55 15.3 % (1.1) 
    80 30.4 % (1.9) 
       
  (16)  30 11.4 % (1.2) 
    55 27.0 % (2.1) 
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DISKHALER       
(Cont’d)  (17)  28.3 20.4 % (8.6) 
    60 26.9 % (5.7) 
       
  (18)  30 26.7 %  
    60 40.3 %  
       
  (19)  60 35.1 % (1.0) 
       
DISKUS       
 In vitro      
   Fluticasone    
  (20)  30 13.3 %  
    60 18.5 %  
    90 16.1 %  
       
  (21)  30 19.2 % (2.6) 
    60 22.4 % (1.4) 
    90 36.9 % (3.4) 
       
  (22)  28.3 16    %  
    60 21    %  
       
  (23)  60 20.1 % (1.4) 
  (19)  60 29.9 % (0.6) 
       
  (24)  87 25.1 % (0.4) 
       
  (25)  PIF? 15    % (2) 
    PIF? 18    % (2) 
       
   Salbutamol Sulphate    
  (26)  30 14.5 %  
    60 20.7 %  
    90 20.1 %  
       
  (17)  28.3 23.3 % (0.9) 
    60 31.6 % (0.9) 
       
  (18)  ---- 26    %  
       
  (27)  PIF 36.8 % (9.8) 
       
   Salmeterol Xinafoate    
  (23)  60 23.4 % (0.8) 
       
   Comination (Advair)    
  (28) Fluticasone 30 10.7 % (0.3) 
   Salmeterol  8.5 % (0.2) 
       
  (28) Fluticasone 30 16.1 % (0.5) 
   Salmeterol  13.3 % (0.03) 
       
  (28) Fluticasone 67 22.5 % (0.9) 
   Salmeterol  24.0 % (1.0) 
       
  (28) Fluticasone 71 26.4 % (1.1) 
   Salmeterol  25.1 % (1.3) 
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DISKUS  (29) Fluticasone 60 26.5 %  
(Cont’d)   Salmeterol  25.6 %  
       
  (30) Fluticasone PIFs 20.4 % (4.8) 
   Salmeterol  18.4 % (4.4) 
       
DRYHALER       
 In vitro      
   Salbutamol Sulphate    
  (31)  28.3 20   % (3.3) 
       
EASYHALER       
 In vitro      
   Beclomethasone    
  (19)  60 23.3 % (0.6) 
       
   Budesonide    
  (32)  58 35.9 % (4.6) 
       
   Salbutamol Sulphate    
  (26)  30 15.6 %  
    40 20.9 %  
    60 23.2 %  
 In vivo      
   Beclomethasone    
  (33)  ----- 18.9 % (9.5) 
       
   Budesonide    
  (32)  63* 18.5 % (7.8) 
       
   Salbutamol Sulphate    
  (34)  32 - 65 24    % (6) 
       
FLOWCAPS       
 In vitro      
   Budesonide    
  (35)  30 20.8 %  
       
   Salbutamol    
  (35)  30 43.6 %  
       
GENUAIR       
 In vitro      
   Aclidinium Bromide    
  (36)  Not specified 23.2 %  
    Not specified 37.1 %  
       
  (37)  90 40.3 % (5.6) 
       
 In vivo      
   Aclidinium Bromide    
  (37)  79* 30.1 % (7.3) 
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HANDIHALER       
 In vitro      
   Ipratropium    
  (38)  20 16.3 %  
    28.3 21.8 %  
    40 23.4 %  
    50 25.3 %  
    60 24.3 %  
       
 In vivo      
   Tiotropium    
  (39)  Healthy 18   %  
    Mild COPD 19   %  
    Moderate COPD 22   %  
    Severe COPD 18   %  
       
       
INHALATOR       
 In vitro      
   Salbutamol Sulphate    
  (40)  28.3 9.6 %  
    60 21.9 %  
   Tiotropium    
  (19)  60 34.7 %  
       
MAGHALER       
 In vitro      
   Salbutamol    
  (41)  60 46.7 %  
       
 In vivo      
   Salbutamol    
  (41)  36.3* 21.1 % (5.1) 
    62.1* 26.4 % (4.3) 
       
MEDTONE       
 In vivo      
   Insulin (Technosphere)    
  (42)  Not Measured 39.5 %  
       
MICRODOSE DPI       
 In vitro      
  (43) Unspecified API 28.3 84   %  
       
MONODOSE       
 In vitro      
   Budesonide    
  (44)  60 33.1 % (1.8) 
       
 In vivo      
   Budesonide    
  (44)  47* 21.4 % (7.5) 
    96*  21.4 % (4.3) 
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NOVOLIZER       
 In vitro      
   Budesonide    
  (45)  35 ~ 15   %  
    60 ~ 34   %  
    100 ~ 48   %  
       
 In vivo      
   Budesonide    
  (46)  54 19.9 %  
    65 25.0 %  
    99 32.1 %  
       
PULVINAL       
 In vitro      
  (47) Beclomethasone    
    28 22    %  
    63 34    %  
 In vivo      
   Salbutamol    
  (48)  27.8* 11.7 % (2.3) 
    46.0* 14.1 % (3.2) 
       
       
ROTAHALER       
 In vitro      
   Beclomethasone    
  (21)  30 10.6 % (1.2) 
    60 15.2 % (1.0) 
    90 24.3 % (2.3) 
       
  (49)  60 12.6 % (1.8) 
  (50)  60 16    % (2.3) 
       
       
   Salbutamol Sulphate    
  (16)  30 12.2 % (1.1) 
    55 15.1 % (1.2) 
    80 18.2 % (3.1) 
       
  (40)  28.3 3.7 %  
    60 14.2 %  
       
  (16)  30 8.6 % (1.1) 
    55 22.6 % (4.2) 
       
  (47)  34 ~ 8    %  
    107 ~ 17   %  
       
  (51, 52)  74 12.9 %  
    144 18.8 %  
       
  (53)  60 16.6 % (0.3) 
  (54)  60 27.1 % (2.0) 
       
 In vivo      
   Salbutamol Sulphate    
  (55)  Unspec. 9.1 % (0.6) 
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SPINHALER       
 In vitro      
   Cromolyn Sodium    
  (19)  60 4.2 % (0.7) 
  (15)  60 7.8 %   
  (56)  60 8.6 %   
  (57)  60 12.5 %     
  (58)  60 15    %  
       
  (59)  100 14.1 % (1.4) 
       
SPIROS       
 In vitro      
   Salbutamol Sulphate    
  (60)  15 25.8 % (9.2) 
    60 19.3 % (7.3) 
       
TAIFUN       
 In vitro      
   Budesonide    
  (61)  28.3 30.2 %  
       
  (62)  28.3 45   %  
    28.3 35   %  
       
   Fentanyl Citrate    
  (63)  33 27.6 % (2.6) 
    33 30.6 % (1.3) 
       
 In vivo      
   Budesonide    
  (61)  20.6* (2.2) 29.6 % (5.9) 
    35.8* (4.5) 34.3 % (5.8) 
       
TURBUHALER       
 In vitro      
   Budesonide    
  (21)  30 12.4 % (2.8) 
    60 28.4 % (2.3) 
    90 40.7 % (5.5) 
       
  (22)  28.3 6    %  
    60 18    %  
       
  (64)  60 27.3 %  
  (13)  60 29.8 % (5.5) 
  (65)  60 34    % (2.5) 
  (32)  60 34.4 % (2.6) 
  (44)  60 36.2 % (1.0) 
  (15)  60 37.5 %  
  (66)  60 38.7 %  
  (19)  60 39.3 % (2.0) 
       
  (25)   21    % (10) 
     32    %   (9) 
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TURBUHALER       
(Cont’d)   Formoterol    
  (1)  28.3 ~ 18    %  
    40 ~ 35    %  
    60 ~ 41    %  
    80 ~ 40    %  
       
  (2)  30 ~  5    %  
    60 ~ 13    %  
    90 ~ 33    %  
    120 ~ 34    %  
       
   Salbutamol Sulphate    
  (17)  28.3 9.7 % (3.2) 
    60 23.3 % (3.0) 
       
  (17)  28.3 13.3 % (1.6) 
    60 27.6 % (8.0) 
       
  (26)  30 11.5 %  
    60 23.8 %  
       
  (51, 52)  30 25.2 %  
    60 41.8 %  
       
  (27)   28.7 % (7.7) 
       
   Terbutaline Sulphate    
  (16)  30 14.8 % (1.7) 
    55 18.7 % (3.2) 
    80 28.0 % (3.8) 
       
  (67)  28.3 12    %  
    60 42    %  
       
  (16)  30 8.8 % (1.1) 
    55 27.1 % (7.6) 
       
  (57)  60 34.6 %  
  (19)  60 35.4 % (1.4) 
       
   Combination (Symbicort)    
  (30) Budesonide  23.1 % (12.9) 
   Formoterol  20.7 % (11.1) 
       
 In vivo      
   Budesonide    
  (66)  29* 17.8 %  
    58* 28.5 %  
       
  (7)  31* 22.7 % (5.6) 
    59* 29.8 % (6.9) 
       
  (44)  33* 18.5 % (6.5) 
    66* 25.1 % (6.1) 
       
  (64)  36* 14.8 % (3.3) 
    58* 27.7 % (9.5) 
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TURBUHALER  (46)  58 21.4 %  
(Cont’d)       
  (32)  64* 21.8 % (8.2) 
       
   Terbutaline Sulphate    
  (68)  ?? 20.8 %  
       
  (64)  57* 27.0 % (7.7) 
       
       
TWISTHALER       
 In vitro      
   Mometasone Furoate    
  (69)  60 35.6 % (3.4) 
    60 39.9 % (2.5) 
       
ULTRAHALER       
 In vitro      
   Nedocromil Sodium    
  (70)  60 18.6 % (1.6) 
       
   HMR 1031    
  (71)  60 34.6 % (4.3) 
       
   Triamcinolone Acetonide    
  (72)  60 44.7 %  
       
 In vivo      
   HMR 1031    
  (71)  60** 24.6 % (7.3) 
       
   Nedocromil Sodium    
  (70)  42.5* (8.6) 9.8 % (3.5) 
    75.3* (19) 13.3 % (4.8) 
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